WO2023044014A1 - Methods, systems and compositions for restoration and preservation of intact organs in a mammal - Google Patents

Methods, systems and compositions for restoration and preservation of intact organs in a mammal Download PDF

Info

Publication number
WO2023044014A1
WO2023044014A1 PCT/US2022/043816 US2022043816W WO2023044014A1 WO 2023044014 A1 WO2023044014 A1 WO 2023044014A1 US 2022043816 W US2022043816 W US 2022043816W WO 2023044014 A1 WO2023044014 A1 WO 2023044014A1
Authority
WO
WIPO (PCT)
Prior art keywords
perfusate
mixture
organex
mammal
perfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/043816
Other languages
French (fr)
Inventor
Nenad SESTAN
Zvonimir VRSELJA
David ANDRIJEVIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to CA3231611A priority Critical patent/CA3231611A1/en
Priority to JP2024516762A priority patent/JP2024535843A/en
Priority to AU2022345865A priority patent/AU2022345865A1/en
Priority to US18/690,785 priority patent/US20240373840A1/en
Priority to EP22870751.9A priority patent/EP4402242A4/en
Publication of WO2023044014A1 publication Critical patent/WO2023044014A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/142—Apparatus
    • A01N1/143—Apparatus for organ perfusion
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
    • A01N1/142—Apparatus
    • A01N1/144—Apparatus for temperature control, e.g. refrigerators or freeze-drying apparatus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time

Definitions

  • the invention provides an isolated perfusate mixture comprising: an inorganic salt solution; an artificial oxygen carrier; and autologous blood.
  • the invention provides a system for the hypothermic preservation of organs in a mammal, the system comprising: a perfusion device for the perfusion of an isolated perfusate mixture into the mammal, the perfusion device comprising: a perfusion loop; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain hypothermic conditions; and the isolated perfusate mixture as described elsewhere herein.
  • the invention provides a mammal perfused with the isolated perfusate composition as described elsewhere herein, wherein mammalian organs are perfused under hypothermic conditions.
  • the invention provides perfused organs in a diseased mammal , wherein the perfused organs maintain one or more properties selected from the group consisting of an in vivo level of cell function and viability, and an in vivo level of morphology
  • the one or more artificial oxygen carriers is selected from the group consisting of hemoglobin glutamer-250, isolated cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers.
  • the artificial oxygen carrier is hemoglobin glutamer-250.
  • the one or more inorganic salts are selected from the group consisting of sodium chloride, sodium bicarbonate, magnesium chloride, and calcium chloride.
  • the perfusate mixture comprises a priming solution containing one or more sugars.
  • the one or more sugars are glucose or dextrane.
  • the isolated perfusate mixture further comprises one or more amino acids.
  • the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L- leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L- tyrosine, L-valine and salts and solvates thereof.
  • the perfusate mixture further comprises one or more vitamins.
  • the one or more vitamins are selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i- inositol and salts and solvates thereof.
  • the perfusate mixture further comprises, ferric nitrate, magnesium sulfate, potassium chloride, sodium phosphate, and derivatives thereof.
  • the perfusate mixture further comprises an anti-clotting agent.
  • the anti-clotting agent is heparin.
  • the percentage of autologous blood in the mixture is between 10% and 50%. In certain embodiments, the percentage of autologous blood in the mixture is approximately 28%.
  • the mixture is dialyzed against a solution comprising inorganic salts. In certain embodiments, the mixture is dialyzed against plasma.
  • the mixture comprises electrolytes and oncotic agents at levels comparable to those in autologous blood.
  • the perfusate further comprises cytoprotective agents.
  • the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and/or any salts, solvates, tautomers, and prodrugs thereof.
  • the mixture further comprises antibiotics.
  • the antibiotic is ceftriazone.
  • the mixture comprises one or more anti-inflammatory agents.
  • the one or more the anti-inflammatory agents is dexamathazone or cetirizine.
  • the temperature of the mixture is approximately 28°C.
  • the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop.
  • the perfusion loop comprises a venous loop, a filtration loop and an arterial loop
  • the venous loop comprises at least one perfusion pump
  • the filtration loop comprises at least one perfusion pump, and at least one hemodiafiltration unit adapted and configured to equilibrate the perfusate
  • the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate
  • the mammal, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the mammal, through the venous loop, through the filtration loop, through the arterial loop and back to the mammal.
  • the one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate.
  • the one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate.
  • the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
  • the mammal perfusion apparatus comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of a pressure and a flow rate.
  • the one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps.
  • the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device.
  • the one or more sensors are adapted and configured to measure the temperature within the perfusion device
  • the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device.
  • the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L-Alanyl- Glutamine, L- Arginine hydrochloride, L-Cystine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Serine, L-Threonine, L- Tryptophan, L-Tyrosine, L-Valine, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i-Inositol, Calcium Chloride (CaC12-2H2O), Ferric Nitrate (Fe(NO3)3 9H2O), Magnesium Sulfate (M
  • the system is configured to perfuse the mammal with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg.
  • the system is configured to perfuse the organs in the mammal with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute.
  • system further comprises a controller in electronic communication with one or more elements of the system.
  • the mammal is a deceased mammal. In certain embodiments, the mammal is a human. In certain embodiments, the deceased mammal is deceased for longer than 1 hour. In certain embodiments, the deceased mammal has been deceased for longer than 4 hours. In certain embodiments, the mammal died of cardiac arrest.
  • the organs in the deceased mammal are ischemic prior to perfusion with the isolated perfusate mixture.
  • rigor mortis is prevented. In certain embodiments, rigor mortis is reversed.
  • the perfusate mixture flows into the ophthalmic artery.
  • the perfusate mixture flows into the renal intralobular arteries.
  • FIGS. 1 A-1G show overview of the OrganEx technology and experimental workflow.
  • FIG 1 A shows connection of the porcine body to the OrganEx perfusion system (or ECMO, not shown) via cannulation of the femoral artery and vein.
  • FIG. IB is a simplified schematic view of the OrganEx perfusion device. The system is equipped with a centrifugal pump, pulse generator, hemodiafiltration gas infusion, drug delivery systems, and sensors to measure metabolic and circulation parameters.
  • FIG.1C is a schematic of the experimental workflow and conditions.
  • FIG. ID the lid of the flow chamber that is connected to the electronic pressure regulator via an air line and the barb connector.
  • FIG. IE the bottom view of the lid showing in green space occupied by air.
  • FIG. IF the isometric view of the body, in green is the fluid path (fluid space) occupied by the mixture of autologous blood and the perfusate.
  • FIG. 1G the side view of the lid, body and the membrane that separates two parts.
  • FIGS. 2A-2E show circulation and blood/perfusate properties during the perfusion protocols.
  • FIGS. 3 A-3K show analysis of tissue integrity across experimental conditions and organs.
  • FIG. 3E are representative images of H&E staining in heart, liver, and kidney.
  • FIGS. 4A-4P show analysis of cell death across experimental conditions and organs.
  • FIGS. 4A, 4F, 4K, and 4N Representative confocal images of immunofluorescent staining for activated caspase 3 (actCASP3) and TUNEL assay in heart, liver, kidney, and brain.
  • FIGS. 4B- 4D Quantification of actCASP3 immunolabeling signal intensity in heart (FIG. 4B), liver (FIG. 4C), and kidney (FIG. 4D).
  • FIGS. 4G-4J Normalized total intensity of TUNEL signal in heart (FIG. 4G), liver (FIG. 4H), and kidney (FIG. 41).
  • FIGS. 40 and 4P Normalized total intensity of TUNEL signal in CAI (FIG. 40) and PFC (FIG. 4P). Scale bars, 50 pm. Data presented are mean ⁇ S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, NS: not significant.
  • FIG. 5A-5K depict functional characterization and metabolic activity of selected organs.
  • FIGS 5A-5C complexes in ECMO and OrganEx treated animals 3 hours into the perfusion (left); Chi-squared test was performed. Representative EKG trances in OrganEx and ECMO group 3 hours into the perfusion (right).
  • FIG. 5F Representative confocal images of immunolabeling for albumin in liver. Scale bars, 50 pm.
  • FIG. 5H Representative images of organotypic hippocampal slices after 14 days in culture. Scale bar, 500 pm.
  • FIG. 5 J Representative confocal images of newly synthesized proteins (AHA, Click-iT chemistry) with DAPI counterstaining in the long-term organotypic hippocampal slice culture. Scale bar, 100 pm.
  • FIG. 5D Observed QRS .
  • FIGS 6A-6D show organ and cell type-specific transcriptomic changes assessed by snRNA-seq across various warm ischemia intervals and different perfusion interventions.
  • Upper panels UMAP layout showing major t-types in the hippocampus (FIG.6A) , heart(FIG.6B), liver(FIG.6C), and kidney(FIG.6D).
  • Middle panels comparison of averaged Augur AUC scores across t-types indicating which cell type underwent the most transcriptomic changes;
  • Lower panels dot plots depicting P values of gene set enrichment of gene sets important in cellular recovery and specific cellular functions in major respective t-types. **P ⁇ 0.01, ***P ⁇ 0.001.
  • FIGS. 7A-7E show analysis of circulation and blood/perfusate properties after Ih of warm ischemia and perfusion interventions.
  • FIG.7A Representative fluoroscopy images of autologous blood flow (ECMO intervention, up) or a mixture of autologous blood and the perfusate (OrganEx intervention, below) in the head captured after 3 and 6 hours respectively of perfusion, showing robust restoration of the circulation in the OrganEx group.
  • a contrast catheter was placed in the left common carotid artery (CCA), except in the ECMO group at 6 hours timepoint where contrast catheter could not be advanced beyond aortic arch in to the left CCA due to pronounced vasoconstriction, thus resulting in bilateral CCA filling.
  • n 6.
  • FIG.7C Longitudinal change in arterial and venous cannula pressures throughout the perfusion demonstrating robust perfusion in OrganEx group.
  • FIG.7D Time-dependent changes in oxygen delivery and consumption demonstrating increased oxygen delivery and stable oxygen consumption over the perfusion period in OrganEx group.
  • FIG.7E Presence of classical signs of death (rigor and livor mortis) in ECMO as compared to OrganEx group at the experimental endpoint. Data presented are mean ⁇ S.E.M. Two-tailed unpaired t-test was performed. For more detailed information on statistics and reproducibility, see methods. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, NS: not significant.
  • FIGS. 8A-8L show Nissl staining and immunohistochemical analysis of the hippocampal CAI region and the prefrontal cortex (PFC).
  • FIG. 8A Representative images of Nissl staining of the CAI (up) and PFC (below).
  • FIGS. 8B and 8C Quantification of the number of cells per standardized area (FIG. 8B) and percentage of ellipsoid cells per area (FIG. 8C) in the CAI between the experimental groups.
  • FIGS. 8D and 8E Quantification of the number of cells per standardized area (FIG. 8D) and percentage of ellipsoid cells per area (FIG. 8E) in the PFC between the experimental groups.
  • FIGS. 8A Representative images of Nissl staining of the CAI (up) and PFC (below).
  • FIGS. 8B and 8C Quantification of the number of cells per standardized area (FIG. 8B) and percentage of ellipsoid cells
  • FIG. 8F and 8H Representative confocal images of immunofluorescent staining for neurons (RBFOX3/NeuN), astrocytes (GFAP), and microglia (IBA1) counterstained with DAPI nuclear stain in CAI (FIG. 8F) and PFC (FIG. 8H).
  • FIG. 8G Quantification of GFAP immunoreactivity in hippocampal CAI region depicting comparable immunoreactivity between OrganEx and Oh WIT group, with a significant increase compared to the other groups.
  • Microglia number (FIG. 8L) shows comparable results between OrganEx and Oh WIT with different dynamics seen in the ECMO group. Scale bars, 50 pm. Data presented are mean ⁇ S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, NS: not significant.
  • FIGS. 9A-9J show representative images of H&E staining across assessed peripheral organs and kidney periodic acid-Schiff (PAS) staining and immunolabeling for HACVR1 and Ki-67.
  • FIG.9A Representative images of the H&E staining in heart, kidney, liver, pancreas, and lungs. Arrows point to nuclear damage, asterisks point to disrupted tissue integrity, empty arrowheads point to hemorrhage, full arrowheads point to cell vacuolization, double arrows point to tissue edema.
  • FIGS. 9B and 9C H&E histopathological scores in lungs (FIG.9B) and pancreas (FIG.9C).
  • FIG.9D Representative images of PAS staining of the kidney. Arrows point to disrupted brush border, full arrowheads point to the presence of casts, asterisks point to tubular dilation, double arrows point to the Bowman space dilation.
  • FIG.9E Kidney PAS histopathological damage score.
  • FIG.9F and FIG.9H Representative confocal images of immunofluorescent staining for HAVCR1 and Ki-67 in kidney, respectively.
  • FIG.9G Quantification of HAVCR1 immunolabeling signal intensity.
  • FIG.9I and FIG.9J Quantification of the kidney Ki-67 positive staining.
  • HACVR1 and Ki-67 immunolabeling quantification results follow a similar pattern seen with other organs with comparable results between Oh WIT and OrganEx group and significant decrease in the 7h WIT and ECMO groups. Scale bars, 100 pm. Data presented are mean ⁇ S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P ⁇ 0.05, **P ⁇ 0.01, NS: not significant.
  • FIGS. 10A-10O show evaluation of different cell death pathways by immunohistochemical staining for important molecules in pyroptosis (IL1B), necroptosis (RIPK3) and ferroptosis (GPX4) across the experimental conditions.
  • FIGS 10A, 10F, 10K Representative confocal images of immunofluorescent staining for pyroptosis marker IL IB, necroptosis marker RIPK3, and ferroptosis marker GPX4, each co-stained with DAPI nuclear stain in CAI, heart, liver, and kidney.
  • FIGS.10B-10E Quantification of IL1B immunolabeling signal intensity in CAI (FIG.10B), heart (FIG.10C), liver (FIG.10D), and kidney (FIG.10E).
  • FIGS.10G-10J Quantification of RIPK3 positive intranuclear co-staining in CAI (FIG.10G), and immunolabeling signal intensity heart (FIG.10H), liver (FIG.101), kidney (FIG.10J).
  • FIGS.10L- 10O Quantification of GPX4 immunolabeling signal intensity in CAI (FIG.10L), heart (FIG.10M), liver (FIG.10N), and kidney (FIG.10O). Scale bars, 50 pm left and right panels.
  • FIGS. 11 A-l 10 EEG setup and recordings, click-iT chemistry and immunohistochemical analysis of factor V and troponin I.
  • FIG.l 1A Placement of EEG electrodes on the porcine scalp.
  • FIG.1 IB Representative snapshot of the EEG recordings after administration of anesthesia and before the induction of cardiac arrest by ventricular fibrillation.
  • FIG.l 1C Representative snapshot of the EEG recordings immediately following the ventricular fibrillation.
  • FIG.l ID Representative snapshot of the EEG during ECMO intervention at around 2h of perfusion protocol.
  • FIG.1 IE Representative snapshot of the EEG during OrganEx intervention at around 2h of perfusion protocol, showing a light pulsatile artefact.
  • FIGS.1 IF and 11G Representative snapshot of the EEG recordings following contrast injection at 3h in ECMO and OrganEx animals, respectively. OrganEx EEG snapshot is consistent with a possible muscle-movement artefact. GND, ground electrode; REF, reference electrode.
  • FIGS.11H and 111 Representative confocal images of AHA through Click-iT chemistry in newly synthesized proteins with DAPI nuclear stain in the long-term organotypic hippocampal slice culture in CA3 (FIG.l 1H) and DG (FIG.11 Al) subregions.
  • FIGS.11 J and 1 IK Relative intensity of nascent protein around nuclei in hippocampal CA3 (FIG.l 1 J) and DG (FIG.l IK) region showing comparable protein synthesis between OrganEx and Oh WIT up to 14 days in culture.
  • FIG.l IL Representative confocal images of immunofluorescent staining for troponin I in the heart.
  • FIG.1 IM Quantification of troponin I immunolabeling signal intensity in heart. A decreased trend in immunolabeling intensity was observed with ischemia time and a significant decrease in immunolabeling intensity in ECMO compared to the OrganEx group.
  • FIG.l IN Representative confocal images of immunofluorescent staining for factor V in liver.
  • FIG.110 Quantification of factor V immunolabeling signal intensity in liver follows a similar pattern seen with other organs with comparable results between Oh WIT, Ih WIT, and OrganEx group and a significant decrease in 7h WIT and ECMO groups. Scale bars, 50 pm. Data presented are mean ⁇ S.E.M. For more detailed information on statistics and reproducibility, see methods. *P ⁇ 0.05, **P ⁇ 0.01, NS: not significant. AU, arbitrary units.
  • FIGS. 12A-12F Quality control of snRNA-seq data in healthy and varying ischemic conditions in the hippocampus, heart, liver, and kidney.
  • a taxonomy of t-types in healthy organs and brain, heart, liver, and kidney that experienced ischemia (Ih WIT, 7h WIT, ECMO and OrganEx) were generated, representing presumptive major cell types across organs of interest.
  • Ih WIT, 7h WIT, ECMO and OrganEx a taxonomy of t-types in healthy organs and brain, heart, liver, and kidney that experienced ischemia
  • These major t-types were further subdivided into high-resolution subclusters that were transcriptomically comparable to publicly available human and mouse single-cell datasets and that were marked by distinct expression profiles.
  • FIG. 12A Bar plot showing the number of cells/nuclei across organs and biological replicates.
  • FIG. 12B Violin plot showing the distribution of the number of unique molecular identifiers - UMIs (upper panel) and genes (lower panel) detected across all biological replicates.
  • FIGS. 12C-12F respective analyses of snRNA-seq in the hippocampus (FIG. 12C), heart (FIG. 12D), liver (FIG. 12E), and kidney (FIG. 12F).
  • the left upper corner depicts detailed UMAP layout showing all t-types in the respective organs.
  • the right side depicts the expression of top t- type markers.
  • the left lower corner depicts transcriptomic correlation between the t-type taxonomy defined in this study and that of previous human and mouse datasets.
  • FIGS. 13A-13D Single-nucleus transcriptome analysis in healthy and varying ischemic conditions in the hippocampus (FIG.13 A), heart(FIG.13 B), liver (FIG.13 C), and kidney(FIG.13D).
  • FIGS.13A-13D From left to right: UMAP layout showing major t-types; UMAP layout , colored by Augur cell type prioritization (AUC) between Oh WIT compared to Ih (up) and 7h WIT (down); statistical comparison of Augur AUC scores between Oh WIT and Ih (up) and 7h (down) of WIT; Volcano plot showing top DEGs in major annotated t-types between Oh and Ih WIT (up), or Oh and 7h WIT (down); GO terms associated with the genes up and downregulated in detected nuclei between Oh and Ih WIT (up), or Oh and 7h WIT (down) with their nominal P-value in respective major annotated t-types.
  • AUC Augur cell
  • FIGS. 14A -14H show hippocampal single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions.
  • FIG.14A AUC scores of the Augur cell type prioritization between OrganEx and other groups.
  • FIG.14B Volcano plot showing DEGs in hippocampal neurons between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO.
  • FIG.14C Trajectories of hippocampal neurons. Color indicates different experimental groups.
  • FIG.14D Sankey plot showing perfusate components and violin plots showing their effects on hippocampal neurons between the OrganEx and ECMO groups.
  • FIG.14E Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left).
  • FIG.14F Expression of the genes involved in cell-death pathways in neurons.
  • FIG.14G Gene expression enrichment of the genes involved in cell-death pathways in neurons.
  • FIG.14H Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray, i, Stacked bar plot showing relative information flow for each signaling pa pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. Genes important in inflammation are highlighted gray.
  • FIGS. 15A-15H show heart single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions.
  • FIG.15 A AUC scores of the Augur cell type prioritization between OrganEx and other groups.
  • FIG.15B Volcano plot showing the DEGs in cardiomyocytes between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO.
  • FIG.15C Trajectories of hippocampal neurons. Color indicates different experimental groups.
  • FIG.15D Sankey plot showing perfusate components and violin plots showing their effects on cardiomyocytes between the OrganEx and ECMO groups.
  • FIG.15E Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left). Eigengene average expression trends exhibit distinct trends between ECMO and OrganEx groups (upper right) of modules whose enriched GO terms are predominantly related to cellular function (below) (FIG. 34).
  • FIG.15F Expression of the genes involved in cell-death pathways in cardiomyocytes.
  • FIG.15G Gene expression enrichment of the genes involved in cell-death pathways in cardiomyocytes.
  • FIG.15H Overall signaling patterns across all experimental conditions.
  • FIGS. 16A-16I show liver single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions.
  • FIG.16 A AUC scores of the Augur cell type prioritization between OrganEx and other groups.
  • FIG.16B Volcano plot showing DEGs in hepatocytes between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO.
  • FIG.16C Trajectories of hippocampal neurons. Color indicates different experimental groups.
  • FIG.16D Sankey plot showing perfusate components and violin plots showing their effects on hepatocytes between the OrganEx and ECMO.
  • FIG.16E Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left).
  • FIG.16F Expression of the genes involved in cell-death pathways in hepatocytes.
  • FIG.16G Gene expression enrichment of the genes involved in cell-death pathways in hepatocytes.
  • FIG.16H Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray.
  • FIG.16A I Stacked bar plot showing relative information flow for each signaling pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO.
  • Necro-1 necrostatin-1
  • Mino minocycline
  • DEXA dexamethasone
  • Met. B methylene blue
  • GEE Glutathione Ethyl Ester. *P ⁇ 0.05, **P ⁇ 0.01, ***P ⁇ 0.001, NS: not significant.
  • FIGS.17A- 171 show kidney single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions.
  • FIG.17 A AUC scores of the Augur cell type prioritization between OrganEx and other groups.
  • FIG.17B Volcano plot showing DEGs in PCT between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO.
  • FIG.17C Trajectories of hippocampal neurons. Color indicates pseudotime progression and different cell states, respectively.
  • FIG.17D Sankey plot showing perfusate components and violin plots showing their effects on PCT between the OrganEx and ECMO groups.
  • FIG.17E Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left).
  • FIG.17F Expression of the genes involved in cell-death pathways in PCT.
  • FIG.17G Gene expression enrichment of the genes involved in cell-death pathways in PCT.
  • PCT proximal convoluted tubule.
  • FIG.17H Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray.
  • the invention provides a novel system for restoration and preservation of an intact mammalian organs.
  • the system is capable of preserving organs in the mammalian body and restoring and maintaining cellular integrity and cellular function for hours post mortem or after global ischemia.
  • the invention also provides novel synthetic organ perfusate formulations, and methods of mixing the perfusate with blood, for example, autologous blood, derived from the mammal.
  • the invention includes surgical methods and procedures to connect the mammal to the OrganEx system.
  • the system, perfusate, and surgical method attenuate organ cell death, preserve anatomical and cellular integrity and restore cellular function as indicated by active metabolism.
  • the invention also provides means to reduce reperfusion injury, stimulate recovery from hypoxia, and metabolically support the energy needs of organ function.
  • the invention further provides methods of using the system and blood perfusate mixture, to prevent the collapse of organ vasculature and to allow for better perfusion of the organs.
  • the invention provides methods to prevent the onset of rigor mortis.
  • the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
  • hypooxic refers to a concentration of dissolved oxygen less than about 13%, corresponding to a partial pressure of about 100 mmHg, the physiologic partial pressure of oxygen in the alveoli of the lung.
  • cellular hypoxia refers to a cellular response to exposure to a hypoxic environment, often resulting in apoptosis, or cellular death.
  • anaerobic metabolism refers to the cellular consumption of glucose to produce two molecules of lactate, with the lactate remaining in dissolved in solution. The ratio of lactate produced to glucose consumed will be 2: 1.
  • the term “aerobic metabolism” refers to the cellular consumption of glucose to produce two molecules of lactate, both of which will be consumed through the Krebs cycle in the presence of sufficient levels of oxygen.
  • the ratio of lactate produced to glucose consumed will be 0: 1.
  • hypothermic refers to a body temperature substantially below normal bounds. Hypothermic temperatures include, but are not limited to, temperatures between 10° and 32° C, between 20°C and 30°C, and about 28°C.
  • salt embraces addition salts of free acids or free bases that are compounds useful within the invention.
  • Suitable acid addition salts may be prepared from an inorganic acid or from an organic acid.
  • inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric acids, perchloric and tetrafluorob or onic acids.
  • organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2- hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, b -hydroxybutyric
  • Suitable base addition salts of compounds useful within the invention include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, lithium, calcium, magnesium, potassium, sodium and zinc salts.
  • Acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding free base compound by reacting, for example, the appropriate acid or base with the corresponding free base.
  • Ranges provided herein are understood to be shorthand for all of the values within the range.
  • a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
  • rigor mortis refers to process that sets in upon the death of a mammal. Rigor mortis is characterized by stiffening of the muscles. Stiffening occurs as a result of ATP depletion. ATP is depleted in ischemic tissues where there is insufficient oxygen available for mitochondria to drive ATP formation. As a result, the bridges between actin and myosin fibers are no longer broken, causing muscle stiffness.
  • OrganEx refers to a system that consists of a perfusion system and synthetic perfusate.
  • the perfusion system consists of a computer driven custom-made pulse generator connected to a centrifugal pump, which enables reproduction of physiological pressure and flow waveforms, together with automated hemodiafiltration, gas mixer, and drug delivery systems which allow control of blood coagulation and supplementation of the perfusate.
  • the perfusion system is also equipped with sensors for electrolytes, blood gases, metabolic parameters, hemoglobin, vessels and cannulas pressures, and total circulatory flow rate.
  • autologous blood of the mammal is drained into the OrganEx system and mixed with the perfusate, which is then used to perfuse the animal.
  • ECMO refers to a clinical standard of a heart-and-lung substitution perfusion device - extracorporeal membrane oxygenation system (ECMO).
  • ECMO heart-and-lung substitution perfusion device - extracorporeal membrane oxygenation system
  • DMEM Dulbecco s Modified Eagle Medium
  • the invention provides a novel OrganEx technology and its experimental application that has the potential for recovery of key molecular and cellular processes in multiple porcine organs after prolonged warm ischemia.
  • the data presented herein demonstrate that mammalian cells are more resilient to ischemic injury than previously understood. Further, the data establish that cellular deterioration is a more protracted process that is not scripted within narrowly-defined sequences or timeframes.
  • the application of the OrganEx technology can halt the process of cell demise.
  • the application of the OrganEx technology can shift cellular states towards recovery at molecular and cellular levels.
  • the application of the present invention can shift cellular states towards recovery, even following prolonged warm ischemia.
  • the invention provides a comprehensive single-cell transcriptomic analysis of the brain and vital peripheral organs over varying warm ischemic intervals.
  • the comprehensive single-cell transcriptomic analysis of the brain and vital peripheral organs over varying warm ischemic intervals is obtained utilizing perfusion with either autologous blood, the OrganEx perfusate, or a mixture of autologous blood and the OrganEx perfusate.
  • the invention provides a transcriptome dataset and a unique resource for future basic and translational studies on cell-types, organs and ischemia.
  • the OrganEx platform and acellular perfusate connected to an intact dead mammal, provides a solution to the problem of ischemic stress in tissue culture and isolated organs.
  • the invention provides a means to reinstate circulation and systemic metabolic parameters across multiple organs in an intact animal.
  • the invention provides for the removal of deleterious processes and lack of oxygen, crucial for the control of multiple non-specific injury mechanisms affecting end-organ recovery and overall prognosis after global ischemia.
  • the invention facilitates or enables repair responses at the molecular and cellular level in several or all organs.
  • the repair at the molecular and cellular level translate to processes supporting recovery of organs.
  • recovery of organs last for an extended period of time.
  • rigor mortis can be prevented in an animal following warm ischemia.
  • rigor mortis can be reversed.
  • dead spots in the heart can be prevented.
  • electrical activity can be measured in the heart.
  • contractile activity can be measured in the heart.
  • electrical activity can be measured in the brain.
  • the movements can be initiated in the animal.
  • the animal may regain consciousness.
  • the animal may regain the ability to move.
  • enduring effects on cellular recovery post perfusion occurs in slices from the tissue most susceptible to ischemia, the hippocampus.
  • long term in vivo recovery of the hippocampus, and other organs is observed at the organ level.
  • long OrganEx perfusions of the whole-body can prevent organs from undergoing ischemic injury.
  • long OrganEx perfusion can lead to recovery of vital organs, including the brain, the hearth, the kidney, the pancreas, or the liver.
  • the OrganEx technology can be used in combination with mammals that are still alive.
  • the live mammal is a human.
  • the live mammal being treated has experienced a stroke or a heart attack prior to perfusion with the blood perfusate mixture.
  • the human recovers and/or recovers more quickly from the stroke or the heart attack.
  • the invention preserves and recovers brain function.
  • the recovery from ischemic injury in the brain is measurable by magnetic resonance imaging (MRI).
  • MRI magnetic resonance imaging
  • long OrganEx perfusion can be applied to the mammal, e.g., a human, following a cardiac event, e.g., a heart attack.
  • the invention preserves and recovers heart function.
  • the mammal recovers and/or recovers more quickly from the heart attack.
  • the recovery from ischemic injury in the heart is measurable with an electrocardiogram (EKG).
  • EKG electrocardiogram
  • death of a mammal may be reversed.
  • the technology provides for new avenues for whole-body global ischemia research.
  • the invention provides a means to conduct clinical resuscitation science or transplantation medicine.
  • the invention provides for larger donor organ pools by recovering previously marginalized organs.
  • the invention includes a novel perfusion composition for the preservation of organs in the mammalian body.
  • the perfusion composition can be used to preserve organs in a mammal after warm ischemia.
  • the blood perfusate mixture can preserve the brain, the liver, lung, heart, pancreas, kidney, and the like.
  • the perfusion composition is a perfusate comprising a solution comprising one or more artificial oxygen carrier compounds and one or more compounds selected from the group consisting of anti-cytotoxic compounds, antioxidants, anti-inflammatory compounds, antiepileptic compounds, anti-apoptotic compounds, antibiotics, cell death inhibitors, neuroprotectants and oxidative/nitrosative stress inhibitors.
  • the perfusate comprises priming solution.
  • the priming solution comprises sodium chloride, sodium bicarbonate, magnesium chloride, calcium chloride, glucose and dextrane.
  • concentrations of the components in the priming solutions is as shown in Table 1.
  • the perfusate comprises hemodiafiltration exchange solution.
  • the hemodiafiltration exchange solution comprises one or more amino acids selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L- threonine, L-tryptophan, L-tyrosine, L-valine and salts and solvates thereof; one or more vitamins selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i-inositol and salts and solvates thereof; and one or more inorganic salts selected from the group consisting of calcium chloride, ferric nitrate, magnesium sulfate
  • the perfusate contains hemoglobin glutamer-250 (Hemopure ® (HBOC-250)) or an alternative oxygen carrier, one or more cytoprotective agents selected from Hexahydro-2-imino-lH-thieno[3,4-d]imidazole-4-pentanoic acid (2-Iminobiotin), 5-(lH-Indol-3- ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone (Necrostatin-1), Sodium 3 -Hydroxybutyric Acid, Glutathione Monoethyl Ester, Minocycline, Lamotrigine, 5-(2,6-Difluorophenoxy)-3-[[3- methyl-l-oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate (QVD-Oph), Methylene Blue, and one or
  • the perfusate comprises one or more artificial oxygen carrier compounds.
  • the one or more artificial oxygen carrier compounds are hemoglobin derivatives.
  • the hemoglobin derivatives can be one or more compounds selected from the group consisting of isolated, cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin and functionalized hemoglobin.
  • the artificial oxygen carrier compound can be hemoglobin glutamer-250 ( HEMOPURE®), a cross-linked hemoglobin tetramer comprising two alpha hemoglobin and two beta hemoglobin subunits cross-linked by a carbon linker.
  • the one or more artificial oxygen carrier compounds can be artificial red blood cell substitutes, such as ERYTHROMERTM, PolyHeme, Oxyglobin, PolyHb-SOD-CAT-CA, PolyHb-Fibrinogen, Hemspan or MP4.
  • the artificial oxygen carrier compound can be any blood substitute compound known in the art.
  • the perfusion composition comprises one or more compounds selected from the group consisting of anti-cytotoxic compounds, antioxidants, anti-inflammatory compounds, antiepileptic compounds, anti-apoptotic compounds, antibiotics, cell death inhibitors, neuroprotectants and nitrite stress inhibitors.
  • the perfusion composition comprises at least one imaging contrast agent.
  • the perfusion composition further comprises one or more ultrasound contrast agents, that also can be used under certain ultrasound settings as clot disintegrator and blood-brain barrier opener.
  • the one or more ultrasound contrast agents can be micrometer-sized air-filled polymeric particles.
  • the perfusion composition comprises at least one MRI contrast agent or CT contrast agent.
  • the perfusion composition comprises one or more compounds selected from the group consisting of the compounds of Tables. 1-3, or salts, solvates, tautomers, and prodrugs thereof.
  • the invention provides a novel system for in situ hypothermic preservation of organs in a mammalian body.
  • the invention provides a system for the hypothermic, in situ preservation system, the system comprising: a perfusion device for the perfusion of a mammalian body, comprising a means for regulating the temperature, flow, pressure, dissolved gases, and concentration of metabolites in the system; and the perfusate composition of the invention.
  • the means for regulating the temperature of the system comprises a controller programmed to regulate at least a perfusate temperature within the system to maintain hypothermic conditions.
  • the means for regulating the flow, pressure, dissolved gases, and metabolite concentrations in the system comprises a controller programmed to regulate these parameters within the system to maintain constant or alterable 1 evel s/ concentrati ons .
  • the system is configured to introduce oxygen to a perfusate of the invention and circulate the perfusate through mammal.
  • the perfusion unit is adapted and configured to introduce oxygen and carbon dioxide to the perfusate.
  • the perfusion unit is adapted and configured to dialyze the perfusate.
  • the system comprises an intrarenal arterial cannula, an animal input line, a pressure sensor, a flow sensor, a pulse generator, an arterial oxygenator, an exchange solution, one or more roller pumps, a hemodiafiltration membrane, one or more reservoirs with perfusate drugs, one or more perfusate reservoirs, a pressure senor, a centrifugal pump, a hemoglobin sensor a return line from the mammal.
  • the electronic components of the perfusion system are built in a modular manner.
  • Each sensor, motor or electronic component that requires external control has a separate logical controller built on chicken Uno platform, local circuits and software.
  • Each logical controller has a serial output and input and is connected via com port to the computer.
  • the computer has modulus, scripts and functions written in Python that either control or collect data from these logical controllers.
  • the pulse generator consists of (1) 3D printed flow chamber (fluid space for blood/perfusate passage, and air space that is separated by a membrane from the fluid space and can change volume against fluid space) connected to the main circuit, downstream from the centrifugal pump, (2) high resolution electronic pressure regulator (0-10 PSI) which is connected to the air source on one end and to the flow chamber on the opposite end, (3) logical controller regulating electronic pressure regulator, (4) and a computer with control software.
  • the Logical controller is made out of chicken Uno microprocessor board and has a DAC converter (MCP 4725) with an operational amplifier (LT1215 CN8); it produces continuous analog output (0-10V) for electronic pressure regulator.
  • Logical controller has a script which runs the electronic pressure regulator, based on sinusoidal function, and it can receive input from a computer via serial port to regulate variables within sinusoidal function (e.g. amplitude, iteration/looping speed, baseline value).
  • sinusoidal function e.g. amplitude, iteration/looping speed, baseline value.
  • continuous output is produced and sent to the electronic pressure regulator which then controls flow chamber volume, by moving a membrane which separates fluid space from the air space, thus producing pulsatility and oscillations in venous and arterial pressures throughout the perfusion system.
  • Computer is connected to the logical controller, and custom-made scripts in Python allow for manual or automatic control.
  • the software also monitors flow and pressure in the arterial and venous cannula and stores the data.
  • the automated hemodiafiltration system consists of (1) two peristaltic pumps which have separate logical controllers and are connected via serial ports to the computer, (2) liquid level solid-state sensor with a resistive output (0-5V), in a clear, elliptical polycarbonate tube integrated with logical controller, for monitoring fluid level in exchange solution canister, connected to the computer.
  • Logical controllers for peristaltic pumps and level sensor have custom made scripts which allow for higher-order language control.
  • the computer governs two peristaltic pumps and collects data from the sensor via Python script. The script performs proportional control over peristaltic pumps and allows for continuous dialysis while keeping the animal euvolemic.
  • the invention provides methods of preserving organs in the mammalian body.
  • the organs are perfused with a solution comprising a priming solution, a hemodialysis solution and a solution comprising pharmacological components.
  • the constituents and concentrations of the components in the priming solution, hemodialysis solution and solution comprising the pharmacological components are as shown in Tables 1-3.
  • the mammalian body is perfused with a mixture of the perfusate and autologous blood.
  • the autologous blood is mixed with any of the components of the perfusate solution before perfusion of the mammalian body.
  • one or more artificial oxygen carriers are present in the mixture.
  • the mammalian organs maintain morphofunctional integrity under hypothermic conditions after perfusion with the blood perfusate mixture.
  • the organs in the mammal are ischemic prior to perfusion with the blood perfusate mixture.
  • the organs are perfused while the mammal is still alive. In other embodiments, the organs are perfused immediately upon death of the mammal. In other embodiments, there is a 20 minute delay between death and perfusion of the organs. In other embodiments, the time between death and perfusion is at least one hour. In other embodiments, the time between death and perfusion is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.
  • the perfused organs are organs that can be transplanted from one mammal to another, including, but not limited to the kidney, the pancreas, the heart, the lung, the intestine, the corneas, the middle ear, bone, bone marrow, heart valves, connective tissue, skin, uterus, muscles, blood vessels, nerves and connective tissue.
  • the organs are removed from the mammal following perfusion with the blood perfusate mixture.
  • perfusion with the blood perfusate mixture helps maintain an in vivo rate of cellular metabolism and preserves functional responses of cells.
  • the blood perfusate perfused organs can maintain longer viability than organs perfused with the ECMO system.
  • the perfused organs belong to any mammal.
  • Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Mammals can also include primates, including humans. In certain embodiments, the perfused mammal is a human.
  • rigor mortis is prevented by perfusion of the deceased mammal.
  • perfusion of the deceased mammal with the technologies described herein prevents stiffening of the muscles.
  • the tissues in the perfused mammal continue or regain the consumption of.
  • the tissues in the perfused mammalian continue or regain the ability to produce ATP.
  • the perfusion system consists of the main closed-loop circuit directly connected to an animal, and it includes a centrifugal pump (Medtronic Bio-Console 560, Medtronic, Minneapolis, MN) that drives the mixture of autologous blood and OrganEx perfusate through the oxygenator (Affinity Fusion, Medtronic), and custom-made pulsatility generator into animal arterial system.
  • the oxygenator is connected to a refrigerated bath (Polystat, Cole-Parmer, Niles, IL) for temperature control and the gas blender (Sechrist Industries, Anaheim, CA), for control of dissolved gases and anesthesia infusion.
  • the perfusion system has a fluid reservoir, which is used to prime the system and hold the supplement fluid.
  • an automated hemodiafiltration system and a reservoir are connected to the main circuit (FIG. IB).
  • the automated hemodiafiltration system is used to exchange plasma fraction against custom-made dialysis exchange solution.
  • the hemodiafiltration system consists of a roller-pump (Cobe Shiley, Stockert, Lake wood, CO), dialyzer (Diacap Pro 13H, Braun, Melsungen, Germany) and two peristaltic pumps (Masterflex L/S, Cole-Parmer) integrated with level sensor (eTape, Milone Technologies, Sewell, NJ) and custom-made logical controller.
  • Two infusion pumps (Sigma Spectrum, Baxter Healthcare Corporation, Deerfield, IL) are connected to the arterial side of the main circuit supplementing heparin and pharmacological compounds of the perfusate.
  • the CDI blood parameter module and the hematocrit/oxygen saturation probe (Terumo Cardiovascular Systems Corp., Elkton, MD) are connected on the arterial and venous side, respectively, along with pressure (PendoTECH, Princeton, NJ) and flow sensors (Bio-Probe TX50, Medtronic).
  • OrganEx perfusion system components, logical controllers and sensors are connected to a computer for automated control and data gathering. Detailed schematics available upon request.
  • the OrganEx perfusate is a final mixture of a custom-made priming solution (Table 1), Hemopure (HbO2 Therapeutics, Waltham, MA), custom-made dialysis exchange solution (Table 2) and the solution of pharmacological compounds (Table 3). Table 1. Components of the priming solution
  • the OrganEx perfusion system prior to connecting an animal, the OrganEx perfusion system is flooded and primed with 2200 mL of custom-made priming solution (5000 mL), followed by infusion of 1000 mL of Hemopure into the system. These solutions are left to mix and equilibrate throughout the perfusion system, after which 600 mL is extracted from the perfusion system to achieve desired concentrations of electrolytes and oncotic agents in the perfusion system and prepare it for addition of the autologous blood.
  • custom-made priming solution 5000 mL
  • Hemopure Hemopure
  • animal femoral vessels Prior to initiation of the perfusion protocol, animal femoral vessels are cannulated and connected to the main circuit. At 30 minutes of WIT, 5 000 USP units of heparin (Sigma- Aldrich, St Louis, MO) is administered into the system, followed by approximately 1000 mL of venous blood from the dead animal, which is drained into the perfusion system. At this point, circulatory volume in the OrganEx perfusion system is approximately 3600 mL, out of which 2600 mL is the priming solution and 1000 mL of autologous blood.
  • heparin Sigma- Aldrich, St Louis, MO
  • the mixture of the perfusate and autologous blood is left to equilibrate, and counter dialyzed against the residual priming solution over 30 minutes to allow for correction of metabolic derangements in the drained venous blood.
  • approximately 1600 mL of fluid is filtered out of the perfusion system over 30 minutes while the residual fluid is cooled to 28°C, yielding a final volume of 2000 mL in the OrganEx perfusion system.
  • 1000 mL of the perfusate and autologous blood mixture is infused back into the animal, ensuring circulatory system filling following venous drainage, and the perfusion protocol is initiated. The remaining 1000 mL of the mixture is stored in the reservoir and used for fluid supplementation, if required.
  • OrganEx perfusion system utilizes automated hemodiafiltration circuit which corrects and maintains certain metabolic and electrolyte parameters by performing 1 :1 (vol: vol) exchange of solutes and particles smaller than 40 kDa against a custom dialysis exchange solution (20,000 mL), while maintaining euvolemia. Hemodiafiltration flux was kept at 30-35 mL/kg/hr throughout 6-hour perfusion.
  • the ECMO perfusion system was assembled according to clinical standard.
  • ECMO perfusion system has the main closed-loop circuit directly connected to an animal and consists of a centrifugal pump (Bio-Console 560, Medtronic) that drives autologous blood through the oxygenator (Affinity Fusion, Medtronic) into animal arterial system.
  • the oxygenator is connected to a refrigerated bath (Polystat, Cole-Parmer) for temperature control and the gas blender (Sechrist Industries), for control of dissolved gases and anesthesia infusion.
  • the perfusion system has a fluid reservoir, which is used to prime the system and hold the supplement fluid.
  • ECMO perfusion system contained the CDI blood parameter module, and the hematocrit/oxygen saturation probe (Terumo Cardiovascular Systems Corp.) are connected on the arterial and venous side, respectively, along with pressure (PendoTECH) and flow sensors (Bio-Probe TX50, Medtronic). All probes and sensors from the ECMO perfusion system are connected to a computer to allow data gathering. Detailed schematics available upon request.
  • the ECMO perfusion system is primed with 1000 mL 0.9% Sodium Chloride (Baxter Healthcare Corporation, Deerfield, IL) and 5000 USP units of heparin (Sigma- Aldrich). Upon initiation of the perfusion protocol, the reservoir is taken out of the main circuit and the residual priming solution is stored for later supplementation. Animal anesthesia and surgical protocol
  • Cardiac arrest and subsequent circulatory collapse were induced by ventricular fibrillation through the substernal window by applying a 9V battery to the myocardial wall.
  • animals Prior to the ventricular fibrillation, animals received 7 000 USP units of heparin (Sigma- Aldrich).
  • heparin Sigma- Aldrich
  • an incision was made in the right inguinal region exposing femoral artery and vein (FIGS.1 A-1G). Both, arterial and venous cannulas were inserted into femoral artery and vein, respectively.
  • Artery was cannulated with 14 Fr and the vein with 19 Fr cannula (Edwards Lifesciences LLC, Irvine, CA). The tip of the venous cannula was placed in the inferior vena cava opening of the right atrium, and arterial cannula was positioned inferior to renal arteries.
  • Targeted arterial pressure was set to 50-80 mmHg, and it was controlled with phenylephrine, not more than 2 mg/hr.
  • flow rate was gradually increased over 25 minutes, targeting flow rates and arterial pressures as in the OrganEx group.
  • Ringer’s lactate (Baxter Healthcare Corporation) was used as a supplementation fluid at 3-4 ml/kg/hr.
  • ECMO and OrganEx group hypothermic perfusion protocol at 28°C was utilized throughout the entire 6- hours of the perfusion protocol.
  • Electrocardiogram (EKG) assessment was done with 4 leads placed at each corner of the trunk. Real time arterial and central venous pressure monitoring was done through cutdown of the brachial artery and jugular vein, respectively. Urine output was measured via Foley catheter. Animal core temperature was continuously monitored with a rectal probe. Monitoring of EKG, pressure and temperature was done utilizing Philips IntelliVue MP50 (Philips, Eindhoven, NL). During the preoperative procedure temperature was kept at 37°C using a heating pad, which was turned off following ventricular fibrillation. Electroencephalogram (EEG) was monitored with Natus long-term monitoring (LTM) system and EMU40 breakout box (Natus Medical Inc., San Carlos, CA).
  • Imaging of the abdominal and head blood vessels was performed using Philips Allura Xper FD20 system.
  • baseline physiological imaging was performed prior to the induction of ventricular fibrillation in both ECMO and OrganEx experimental protocol.
  • the contrast-injecting catheter was introduced through the femoral artery cutdown and positioned in suprarenal aorta for renal and in the common carotid artery for brain imaging.
  • Omnipaque Contrast 350 mg/mL (General Electric Inc., Boston, MA), 24 mL and 45 mL were introduced utilizing Medrad power injector (Bayer Vital GmbH, Leverkusen, Germany) for brain and kidney imaging acquisition. Following baseline imaging, all animals underwent additional fluoroscopy at hour 3 of perfusion.
  • Perfusion dynamics were monitored via Triplex Ultrasonography (Spectral Doppler, Colour Doppler, and B-mode) using the LOGIQe portable ultrasound system (General Electric) and an 8L-RS linear array probe (General Electric). In all assessed animals, left ophthalmic artery, common carotid artery and intrarenal arteries were used to profile perfusion dynamics. Power waveform analysis was done using Frq 4.4 MHz, Gn 17, SV 2 and DR 40.
  • regions of interest were extracted from each organ and frozen at -80 °C. To ensure consistency between the specimens, all dissections were performed by the same person. Cell nuclei isolation from each organ (brain, heart, liver, kidney) were treated the same according to our already established protocol with some modifications in order to acknowledge each organ’s specific structural qualities and to have identical buffers to enable inter-organ comparison within the same experimental animal. To avoid experimental bias nuclei isolation was done by the same person blinded for the replicates of experimental conditions. Furthermore, to randomly and fully represent the full tissue section, each tissue was pulverized to fine powder in liquid nitrogen with mortar and pestle (Coorstek, Golden, CO). All reagents were molecular biology grade and sourced from Sigma unless stated otherwise.
  • pulverized tissue Small amounts of pulverized tissue (5-10 mg) were then added into 1 ml of ice-cold lysis buffer (“Buffer A” is 250 mM sucrose, 25 mM KC1, 5 mM MgCh, lOmM NaCl, 10 mM Tris-HCl (pH 7.4), protease inhibitors w/o EDTA (Roche), RNAse inhibitor (80 U/ml) (Roche), ImM DTT, 1% BSA (m/v) (Gemini Bio-Products, Woodland, CA), 0.1% NP-40 (v/v), 0.1% Tween-20 (v/v) (Bio-Rad), 0.01% Digitonin (m/v) (Thermo-Fisher, Cleveland, OH).
  • Buffer A is 250 mM sucrose, 25 mM KC1, 5 mM MgCh, lOmM NaCl, 10 mM Tris-HCl (pH 7.4),
  • TX-100 0.1% TX-100 (v/v) was additionally added. DTT, RNAse Protector, protease inhibitors, and all detergents were added immediately before use. The suspension was transferred to 2ml Dounce tissue homogenizer and lysed with constant pressure and without introduction of air with pestle A (30x) and pestle B (30x). The homogenate was strained through pre-wetted 40 pm tube top cell strainer (Thermo-Fisher). All subsequent centrifugation was performed in a refrigerated, bench-top centrifuge with swing-out rotor (Eppendorf, Hamburg, Germany).
  • Heart lysate was centrifuged at 100g for 5 min at 4°C, pellet of myofibrils and non-dissociated connective tissue was discarded, and supernatant saved. All lysates (brain, liver, kidney) and heart supernatant (post 100g) were centrifuged at 1000g, 10 min, 4 °C, pellets were saved, and resuspended in 0.4 ml resuspension buffer (“Buffer B” is “Buffer A” w/o detergents).
  • the tubes were then centrifuged at 3000g, for 30 min at 4°C. Following centrifugation, the supernatant was removed and total of 1 ml of wash buffer (“Buffer D” is 25 mM KC1, 5 mM MgC12, lOmM NaCl, 10 mM Tris-HCl (pH 7.4), RNAse inhibitor (80 U/ml), 1 mM DTT, 1% BSA (m/v), 0.1% Tween 20 (v/v), in DPBS (w/o Ca2+ and Mg2+) (Gibco) )was added in tubes and centrifuged at 1000g, for 10 min at 4 °C.
  • Buffer D is 25 mM KC1, 5 mM MgC12, lOmM NaCl, 10 mM Tris-HCl (pH 7.4), RNAse inhibitor (80 U/ml), 1 mM DTT, 1% BSA (m/v), 0.1% Twe
  • Sequencing reads were aligned to the reference pig genome (susScrl 1) with the combined exon-intron gene annotations from NCBI RefSeq using CellRanger 5.0.1. pipeline, which also performed UMI counting, barcode counting and distinguishing true cells from background.
  • the filtered count matrices were then moralized by library size using the “NormalizeData” function in Seurat.
  • feature selection was first performed for each batch and the features from the same conditions were summarized using “SelectlntegrationFeatures”. The union of the highly variable genes across conditions were then passed to the data integration pipeline in Seurat to generate a batch-corrected expression matrix.
  • the cluster markers were calculated using “FindMarkers” function and manually removed the doublet clusters that showing high expression of markers of two different type of cells. To gain more accurate cell annotations and clearer UMAP visualizations, the same pipelines of data integration, dimension reduction and cell clustering were reperformed on the filtered data.
  • the cell type classification for hippocampus data was based on the gene markers derived from recent data in adult human hippocampus and entorhinal cortex. The cells were initially classified into several major groups based on marker gene expression: excitatory neurons (SLC17A7+), inhibitory neurons (GAD1+), oligodendrocyte progenitor cells (PDGFRA+), oligodendrocytes (PLPl+ astrocytes (AQP4+ microglia (PTPRC+), vascular cells (COL1A1+). Because of the high heterogeneity present in excitatory and inhibitory neuron populations, these two populations were further subclustered.
  • excitatory neurons For excitatory neurons, they were classified to mature granule cells (PROX1+), mossy cells (ADCYAP1+), CA2-4 excitatory neurons (FREM1+IGALNT3+), CAI and subiculum excitatory neurons (SATB2+IBCL11B+ITLE-), entorhinal cortex upper layer (CUX2+) and deep layer (TLE4+) excitatory neurons.
  • PROX1+ mature granule cells
  • ADCYAP1+ ADCYAP1+
  • CA2-4 excitatory neurons FREM1+IGALNT3+
  • CAI and subiculum excitatory neurons SATB2+IBCL11B+ITLE-
  • CUX2+ entorhinal cortex upper layer
  • TLE4+ deep layer excitatory neurons.
  • inhibitory neurons they were classified based on their developmental origins, either derived from medial ganglionic eminence (MGE, LHX6+) and caudal ganglionic e
  • the heart data (FIG. 12D) was annotated based on the gene markers derived from recent data in adult human heart.
  • the endothelial cells have two subgroups that have differential expression of FWF and TBX1. Immune cells were further classified to myeloid cells (BANK1+/C1QA+) and lymphoid cells (SKAP 1+/CD8A+).
  • the kidney data (FIG.12E) was annotated based on the gene markers derived from recent data in adult human kidney.
  • the liver data (FIG.12F) was annotated based on the gene markers derived from recent data in adult mouse liver.
  • the cells were classified based on marker expression: hepatocytes (APOB+/PCK1+), stellate cells (RELN+/ ACTA2+), cholangiocytes (CFTR+/PKHDl+ ⁇ immune cells (PTPRC+), endothelial cells (FLT1+/PECAM1+).
  • the immune cells were further classified to multiple subgroups: B cells (MS4A1+), plasma cells JCHAIN+!MZBl+ natural killer cell and T cells (SKAP1+), myeloid cells (CD163+/EMR4+, which are predominantly Kupffer cells).
  • FindMarkers function from Seurat was used to determine marker genes for high resolution clusters. P-value adjustment is performed using Bonferroni correction with the cutoff set at 0.05. Top 10 genes for each cluster were ranked by fold changes and were visualized on a heatmap by using DoHeatmap function (Seurat). The dataset was randomly sampled to have 1000 cells per condition for each t-type prior to differential expression analysis.
  • Augur was applied to prioritize the cell types between each pair of conditions. Since there are three samples per condition, the Augur analysis was performed on all of the nine sample pairs in each condition pair using the high-resolution cell clusters identified via Seurat. The median of the calculated area under curve (AUC) scores of each cluster were then visualized on the UMAP layout. Comparison of the AUC scores for each specific cell type and a given condition pair were done by comparing the specific cell type of interest AUC score and AUC scores of all the other cell types in that given condition pair by using Wilcoxon Rank Sum test (one tailed).
  • DEGs differentially expressed genes between OrganEx and other conditions (Oh PMI, Ih PMI, 7h PMI, ECMO) in major cell-types for each organ Seurat “FindMarkers” function was used.
  • DEGs were defined at cut-off criteria of adjusted P-value (Bonferroni) ⁇ 0.05, expression ratio greater than 0.1 in one condition and average log2 fold change (log2FC) greater than 0.2 in the same condition.
  • Top 15 DEGs ranked by absolute values of log2FC, were visualized using Bioconductor EnhancedVolcano package.
  • Top 100 DEGs were used for HumanBase Functional Module Detection. Gene symbols starting with ma and LOC were excluded since HumanBase Functional Module Detection does not recognize those gene symbols.
  • Identifying enriched biological pathways between OrganEx and all other groups in major cell-types for each organ was performed using “enrichGO” function from clusterProfiler. Multiple testing was adjusted by false discovery rate (FDR) with the cutoff set at 0.2. Top 15 biological processes ranked by P-value were visualized by in-house made ggplot2 script.
  • gene set enrichment analysis was performed in hippocampal neurons, astrocytes and microglial cells, cardiomyocytes in the heart, hepatocytes in the liver and proximal convoluted tubule cells in the kidney. This method is commonly used in Gene Ontology enrichment analysis and has been widely applied in multiple published studies. Specifically, all the expressed genes (expressed in at least one cell) were set as the gene universe and considered each set of condition-enriched genes as a sampling from the gene universe.
  • a specific condition e.g., Oh WIT, Ih WIT, 7h WIT, ECMO and OrganEx
  • the gene set enrichment performed by Hypergeometric test (also named one- tailed Fisher’s Exact test), is an assessment of whether genes from a given gene sets are overrepresented in condition-enriched genes than drawing from the gene universe by chance.
  • Hypergeometric test also named one- tailed Fisher’s Exact test
  • DE differential expression
  • Seurat FindMarkers function Seurat FindMarkers function.
  • one condition group was taken, its expression profiles were compared with the rest of the conditions using Wilcoxon Rank Sum test. For any given comparison, genes with false discovery rate (FDR) smaller than 0.01 were considered statistically significant and were kept.
  • Cardiomyocytes in heart were tested for Cardiac Muscle Cell Action Potential (GO: 0086001), Fatty Acid Beta-Oxidation (GO: 0006635) and Glycolysis (G0:0006096) as can be seen in FIG.6B.
  • FIG.6C Hepatocytes enrichment of acute phase reactants and all expressed CYP isoforms (FIG.6C) were tested in, and at last, proximal tubule cells in the kidney were tested for injury molecule genes and PCT transporter genes (FIG.6D).
  • the top differential expressed genes for all the paired conditions were identified: Oh vs Ih, Oh vs 7h, Oh vs ECMO, Oh vs OrganEx, Ih vs 7h, Ih vs ECMO, Ih vs OrganEx, 7h vs OrganEx, and ECMO vs OrganEx using FindMarkers() function in Seurat.
  • significant DEG was selected with average log2FC greater than 0.5 or less than -0.5.
  • the top 50 upregulated genes were merged with 50 downregulated differentially expressed genes (DEGs, in total 100 genes) from each paired condition for the following analysis.
  • TopGO the gene ontology analysis was performed for the genes in each module, and used fisher’s exact test to calculate the P values.
  • heart, kidney and liver the same methods with hippocampal data to select the genes were used.
  • To keep the numbers of selected gene are comparable with hippocampus samples significantly DEG with average log2FC greater than 0.75 or less than -0.75 in heart data, significantly DEG with average log2FC greater than 1.00 or less than -1.00 in kidney data and selected significantly DEG with average log2FC greater than 1.75 or less than -1.75 in liver data.
  • Then the same setting was used to build the gene expression network using hierarchical clustering.
  • the scaled eigengenes of each module was plotted and used the same method (TopGO) for gene ontology analysis.
  • the monocle2 was used and in-house R scripts to conduct pseudotime analysis for hippocampus, heart, liver, and kidney.
  • the recommended analysis protocol was followed, except using FindMarkers function from Seurat package to perform pairwise comparison across different conditions to find the statistically significant up- and down-regulated genes.
  • Some parameters were customized based on computational permutation. For examples, it was required that minimum percentage of expressed cells for each gene in either condition is larger than 0.1, and fold change larger than 1.25. Maximum number of cells in either condition was down sampled to 1000 cells to balance the comparison. Consequently, the identified differentially expressed genes by Seurat were used as the informative genes to order cells using setOrderingFilter function from monocle2, and the advanced nonlinear reconstruction algorithm called DDRTree was chosen to execute data dimensional reduction.
  • Cell-cell communication analysis Cell-cell interactions based on the expression of known ligand-receptor pairs in different t-types were inferred using CellChat (v.1.1.3). The official CellChat workflow was followed for analyzing multiple datasets (Oh WIT, Ih WIT, 7h WIT, ECMO and OrganEx). each dataset was first randomly down sampled to 1000 cells per t-type to to balance the comparison. Next, normalized counts were loaded into CellChat. After that, CellChatDB human database was selected for cell-cell communication analysis. The preprocessing was then applied as functions identifyOverExpressedGenes and identifyOverExpressedlnteractions with standard parameters set. Next, communication probability was computed between interacting cell groups with truncated mean set at 0.1.
  • the monocle2 and in-house R scripts were used to conduct pseudotime analysis for all major organs, including hippocampus, heart, liver, and kidney.
  • the recommended analysis protocol was followed, except using FindMarkers function from Seurat package to perform pairwise comparison across different conditions to find the statistically significant up- and down- regulated genes.
  • Some parameters were customized based on computational permutation. For examples, it was required that minimum percentage of expressed cells for each gene in either condition is larger than 0.1, and fold change larger than 1.25. Maximum number of cells in either condition was down sampled to 1000 cells to balance the comparison. Consequently, the identified differentially expressed genes by Seurat were used as the informative genes to order cells using setOrd eringFilter function from monocle2, and the advanced nonlinear reconstruction algorithm called DDRTree was chosen to execute data dimensional reduction.
  • Tissue sections were imaged using an LSM880 confocal microscope (Zeiss; Jena, Germany) equipped with a motorized stage using 10x (0.3 NA) or 20* (0.8 NA) objective lenses with identical settings across all experimental conditions.
  • Lasers used argon 458, 488, and 514; diode 405; and DPSS 561-10.
  • the DPSS 561-10 laser intensity was increased during imaging of the control perfusate samples for the intravascular hemoglobin fluorescence study in order to obtain a background signal comparable to other groups. Images were acquired at either 1,024 x 1,024 or 2,048 x 2,048-pixel resolution.
  • Images are either representative confocal tile scans, high-magnification maximum intensity Z-stack projections (approximately 7-9-pm stacks; ⁇ 1 pm per Z-step), or high magnification confocal images.
  • histological images were acquired using an Aperio CS2 Pathology Slide Scanner (Leica; Wetzlar, Germany) as described above. Image adjustments were uniformly applied to all experimental conditions in Zeiss Zen. Digitized images were assembled in Zeiss Zen, ImageScope, and Adobe Illustrator.
  • Criteria for heart were nuclear damage, myocyte vacuolization, widened spaces between myofibers and edema.
  • Criteria for lungs were nuclear damage, pneumocyte vacuolization and hemorrhage.
  • Criteria for kidney were nuclear damage, tubule vacuolization, hemorrhage, and tubule damage.
  • Criteria for liver were nuclear damage, tissue vacuolization, hepatocyte vacuolization, and congestion.
  • Criteria for pancreas were nuclear damage, cell vacuolization, hemorrhage, edema.
  • Kidney periodic acid-Schiff (PAS) staining - pathology injury score Kidney periodic acid-Schiff (PAS) staining - pathology injury score.
  • GFAP+ cells labeled astrocytes
  • IBA1+ cells microglia cells
  • the particle analysis of astrocytes was performed using a custom pipeline in the open-source software, CellProfiler56, where a uniform threshold was set on GFAP to identify GFAP+ skeleton objects. The number of GFAP+ fragments in each area were then auto-counted and averaged according to the number of the astrocytes.
  • the mean intensity of NeuN per neuron were quantified by a custom pipeline where neurons were identified based on the DAPI segmented objects expressing NeuN. Data were analyzed and plotted in GraphPad Prism9 software. All data are shown as mean ⁇ SEM. “n” refers to the number of biological replicates.
  • actCASP3+ cell intensity was quantified manually by a blinded observer using ImageJ.
  • Mean immunolabelling intensity of IL1B, RIPK3 and GPX4 in kidney, liver and heart was quantified using ImageJ with background subtraction and measure functions.
  • the number of actCASP3+ and RIPK3+ cells were counted manually in the hippocampal CAI region and prefrontal cortex.
  • Expression of IL IB and GPX4 in hippocampal CAI was measured in cells that were manually selected in the granule cell layer using ImageJ measure function. TUNEL quantification and analysis.
  • the images were acquired immediately using widefield microscope (Zeiss) under 2.5x objective (Ex: 465-495 nm, Em: 5210-560 nm) with exposure time of 295 ms (kidney and heart) and 50 ms (cerebral cortex). Images were analyzed using Imaged to quantify the mean intensity of the ROI with normalization based on the fixed controls.
  • Hippocampal slices were then collected and transferred onto culture membranes (Falcon culture insert, 0.4 pm) and cultured in a six-well culture dish with 1.5 ml medium (48% DMEM/F-12 (Gibco), 48% Neurobasal (Gibco), lx N-2 (Gibco), lx B-27 (Gibco), lx Glutamax (Gibco), lx NEAA (Gibco), lx Pen Strep (Gibco).
  • the plates were maintained in an incubator at 37°C with 5% CO2 for up to 2 weeks.
  • the amino acid methionine analog, azidohomoalanine was added to the hippocampal slice at a final concentration of 50 pM in HEPES buffered solution (HBS) followed by the incubation of 6 hours at 37°C. Slices were washed with PBS and immediately fixed in 4% paraformaldehyde at 4°C overnight. Detection of nascent protein synthesis was performed with the modified Click-iT 1-azidohomoalanine (AHA) Alexa Fluor 488 Protein Synthesis HCS Assay kit (ThermoFisher).
  • HBS HEPES buffered solution
  • the slices were then blocked with 5% NDS for 1 hour at room temperature, and incubated with Rabbit anti-NeuN antibody (abeam, 1 : 1000) overnight at 4°C followed by the incubation of anti-rabbit AlexaFluor647 (1 :500) for 1 hour at room temperature.
  • the slices were then co-stained with DAPI to visualize nuclei. Images were acquired using Zeiss LSM800 confocal microscope with 20x objective. The combined Z-stack images of DAPI, Al exaFluor 488 and Al exaFluor 647 channels were acquired with optical slice thickness of around 20 pm and images of maximum projection are shown. Proteins detected around the nucleus (perinuclear) are the most abundant newly synthesized proteins in cells28, and were quantified using Imaged intensity measurement function.
  • FIG. 2C Total flow rate: P values for hours 1-6, Ih: ⁇ 0.0001, 2h: ⁇ 0.0001, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; t values for hours 1- 6, Ih: 12.34, 2h: 8.120, 3h: 8.869, 4h: 9.683, 5h: 17.64, 6h: 22.96.
  • Brachial arterial pressure P values for hours 0-6, Oh: 0.9704, Ih: ⁇ 0.0001, 2h: 0.0002, 3h: 0.0003, 4h: 0.0006, 5h: 0.0027, 6h: ⁇ 0.0001; / values for hours 0-6, Oh: 0.03807, Ih: 12.24, 2h: 5.645, 3h: 5.480, 4h: 4.890, 5h: 3.953, 6h: 7.590.
  • Serum K + P values for hours 0-6, Oh: 0.8365, Ih: 0.0001, 2h: 0.0008, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; / values for hours 0-6, Oh: 0.2118, Ih: 6.156, 2h: 4.707, 3h: 7.224, 4h: 12.24, 5h: 7.401, 6h: 9.358.
  • Serum pH P values for hours 0-6, Oh: 0.3489, Ih: ⁇ 0.0001, 2h: ⁇ 0.0001, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; t values for hours 0-6, Oh: 0.9827, Ih: 6.285, 2h: 9.256, 3h: 9.668, 4h: 8.427, 5h: 7.056, 6h: 7.034.
  • Arterial cannula pressure P values for hours 1-6, Ih: ⁇ 0.0001, 2h: ⁇ 0.0001, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; / values for hours 1-6, Ih: 12.34, 2h: 8.120, 3h: 8.869, 4h: 9.683, 5h: 17.64, 6h: 22.96.
  • FIG. 7C Arterial cannula pressure: P values for hours 1-6, Ih: ⁇ 0.0001, 2h: ⁇ 0.0001, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; / values for hours 1-6, Ih: 12.34, 2h: 8.120, 3h: 8.869, 4h: 9.683, 5h: 17.64, 6h: 22.96.
  • Ih: 9.058 2h: 2.516, 3h: 2.665, 4h: 5.516, 5h: 3.386, 6h: 3.946.
  • O2 delivery P values for hours 1-6, Ih: ⁇ 0.0001, 2h: ⁇ 0.0001, 3h: ⁇ 0.0001, 4h: ⁇ 0.0001, 5h: ⁇ 0.0001, 6h: ⁇ 0.0001; / values for hours 1-6, Ih: 10.44, 2h: 6.957, 3h: 8.578, 4h: 9.462, 5h: 14.32, 6h: 18.56.
  • P OrganEx vs 7h WIT
  • P 0.0159
  • FIG. 4K One-
  • n 5 independent brains per condition.
  • the OrganEx technology consists of a perfusion system and synthetic perfusate (FIG. 1 A, FIG. IB).
  • the perfusion system consists of a computer driven custom-made pulse generator connected to a centrifugal pump, which enables reproduction of physiological pressure and flow waveforms, together with automated hemodiafiltration, gas mixer, and drug delivery systems which allow control of blood coagulation and supplementation of the perfusate.
  • the perfusion system is also equipped with sensors for electrolytes, blood gases, metabolic parameters, hemoglobin, vessels and cannulas pressures, and total circulatory flow rate.
  • the perfusate is optimized for wholebody compatibility.
  • the OrganEx perfusate is a final mixture of a custom-made priming solution (Table 1), Hemopure (HbO2 Therapeutics, Waltham, MA), custom-made dialysis exchange solution (Table 2) and the solution of pharmacological compounds (Table 3).
  • FIG. 1 A To evaluate OrganEx technology in large mammals, a porcine global warm ischemia model induced by cardiac arrest on anesthetized and heparinized animals (FIG. 1 A) was implemented. Following cardiac arrest and cessation of the systemic circulation, animals were left dead for one hour, allowing warm ischemic damage to ensue at core temperature of 36-37°C. Subsequently, animals were connected to one of the two perfusion systems via a femoral artery/vein approach with the goal of reinstating systemic circulation and nutritive rather than functional circulation of heart and lungs (FIG. 1A). Overall, this study consisted of five groups.
  • OrganEx Upon restoration of systemic circulation and certain key metabolic parameters following OrganEx perfusion, next investigated was its effects on organ structural integrity and cytoarchitecture.
  • the brain s three major cell types, neurons, astrocytes, and microglia in two regions most vulnerable to ischemia, the hippocampal CAI subregion and the prefrontal cortex (PFC) were analyzed.
  • OrganEx hematoxylin and eosin staining
  • hemorrhage hematoxylin and eosin staining
  • tissue edema tissue edema
  • nuclear pyknosis cell vacuolization
  • cellular integrity were evaluated and were combined into a cumulative damage score according to the standard pathologic criteria.
  • the OrganEx group showed a decrease in the H&E damage score, as compared to 7h WIT and ECMO groups (FIG. 3E-3H, FIGS. 9A-9J,).
  • organs treated with OrganEx perfusion exhibited signs of reduced hemorrhage and tissue edema when compared to the Ih WIT group. These results are indicative of the absence of injury promotion and cytoarchitectural damage as compared to ECMO, and more importantly, a reduction of H&E damage scores towards the Oh WIT state with OrganEx perfusion.
  • Example 4 Analysis of cell death processes Because the OrganEx perfusate contains pharmacological suppressors of cell death and decreased cellular demise based on the histopathological analysis in the OrganEx group (FIG. 3E-3H, FIGS. 9A-9J) was observed, key proteins of key cell death pathways were next investigated by immunohistochemistry analysis. For apoptosis, immunolabeling intensity of activated caspase3 (actCASP3) and TUNEL assay was measured, and an increase was observed across peripheral organs such as heart, liver, kidney, and pancreas in the ECMO compared to the OrganEx group.
  • actCASP3 activated caspase3
  • TUNEL assay was measured, and an increase was observed across peripheral organs such as heart, liver, kidney, and pancreas in the ECMO compared to the OrganEx group.
  • interleukin 1 beta (IL1B) immunohistochemistry was utilized. Across all investigated peripheral organs such as heart, liver, and kidney, IL1B immunolabeling intensity was comparable in Oh WIT and increased in ECMO when compared to OrganEx. In the brain, immunolabeling intensity was decreased in ECMO when compared to OrganEx group (FIGS. 10A-10E). Trends in both peripheral organs, and the brain are similar to the observed actCASP3 results (FIG. 4A-4E).
  • necroptosis and ferroptosis two distinct cell death pathways were investigated by utilizing immunohistochemistry of their important proteins in the pathways, the receptorinteracting ser/thr kinase 3 (RIPK3) and the glutathione peroxidase 4 (GPX4), respectively.
  • the results were consistent between the two cell death pathways and between all the organs evaluated such as brain, heart, liver, and kidney.
  • immunolabeling intensity was comparable in Oh WIT and significantly decreased in 7h WIT and ECMO groups (FIGS. 10F- 10O).
  • Liver cellular recovery was assessed using immunostaining for albumin and factor V, which are non- structural liver-synthesized proteins with great abundance and short half-life, respectively. Compared to OrganEx group, immunolabeling intensities of both proteins were comparable in Oh WIT and significantly diminished in 7h WIT and ECMO groups (FIGS. 5F, 5G, UN, 110).
  • kidney functional metric In the kidney, although many cellular features were preserved similar to Oh WIT in OrganEx groups, including tissue integrity (FIGS. 3H, 9D,9E), cell death (FIGS. 4A-4P, 10A- 10O), molecular and proliferative injury responses (FIGS. 9F-9J), and cellular metabolic indicators (FIG. 5C), the primary kidney functional metric, urine output, was minimal. Yet hypothermic perfusion is known to slow kidney function in patients with healthy organs and extracorporeal perfusion circuits can perturb endocrine, humoral, and neural factors regulating glomerular filtration even when renal perfusion and cellular health is adequate. Longer recovery time also may be required since low urine output often follows shock resuscitation.
  • EEG patterns during these movements were not interpretable due to movement-induced artifacts but were flat immediately before and after the movements (FIG. 11G). Whether these movements are initiated from preferential interruption of cerebral descending inhibition of motor patterns or from positive action at subcortical, spinal, peripheral nerve, or neuromotor unit levels is difficult to determine. However, the ability for them to be executed does indicate the preservation of efferent motor output function at least at the level of the spinal cervical cord or its roots.
  • BSCs organotypic hippocampal brain slice cultures
  • BSCs from the ECMO group were more fragile than OrganEx samples, and most disintegrated by day 14 (FIGS 5H, 51). BSC tissue integrity was preserved through day-14 in the OrganEx group equal to Oh WIT despite having had one additional ischemic exposure (lx during initial Ih warm ischemia, lx during brain extraction, 5-10mins). Similarly, protein synthesis was comparable through day-14 in the OrganEx and Oh WIT groups and decreased in ECMO across different hippocampal regions (FIGS 5J, 5K, 11H-11K).
  • snRNA-seq single-nucleus RNA-sequencing
  • FIG. 6B The transcriptomic signatures of tissue and cellular functioning in heart, liver, and kidney specimens were then evaluated. Cardiomyocytes in the OrganEx group exhibited enrichment of genes orchestrating action potential formation and the well-described shift28 toward glycolytic metabolism following ischemia signifying cardiomyocyte viability (FIG. 6B). In the liver and kidney, hepatocytes and PCT cells were enriched for cytochrome P450 and PCT transporter genes, respectively, in OrganEx versus other groups — though not quite to levels of Oh WIT controls — suggesting preservation of organ-specific functions (FIGS. 6C, 6D). Liver acutephase reactant and kidney injury marker genes also were notably lower following OrganEx reperfusion than after ECMO or 7h WIT (FIGS. 6C,6D). These data corroborate earlier findings on tissue integrity and cellular activity (FIGS.3E-3H, FIGS. 5B, 5G; FIGS.9A-9J; FIGS 11 A- 110).
  • snRNA-seq analysis supports cellular and tissue-level findings of decreased cellular injury and the initiation of certain molecular and cellular repair processes following OrganEx intervention.
  • Table 18 Downregulated modules in the heart for OrganEx vs other experimental conditions
  • Table 19 Upregulated modules in the liver for OrganEx vs other experimental condition
  • Table 23 List of Enriched GO terms.
  • OrganEx technology and its potential to support recovery of key molecular and cellular processes in multiple porcine organs after prolonged global warm ischemia are described.
  • This also demonstrates the underappreciated capacity of the large mammalian body for restoration of hemodynamic and metabolic parameters following circulatory arrest or other severe ischemic stress.
  • This application of the OrganEx technology demonstrates that cellular demise can be halted, and their state be shifted towards recovery at molecular and cellular levels, even following prolonged warm ischemia.
  • a comprehensive single-cell transcriptomic analysis of multiple porcine organs was generated to provide a unique resource for future studies on cell-types, ischemia, and reperfusion.
  • OrganEx technology was able to bridge prior clinical- translational gaps by restoring circulation and metabolic homeostasis across the whole body. This quells deleterious processes caused by disturbed cellular environments and lack of oxygen, representing a distinct feature of this technology and an essential control for multiple nonspecific injury mechanisms affecting end-organ recovery and overall prognosis after global ischemia. Potential applications of this technology are manifold and could provide novel pathways in ischemia research and advance related clinical disciplines.
  • OrganEx has the potential to extend limits of allowable warm ischemia times through regional abdominal/thoracic reperfusion, thereby increasing organ availability for transplantation. This approach would require obligatory antecedent clamping of the aorta/carotid arteries to prevent brain recirculation in the organ donor. Conversely, if any future refinements of the technology could be aimed at the recovery of the brain function after injury, then the brain circulation would remain patent. In this regard, OrganEx technology may improve outcomes in extracorporeal cardiopulmonary resuscitation with the needed circulatory support, or the OrganEx perfusate could aid in recovery wherein cardiac function is preserved but the brain is damaged, as seen in stroke. Thus, a clear distinction should be made before possible utilization of OrganEx technology, relative to inclusion of the brain circulation.
  • Embodiment 1 provides an isolated perfusate mixture comprising: an inorganic salt solution; an artificial oxygen carrier; and autologous blood.
  • Embodiment 2 provides the isolated perfusate mixture of embodiment 1, wherein the one or more artificial oxygen carriers is selected from the group consisting of hemoglobin glutamer- 250, isolated cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers.
  • the one or more artificial oxygen carriers is selected from the group consisting of hemoglobin glutamer- 250, isolated cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers.
  • Embodiment 3 provides the isolated perfusate mixture of embodiments 1-2, wherein the artificial oxygen carrier is hemoglobin glutamer-250.
  • Embodiment 4 provides the isolated perfusate mixture of embodiments 1-3, wherein the one or more inorganic salts are selected from the group consisting of sodium chloride, sodium bicarbonate, magnesium chloride, and calcium chloride.
  • Embodiment 5 provides the isolated perfusate mixture of embodiments 1-4, wherein the perfusate comprises a priming solution containing one or more sugars.
  • Embodiment 6 provides the isolated perfusate mixture of embodiments 1-5 wherein the one or more sugars are glucose or dextrane.
  • Embodiment 7 provides the isolated perfusate mixture of embodiments 1-6, further comprising one or more amino acids.
  • Embodiment 8 provides the isolated perfusate mixture of embodiments 1-7, wherein the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and salts and solvates thereof.
  • the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyros
  • Embodiment 9 provides the isolated perfusate mixture of embodiments 1-8, wherein the mixture further comprises one or more vitamins.
  • Embodiment 10 provides the isolated perfusate mixture of embodiments 1-9, wherein the one or more vitamins are selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i-inositol and salts and solvates thereof.
  • Embodiment 11 provides the isolated perfusate mixture of embodiments 1-10, wherein the mixture further comprises, ferric nitrate, magnesium sulfate, potassium chloride, sodium phosphate, and derivatives thereof.
  • Embodiment 12 provides the isolated perfusate mixture of embodiments 1-11, wherein the mixture further comprises an anti-clotting agent.
  • Embodiment 13 provides the isolated perfusate mixture of embodiments 1-12, wherein the anti-clotting agent is heparin.
  • Embodiment 14 provides the isolated perfusate mixture of embodiments 1-13, wherein the percentage of autologous blood in the mixture is between 10% and 50%.
  • Embodiment 15 provides the isolated perfusate mixture of embodiments 1-14, wherein the percentage of autologous blood in the mixture is approximately 28%.
  • Embodiment 16 provides the isolated perfusate mixture of embodiments 1-15, wherein the mixture is dialyzed against a solution comprising inorganic salts.
  • Embodiment 17 provides the isolated perfusate mixture of embodiments 1-16, wherein the mixture is dialyzed against plasma.
  • Embodiment 18 provides the isolated perfusate mixture of embodiments 1-17, wherein the mixture comprises electrolytes and oncotic agents at levels comparable to those in autologous blood.
  • Embodiment 19 provides the isolated perfusate mixture of embodiments 1-18, wherein the perfusate further comprises cytoprotective agents.
  • Embodiment 20 provides the isolated perfusate mixture of embodiments 1-19, wherein the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and or any salts, solvates, tautomers, and prodrugs thereof.
  • the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and or any salts, solvates, tautomers, and prodrugs thereof.
  • Embodiment 21 provides the isolated perfusate mixture of embodiments 1-20, wherein the mixture further comprises antibiotics.
  • Embodiment 22 provides the isolated perfusate mixture of embodiments 1-21, wherein the antibiotic is ceftriazone.
  • Embodiment 23 provides the isolated perfusate mixture of embodiments 1-22, wherein the mixture comprises one or more anti-inflammatory agents.
  • Embodiment 24 provides the isolated perfusate mixture of embodiments 1-23, wherein the one or more the anti-inflammatory agents is dexamathazone or cetirizine.
  • Embodiment 25 provides the isolated perfusate mixture of embodiments 1-24, wherein the temperature of the mixture is approximately 28°C.
  • Embodiment 26 provides a system for the hypothermic preservation of organs in a mammal, the system comprising: a perfusion device for the perfusion of an isolated perfusate mixture into the mammal, the perfusion device comprising: a perfusion loop; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain hypothermic conditions; and the isolated perfusate mixture of any of embodiments 1-25.
  • Embodiment 27 provides the system of embodiment 26 , wherein the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop.
  • Embodiment 28 provides the system of embodiments 26-27, wherein the perfusion loop comprises a venous loop, a filtration loop and an arterial loop, wherein: the venous loop comprises at least one perfusion pump; the filtration loop comprises at least one perfusion pump, and at least one hemodiafiltration unit adapted and configured to equilibrate the perfusate; the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate; wherein the mammal, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the mammal, through the venous loop, through the filtration loop, through the arterial loop and back to the mammal.
  • Embodiment 29 provides the system of embodiments 26-28, wherein one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate.
  • Embodiment 30 provides the system of embodiments 26-29, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate.
  • Embodiment 31 provides the system of embodiments 26-30, wherein the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
  • the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
  • Embodiment 32 provides the system of embodiments 26-31, wherein the mammal perfusion apparatus comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pressure and flow rate.
  • Embodiment 33 provides the system of embodiments 26-32, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps.
  • one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more
  • Embodiment 34 provides the system of embodiments 26-33, wherein the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device.
  • Embodiment 35 provides the system of embodiments 26-34, wherein the one or more sensor(s) is/are adapted and configured to measure the temperature within the perfusion device, the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device.
  • Embodiment 36 provides the system of embodiments 26-35, wherein the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L-Al any 1 -Glutamine, L- Arginine hydrochloride, L-Cystine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L- Methionine, L-Phenylalanine, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i-Inositol, Calcium Chloride (CaC12-2H2O), Ferric Nitrate (Fe(NO3)3 9H
  • Embodiment 37 provides the system of embodiments 26-36, wherein the system is configured to perfuse the mammal with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg.
  • Embodiment 38 provides the system of embodiments 26-37, wherein the system is configured to perfuse the organs in the mammal with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute.
  • Embodiment 39 provides the system of embodiments 26-38, further comprising a controller in electronic communication with one or more elements of the system.
  • Embodiment 40 provides a mammal perfused with the isolated perfusate composition of any of embodiments 1-25, wherein mammalian organs are perfused under hypothermic conditions.
  • Embodiment 41 provides the mammal of embodiment 40, wherein the mammal is a deceased mammal.
  • Embodiment 42 provides the mammal of embodiments 40-41, wherein the mammal is a human.
  • Embodiment 43 provides the mammal of embodiments 40-42, wherein the deceased mammal is deceased for longer than 1 hour.
  • Embodiment 44 provides the mammal of embodiments 40-45, wherein the deceased mammal has been deceased for longer than 4 hours.
  • Embodiment 45 provides the mammal of embodiments 40-45, wherein the mammal died of cardiac arrest.
  • Embodiment 46 provides the mammal of embodiments 40-45, wherein the organs in the deceased mammal are ischemic prior to perfusion with the isolated perfusate mixture of any of claims 1-25.
  • Embodiment 47 provides the mammal of embodiments 40-46, wherein rigor mortis is prevented.
  • Embodiment 48 provides the mammal of embodiments 40-47, wherein rigor mortis is reversed.
  • Embodiment 49 provides the mammal of embodiments 40-48, wherein the perfusate mixture flows into the ophthalmic artery.
  • Embodiment 50 provides the mammal of embodiments 40-49, wherein the perfusate mixture flows into the renal intralobular arteries.
  • Embodiment 51 provides perfused organs in a diseased mammal , wherein the perfused organs maintain one or more properties selected from the group consisting of an in vivo level of cell function and viability, and an in vivo level of morphology.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)

Abstract

The invention provides a system for hypothermic, restoration and preservation of organs in a mammal. In certain aspects, the system is capable of preserving organs, maintaining cellular integrity and cellular function for hours postmortem or after global ischemia. The invention also provides synthetic organ perfusate formulations, including a novel perfusate autologous blood mixture, which is able to reduce reperfusion injury, stimulate recovery from hypoxia, metabolically support the energy needs of organs and prevent rigor mortis.

Description

METHODS, SYSTEMS AND COMPOSITIONS FOR RESTORATION AND
PRESERVATION OF INTACT ORGANS IN A MAMMAL
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 63/245,632, filed September 17, 2021, which application is incorporated herein by reference in its entirety.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
This invention was made with government support under MH117064 and MH117064- 01 SI, awarded by the National Institute of Mental Health. The government has certain rights in the invention.
SUMMARY OF THE INVENTION
In one aspect, the invention provides an isolated perfusate mixture comprising: an inorganic salt solution; an artificial oxygen carrier; and autologous blood.
In another aspect, the invention provides a system for the hypothermic preservation of organs in a mammal, the system comprising: a perfusion device for the perfusion of an isolated perfusate mixture into the mammal, the perfusion device comprising: a perfusion loop; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain hypothermic conditions; and the isolated perfusate mixture as described elsewhere herein.
In yet another aspect, the invention provides a mammal perfused with the isolated perfusate composition as described elsewhere herein, wherein mammalian organs are perfused under hypothermic conditions.
In yet another aspect, the invention provides perfused organs in a diseased mammal , wherein the perfused organs maintain one or more properties selected from the group consisting of an in vivo level of cell function and viability, and an in vivo level of morphology
In certain embodiments, the one or more artificial oxygen carriers is selected from the group consisting of hemoglobin glutamer-250, isolated cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers. In certain embodiments, the artificial oxygen carrier is hemoglobin glutamer-250.
In certain embodiments, the one or more inorganic salts are selected from the group consisting of sodium chloride, sodium bicarbonate, magnesium chloride, and calcium chloride.
In certain embodiments, the perfusate mixture comprises a priming solution containing one or more sugars. In certain embodiments, the one or more sugars are glucose or dextrane.
In certain embodiments, the isolated perfusate mixture further comprises one or more amino acids. In certain embodiments, the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L- leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L- tyrosine, L-valine and salts and solvates thereof.
In certain embodiments, the perfusate mixture further comprises one or more vitamins. In certain embodiments, the one or more vitamins are selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i- inositol and salts and solvates thereof.
In certain embodiments, the perfusate mixture further comprises, ferric nitrate, magnesium sulfate, potassium chloride, sodium phosphate, and derivatives thereof.
In certain embodiments, the perfusate mixture further comprises an anti-clotting agent. In certain embodiments, the anti-clotting agent is heparin.
In certain embodiments, the percentage of autologous blood in the mixture is between 10% and 50%. In certain embodiments, the percentage of autologous blood in the mixture is approximately 28%.
In certain embodiments, the mixture is dialyzed against a solution comprising inorganic salts. In certain embodiments, the mixture is dialyzed against plasma.
In certain embodiments, the mixture comprises electrolytes and oncotic agents at levels comparable to those in autologous blood. In certain embodiments, the perfusate further comprises cytoprotective agents.
In certain embodiments, the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and/or any salts, solvates, tautomers, and prodrugs thereof. In certain embodiments, the mixture further comprises antibiotics. In certain embodiments, the antibiotic is ceftriazone. In certain embodiments, the mixture comprises one or more anti-inflammatory agents.
In certain embodiments, the one or more the anti-inflammatory agents is dexamathazone or cetirizine.
In certain embodiments, the temperature of the mixture is approximately 28°C.
In certain embodiments, the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop.
In certain embodiments, the perfusion loop comprises a venous loop, a filtration loop and an arterial loop, wherein: the venous loop comprises at least one perfusion pump; the filtration loop comprises at least one perfusion pump, and at least one hemodiafiltration unit adapted and configured to equilibrate the perfusate; the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate; wherein the mammal, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the mammal, through the venous loop, through the filtration loop, through the arterial loop and back to the mammal.
In certain embodiments, the one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate.
In certain embodiments, the one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate.
In certain embodiments, the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
In certain embodiments, the mammal perfusion apparatus comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of a pressure and a flow rate.
In certain embodiments, the one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps.
In certain embodiments, the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device.
In certain embodiments, the one or more sensors are adapted and configured to measure the temperature within the perfusion device, the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device.
In certain embodiments, the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L-Alanyl- Glutamine, L- Arginine hydrochloride, L-Cystine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Serine, L-Threonine, L- Tryptophan, L-Tyrosine, L-Valine, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i-Inositol, Calcium Chloride (CaC12-2H2O), Ferric Nitrate (Fe(NO3)3 9H2O), Magnesium Sulfate (MgSO4-7H2O), Potassium Chloride (KC1), Sodium Bicarbonate (NaHCO3), Sodium Chloride (NaCl), Sodium Phosphate monobasic (NaH2PO4-2H2O), D-Glucose (Dextrose), Phenol Red, Sodium Pyruvate, free fatty acids, cholesterol and nucleic acid constitutes.
In certain embodiments, the system is configured to perfuse the mammal with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg.
In certain embodiments, the system is configured to perfuse the organs in the mammal with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute.
In certain embodiments, the system further comprises a controller in electronic communication with one or more elements of the system.
In certain embodiments, the mammal is a deceased mammal. In certain embodiments, the mammal is a human. In certain embodiments, the deceased mammal is deceased for longer than 1 hour. In certain embodiments, the deceased mammal has been deceased for longer than 4 hours. In certain embodiments, the mammal died of cardiac arrest.
In certain embodiments, the organs in the deceased mammal are ischemic prior to perfusion with the isolated perfusate mixture.
In certain embodiments, rigor mortis is prevented. In certain embodiments, rigor mortis is reversed.
In certain embodiments, the perfusate mixture flows into the ophthalmic artery.
In certain embodiments, the perfusate mixture flows into the renal intralobular arteries.
BACKGROUND OF THE INVENTION
Cells lack meaningful oxygen-storage capacity, leading to obligate oxygen-dependence. At the cellular level, in just minutes following ischemia, intracellular acidosis and edema develop, and cause secondary damage to cellular membranes, organelles, and ultimately cell death. At the whole-body scale, there is a systemic release of hormones and cytokines, and activation of autonomic nervous, immune, and coagulation systems, leading to end-organ injury and feedback onto cellular injury cascades that culminate in systemic metabolic acidosis and hyperkalemia.
Reperfusion of the whole-body with autologous blood has several deleterious issues, including coagulation, microvascular plugging, inflammation, and blood-intrinsic cellular dysfunction. These obstacles have limited whole-body reperfusion and recovery of large mammals to 20 minutes of warm ischemia. Appropriate interventions are needed for molecular and cellular recovery across all vital organs in the large mammalian body following prolonged warm ischemia. The present invention addresses this need.
BRIEF DESCRIPTION OF THE DRAWINGS
The following detailed description of preferred embodiments of the invention will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities of the embodiments shown in the drawings.
FIGS. 1 A-1G show overview of the OrganEx technology and experimental workflow. FIG 1 A shows connection of the porcine body to the OrganEx perfusion system (or ECMO, not shown) via cannulation of the femoral artery and vein. FIG. IB is a simplified schematic view of the OrganEx perfusion device. The system is equipped with a centrifugal pump, pulse generator, hemodiafiltration gas infusion, drug delivery systems, and sensors to measure metabolic and circulation parameters. FIG.1C is a schematic of the experimental workflow and conditions. FIG. ID, the lid of the flow chamber that is connected to the electronic pressure regulator via an air line and the barb connector. FIG. IE, the bottom view of the lid showing in green space occupied by air. FIG. IF, the isometric view of the body, in green is the fluid path (fluid space) occupied by the mixture of autologous blood and the perfusate. FIG. 1G, the side view of the lid, body and the membrane that separates two parts.
FIGS. 2A-2E show circulation and blood/perfusate properties during the perfusion protocols. FIGS. 2A -2B are representative images of abdominal fluoroscopy (FIG. 2A, n=9) and ophthalmic and renal ultrasound (FIG. 2B, n=6) at 3h of perfusion. ECMO is depicted on upper and OrganEx on lower panels. FIGS. 2C -2E show changes in total flow rate, brachial arterial pressure (FIG. 2C), percentage of venous O2 saturation (FIG. 2D), K+ concentration, and pH in serum (FIG. 2E) throughout the perfusion protocols; n=6. Data presented are mean ± S.E.M. Two-tailed unpaired t-test was performed. **P<0.01, ***P<0.001, NS: not significant.
FIGS. 3 A-3K show analysis of tissue integrity across experimental conditions and organs. FIG. 3 A show representative confocal images of immunofluorescent staining for neurons (RBFOX3/NeuN), astrocytes (GFAP), and microglia (IBA1) counterstained with DAPI nuclear stain in hippocampal CAI region; n=3. Quantification of NeuN immunoreactivity intensity (FIG. 3B), number of GFAP fragments (FIG. 3C), and microglia number in CAI (FIG. 3D). FIG. 3E are representative images of H&E staining in heart, liver, and kidney. FIGS. 3F-3H are related to evaluation of histopathological criteria that include nuclear pyknosis (arrow), tissue integrity (*), hemorrhage/congestion (empty arrowhead), cell vacuolization (full arrowhead), and tissue edema (double arrow) in heart (FIG. 3F), liver (FIG. 3G) and kidney (FIG. 3H); n=5. FIGS. 3F-3H are representative confocal images of immunofluorescent staining for ACTB in kidney (FIG.3I) and its quantification in glomerulus (FIG.3 J) and proximal convoluted tubule (PCT) (FIG.3K); n=3. Scale bars, 40 pm. Data presented are mean ± S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIGS. 4A-4P show analysis of cell death across experimental conditions and organs. FIGS. 4A, 4F, 4K, and 4N, Representative confocal images of immunofluorescent staining for activated caspase 3 (actCASP3) and TUNEL assay in heart, liver, kidney, and brain. FIGS. 4B- 4D, Quantification of actCASP3 immunolabeling signal intensity in heart (FIG. 4B), liver (FIG. 4C), and kidney (FIG. 4D). FIGS. 4G-4J, Normalized total intensity of TUNEL signal in heart (FIG. 4G), liver (FIG. 4H), and kidney (FIG. 41). FIGS. 4L and 4M, Percentage of actCASP3 positively stained nuclei in the CAI (FIG.4L) and PFC (FIG.4M). FIGS. 40 and 4P, Normalized total intensity of TUNEL signal in CAI (FIG. 40) and PFC (FIG. 4P). Scale bars, 50 pm. Data presented are mean ± S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIG. 5A-5K depict functional characterization and metabolic activity of selected organs. FIGS 5A-5C, complexes in ECMO and OrganEx treated animals 3 hours into the perfusion (left); Chi-squared test was performed. Representative EKG trances in OrganEx and ECMO group 3 hours into the perfusion (right). FIG. 5E, Measurement of cardiomyocyte contraction velocity in acute heart slices in the Oh WIT, OrganEx, and ECMO groups (left), and cardiomyocyte contraction duration (right); n=5. FIG. 5F, Representative confocal images of immunolabeling for albumin in liver. Scale bars, 50 pm. FIG. 5G, Measurement of normalized immunolabeling signal intensity of albumin in liver demonstrating similar expression between OrganEx and Oh WIT groups; n=3. FIG. 5H, Representative images of organotypic hippocampal slices after 14 days in culture. Scale bar, 500 pm. FIG. 51, Quantification of hippocampal slice integrity; n=4-5. FIG. 5 J, Representative confocal images of newly synthesized proteins (AHA, Click-iT chemistry) with DAPI counterstaining in the long-term organotypic hippocampal slice culture. Scale bar, 100 pm. FIG. 5K, Quantification of AHA relative intensity in the CAI; n=3- 5. Data presented are mean ± S.E.M. One way ANOVA was performed with post-hoc Dunnett’s adjustments was performed. *P<0.05, **P<0.01, ***P<0.001, NS: not significant. AU, arbitrary units. Measurement of 2-NBDG uptake in heart (FIG.5A), kidney (FIG.5B), and brain (FIG.5C); n=3. FIG. 5D, Observed QRS .
FIGS 6A-6D show organ and cell type-specific transcriptomic changes assessed by snRNA-seq across various warm ischemia intervals and different perfusion interventions. Upper panels: UMAP layout showing major t-types in the hippocampus (FIG.6A) , heart(FIG.6B), liver(FIG.6C), and kidney(FIG.6D). Middle panels: comparison of averaged Augur AUC scores across t-types indicating which cell type underwent the most transcriptomic changes; Lower panels: dot plots depicting P values of gene set enrichment of gene sets important in cellular recovery and specific cellular functions in major respective t-types. **P<0.01, ***P<0.001.
FIGS. 7A-7E show analysis of circulation and blood/perfusate properties after Ih of warm ischemia and perfusion interventions. FIG.7A, Representative fluoroscopy images of autologous blood flow (ECMO intervention, up) or a mixture of autologous blood and the perfusate (OrganEx intervention, below) in the head captured after 3 and 6 hours respectively of perfusion, showing robust restoration of the circulation in the OrganEx group. A contrast catheter was placed in the left common carotid artery (CCA), except in the ECMO group at 6 hours timepoint where contrast catheter could not be advanced beyond aortic arch in to the left CCA due to pronounced vasoconstriction, thus resulting in bilateral CCA filling. n=6. FIG.7B, Representative color Doppler images of the CCA demonstrating robust flow in OrganEx group. Ultrasound waveform analysis demonstrated that OrganEx produced pulsatile, biphasic flow pattern (lower panel). SCM, sternocleidomastoid muscle. n=6. FIG.7C, Longitudinal change in arterial and venous cannula pressures throughout the perfusion demonstrating robust perfusion in OrganEx group. FIG.7D, Time-dependent changes in oxygen delivery and consumption demonstrating increased oxygen delivery and stable oxygen consumption over the perfusion period in OrganEx group. FIG.7E, Presence of classical signs of death (rigor and livor mortis) in ECMO as compared to OrganEx group at the experimental endpoint. Data presented are mean ± S.E.M. Two-tailed unpaired t-test was performed. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIGS. 8A-8L show Nissl staining and immunohistochemical analysis of the hippocampal CAI region and the prefrontal cortex (PFC). FIG. 8A, Representative images of Nissl staining of the CAI (up) and PFC (below). FIGS. 8B and 8C, Quantification of the number of cells per standardized area (FIG. 8B) and percentage of ellipsoid cells per area (FIG. 8C) in the CAI between the experimental groups. FIGS. 8D and 8E , Quantification of the number of cells per standardized area (FIG. 8D) and percentage of ellipsoid cells per area (FIG. 8E) in the PFC between the experimental groups. FIGS. 8F and 8H, Representative confocal images of immunofluorescent staining for neurons (RBFOX3/NeuN), astrocytes (GFAP), and microglia (IBA1) counterstained with DAPI nuclear stain in CAI (FIG. 8F) and PFC (FIG. 8H). FIG. 8G, Quantification of GFAP immunoreactivity in hippocampal CAI region depicting comparable immunoreactivity between OrganEx and Oh WIT group, with a significant increase compared to the other groups. FIGS. 81- 8L Quantification of NeuN immunolabeling intensity (FIG. 81), number of GFAP+ fragments (FIG. 8J), and number of GFAP+ cells (k) depict similar trends between the groups as seen in the CAI. Microglia number (FIG. 8L) shows comparable results between OrganEx and Oh WIT with different dynamics seen in the ECMO group. Scale bars, 50 pm. Data presented are mean ± S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIGS. 9A-9J show representative images of H&E staining across assessed peripheral organs and kidney periodic acid-Schiff (PAS) staining and immunolabeling for HACVR1 and Ki-67. FIG.9A, Representative images of the H&E staining in heart, kidney, liver, pancreas, and lungs. Arrows point to nuclear damage, asterisks point to disrupted tissue integrity, empty arrowheads point to hemorrhage, full arrowheads point to cell vacuolization, double arrows point to tissue edema. FIGS. 9B and 9C, H&E histopathological scores in lungs (FIG.9B) and pancreas (FIG.9C). FIG.9D, Representative images of PAS staining of the kidney. Arrows point to disrupted brush border, full arrowheads point to the presence of casts, asterisks point to tubular dilation, double arrows point to the Bowman space dilation. FIG.9E, Kidney PAS histopathological damage score. FIG.9F and FIG.9H, Representative confocal images of immunofluorescent staining for HAVCR1 and Ki-67 in kidney, respectively. FIG.9G, Quantification of HAVCR1 immunolabeling signal intensity. FIG.9I and FIG.9J, Quantification of the kidney Ki-67 positive staining. HACVR1 and Ki-67 immunolabeling quantification results follow a similar pattern seen with other organs with comparable results between Oh WIT and OrganEx group and significant decrease in the 7h WIT and ECMO groups. Scale bars, 100 pm. Data presented are mean ± S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, NS: not significant.
FIGS. 10A-10O show evaluation of different cell death pathways by immunohistochemical staining for important molecules in pyroptosis (IL1B), necroptosis (RIPK3) and ferroptosis (GPX4) across the experimental conditions. FIGS 10A, 10F, 10K, Representative confocal images of immunofluorescent staining for pyroptosis marker IL IB, necroptosis marker RIPK3, and ferroptosis marker GPX4, each co-stained with DAPI nuclear stain in CAI, heart, liver, and kidney. FIGS.10B-10E, Quantification of IL1B immunolabeling signal intensity in CAI (FIG.10B), heart (FIG.10C), liver (FIG.10D), and kidney (FIG.10E). FIGS.10G-10J, Quantification of RIPK3 positive intranuclear co-staining in CAI (FIG.10G), and immunolabeling signal intensity heart (FIG.10H), liver (FIG.101), kidney (FIG.10J). FIGS.10L- 10O, Quantification of GPX4 immunolabeling signal intensity in CAI (FIG.10L), heart (FIG.10M), liver (FIG.10N), and kidney (FIG.10O). Scale bars, 50 pm left and right panels. Data presented are mean ± S.E.M. One-way ANOVA with post-hoc Dunnett’s adjustments was performed. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, ***P<0.001, NS: not significant, IN: intranuclear.
FIGS. 11 A-l 10 EEG setup and recordings, click-iT chemistry and immunohistochemical analysis of factor V and troponin I. FIG.l 1A, Placement of EEG electrodes on the porcine scalp. FIG.1 IB, Representative snapshot of the EEG recordings after administration of anesthesia and before the induction of cardiac arrest by ventricular fibrillation. FIG.l 1C, Representative snapshot of the EEG recordings immediately following the ventricular fibrillation. FIG.l ID, Representative snapshot of the EEG during ECMO intervention at around 2h of perfusion protocol. FIG.1 IE, Representative snapshot of the EEG during OrganEx intervention at around 2h of perfusion protocol, showing a light pulsatile artefact. FIGS.1 IF and 11G, Representative snapshot of the EEG recordings following contrast injection at 3h in ECMO and OrganEx animals, respectively. OrganEx EEG snapshot is consistent with a possible muscle-movement artefact. GND, ground electrode; REF, reference electrode. FIGS.11H and 111, Representative confocal images of AHA through Click-iT chemistry in newly synthesized proteins with DAPI nuclear stain in the long-term organotypic hippocampal slice culture in CA3 (FIG.l 1H) and DG (FIG.11 Al) subregions. FIGS.11 J and 1 IK, Relative intensity of nascent protein around nuclei in hippocampal CA3 (FIG.l 1 J) and DG (FIG.l IK) region showing comparable protein synthesis between OrganEx and Oh WIT up to 14 days in culture. FIG.l IL, Representative confocal images of immunofluorescent staining for troponin I in the heart. FIG.1 IM, Quantification of troponin I immunolabeling signal intensity in heart. A decreased trend in immunolabeling intensity was observed with ischemia time and a significant decrease in immunolabeling intensity in ECMO compared to the OrganEx group. FIG.l IN, Representative confocal images of immunofluorescent staining for factor V in liver. FIG.110, Quantification of factor V immunolabeling signal intensity in liver follows a similar pattern seen with other organs with comparable results between Oh WIT, Ih WIT, and OrganEx group and a significant decrease in 7h WIT and ECMO groups. Scale bars, 50 pm. Data presented are mean ± S.E.M. For more detailed information on statistics and reproducibility, see methods. *P<0.05, **P<0.01, NS: not significant. AU, arbitrary units.
FIGS. 12A-12F Quality control of snRNA-seq data in healthy and varying ischemic conditions in the hippocampus, heart, liver, and kidney. Through transcriptomic integration and iterative clustering, a taxonomy of t-types in healthy organs and brain, heart, liver, and kidney that experienced ischemia (Ih WIT, 7h WIT, ECMO and OrganEx) were generated, representing presumptive major cell types across organs of interest. These major t-types were further subdivided into high-resolution subclusters that were transcriptomically comparable to publicly available human and mouse single-cell datasets and that were marked by distinct expression profiles. FIG. 12A, Bar plot showing the number of cells/nuclei across organs and biological replicates. FIG. 12B, Violin plot showing the distribution of the number of unique molecular identifiers - UMIs (upper panel) and genes (lower panel) detected across all biological replicates. FIGS. 12C-12F, respective analyses of snRNA-seq in the hippocampus (FIG. 12C), heart (FIG. 12D), liver (FIG. 12E), and kidney (FIG. 12F). The left upper corner depicts detailed UMAP layout showing all t-types in the respective organs. The right side depicts the expression of top t- type markers. The left lower corner depicts transcriptomic correlation between the t-type taxonomy defined in this study and that of previous human and mouse datasets.
FIGS. 13A-13D Single-nucleus transcriptome analysis in healthy and varying ischemic conditions in the hippocampus (FIG.13 A), heart(FIG.13 B), liver (FIG.13 C), and kidney(FIG.13D). FIGS.13A-13D, From left to right: UMAP layout showing major t-types; UMAP layout , colored by Augur cell type prioritization (AUC) between Oh WIT compared to Ih (up) and 7h WIT (down); statistical comparison of Augur AUC scores between Oh WIT and Ih (up) and 7h (down) of WIT; Volcano plot showing top DEGs in major annotated t-types between Oh and Ih WIT (up), or Oh and 7h WIT (down); GO terms associated with the genes up and downregulated in detected nuclei between Oh and Ih WIT (up), or Oh and 7h WIT (down) with their nominal P-value in respective major annotated t-types.
FIGS. 14A -14H show hippocampal single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions. FIG.14A, AUC scores of the Augur cell type prioritization between OrganEx and other groups. . FIG.14B, Volcano plot showing DEGs in hippocampal neurons between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. . FIG.14C, Trajectories of hippocampal neurons. Color indicates different experimental groups. . FIG.14D, Sankey plot showing perfusate components and violin plots showing their effects on hippocampal neurons between the OrganEx and ECMO groups. FIG.14E, Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left). Eigengene average expression trends exhibit distinct trends between ECMO and OrganEx groups (upper right) of modules whose enriched GO terms are predominantly related to cellular function (below) (FIG. 34) . FIG.14F, Expression of the genes involved in cell-death pathways in neurons. FIG.14G, Gene expression enrichment of the genes involved in cell-death pathways in neurons. FIG.14H, Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray, i, Stacked bar plot showing relative information flow for each signaling pa pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. Genes important in inflammation are highlighted gray. Necro-1, necrostatin-1; Mino, minocycline; DEXA, dexamethasone; Met. B, methylene blue; GEE, Glutathione Ethyl Ester. *P<0.05, **P<0.01, ***P<0.001, NS: not significant. FIGS. 15A-15H show heart single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions. FIG.15 A, AUC scores of the Augur cell type prioritization between OrganEx and other groups. FIG.15B, Volcano plot showing the DEGs in cardiomyocytes between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. FIG.15C, Trajectories of hippocampal neurons. Color indicates different experimental groups. FIG.15D, Sankey plot showing perfusate components and violin plots showing their effects on cardiomyocytes between the OrganEx and ECMO groups. FIG.15E, Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left). Eigengene average expression trends exhibit distinct trends between ECMO and OrganEx groups (upper right) of modules whose enriched GO terms are predominantly related to cellular function (below) (FIG. 34). FIG.15F, Expression of the genes involved in cell-death pathways in cardiomyocytes. FIG.15G, Gene expression enrichment of the genes involved in cell-death pathways in cardiomyocytes. FIG.15H, Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray, i, Stacked bar plot showing relative information flow for each signaling pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. Genes important in inflammation are highlighted gray. HIP, hippocampus; Necro-1, necrostatin-1; Mino, minocycline; DEXA, dexamethasone; Met. B, methylene blue; GEE, Glutathione Ethyl Ester. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIGS. 16A-16I show liver single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions. FIG.16 A, AUC scores of the Augur cell type prioritization between OrganEx and other groups. FIG.16B, Volcano plot showing DEGs in hepatocytes between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. FIG.16C, Trajectories of hippocampal neurons. Color indicates different experimental groups. FIG.16D, Sankey plot showing perfusate components and violin plots showing their effects on hepatocytes between the OrganEx and ECMO. FIG.16E, Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left). Eigengene average expression trends exhibit distinct trends between ECMO and OrganEx groups (upper right) of modules whose enriched GO terms are predominantly related to cellular function or cell death (below) (Table 23). FIG.16F, Expression of the genes involved in cell-death pathways in hepatocytes. FIG.16G, Gene expression enrichment of the genes involved in cell-death pathways in hepatocytes. FIG.16H, Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray. FIG.16A I, Stacked bar plot showing relative information flow for each signaling pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. Genes important in inflammation are highlighted gray. Necro-1, necrostatin-1; Mino, minocycline; DEXA, dexamethasone; Met. B, methylene blue; GEE, Glutathione Ethyl Ester. *P<0.05, **P<0.01, ***P<0.001, NS: not significant.
FIGS.17A- 171 show kidney single-nucleus transcriptome analysis comparing OrganEx to other experimental conditions. FIG.17 A, AUC scores of the Augur cell type prioritization between OrganEx and other groups. FIG.17B, Volcano plot showing DEGs in PCT between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. FIG.17C, Trajectories of hippocampal neurons. Color indicates pseudotime progression and different cell states, respectively. FIG.17D, Sankey plot showing perfusate components and violin plots showing their effects on PCT between the OrganEx and ECMO groups. FIG.17E, Hierarchical clustering of the top DEGs across experimental groups and derived functional gene modules (upper left). Eigengene average expression trends exhibit distinct trends between ECMO and OrganEx groups (upper right) of modules whose enriched GO terms are predominantly related to cellular function or cell death (below) (FIG. 34). FIG.17F, Expression of the genes involved in cell-death pathways in PCT. FIG.17G, Gene expression enrichment of the genes involved in cell-death pathways in PCT. PCT, proximal convoluted tubule. FIG.17H, Overall signaling patterns across all experimental conditions. Genes important in inflammation are highlighted gray. FIG.171, Stacked bar plot showing relative information flow for each signaling pathway across experimental group pairs. Significant signaling pathways were ranked based on differences in the overall information flow within the inferred networks between OrganEx and Oh WIT, Ih WIT, 7h WIT, and ECMO. Genes important in inflammation are highlighted gray. PCT, proximal convoluted tubules; DCT, distal convoluted tubules; Necro-1, necrostatin-1; Mino, minocycline; DEXA, dexamethasone; Met. B, methylene blue; GEE, Glutathione Ethyl Ester. *P<0.05, **P<0.01, ***P<0.001, NS: not significant. DETAILED DESCRIPTION OF THE INVENTION
The invention provides a novel system for restoration and preservation of an intact mammalian organs. In certain aspects, the system is capable of preserving organs in the mammalian body and restoring and maintaining cellular integrity and cellular function for hours post mortem or after global ischemia. The invention also provides novel synthetic organ perfusate formulations, and methods of mixing the perfusate with blood, for example, autologous blood, derived from the mammal.
The invention includes surgical methods and procedures to connect the mammal to the OrganEx system. In combination, the system, perfusate, and surgical method attenuate organ cell death, preserve anatomical and cellular integrity and restore cellular function as indicated by active metabolism. The invention also provides means to reduce reperfusion injury, stimulate recovery from hypoxia, and metabolically support the energy needs of organ function. The invention further provides methods of using the system and blood perfusate mixture, to prevent the collapse of organ vasculature and to allow for better perfusion of the organs. In addition, the invention provides methods to prevent the onset of rigor mortis.
Definitions
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, exemplary methods and materials are described. As used herein, each of the following terms has the meaning associated with it in this section.
The instant invention is most clearly understood with reference to the following definitions.
As used herein, the singular form “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise.
Unless specifically stated or obvious from context, as used herein, the term “about” is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. “About” can be understood as within 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. Unless otherwise clear from context, all numerical values provided herein are modified by the term about.
As used herein, the term “hypoxic” refers to a concentration of dissolved oxygen less than about 13%, corresponding to a partial pressure of about 100 mmHg, the physiologic partial pressure of oxygen in the alveoli of the lung.
As used herein, the term “cellular hypoxia” refers to a cellular response to exposure to a hypoxic environment, often resulting in apoptosis, or cellular death.
As used herein, the term “anaerobic metabolism” refers to the cellular consumption of glucose to produce two molecules of lactate, with the lactate remaining in dissolved in solution. The ratio of lactate produced to glucose consumed will be 2: 1.
As used herein, the term “aerobic metabolism” refers to the cellular consumption of glucose to produce two molecules of lactate, both of which will be consumed through the Krebs cycle in the presence of sufficient levels of oxygen. The ratio of lactate produced to glucose consumed will be 0: 1.
As used herein, the term “hypothermic” refers to a body temperature substantially below normal bounds. Hypothermic temperatures include, but are not limited to, temperatures between 10° and 32° C, between 20°C and 30°C, and about 28°C.
As used herein, the term “salt” embraces addition salts of free acids or free bases that are compounds useful within the invention. Suitable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric, phosphoric acids, perchloric and tetrafluorob or onic acids. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2- hydroxyethanesulfonic, p-toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, stearic, alginic, b -hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable base addition salts of compounds useful within the invention include, for example, metallic salts including alkali metal, alkaline earth metal and transition metal salts such as, for example, lithium, calcium, magnesium, potassium, sodium and zinc salts. Acceptable base addition salts also include organic salts made from basic amines such as, for example, N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methyl-glucamine) and procaine. All of these salts may be prepared by conventional means from the corresponding free base compound by reacting, for example, the appropriate acid or base with the corresponding free base.
As used in the specification and claims, the terms “comprises,” “comprising,” “containing,” “having,” and the like can have the meaning ascribed to them in U.S. patent law and can mean “includes,” “including,” and the like.
Unless specifically stated or obvious from context, the term “or,” as used herein, is understood to be inclusive.
Ranges provided herein are understood to be shorthand for all of the values within the range. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 (as well as fractions thereof unless the context clearly dictates otherwise).
As described herein, rigor mortis refers to process that sets in upon the death of a mammal. Rigor mortis is characterized by stiffening of the muscles. Stiffening occurs as a result of ATP depletion. ATP is depleted in ischemic tissues where there is insufficient oxygen available for mitochondria to drive ATP formation. As a result, the bridges between actin and myosin fibers are no longer broken, causing muscle stiffness.
As used herein, OrganEx refers to a system that consists of a perfusion system and synthetic perfusate. The perfusion system consists of a computer driven custom-made pulse generator connected to a centrifugal pump, which enables reproduction of physiological pressure and flow waveforms, together with automated hemodiafiltration, gas mixer, and drug delivery systems which allow control of blood coagulation and supplementation of the perfusate. To ensure homeostasis and maintain the targeted perfusion parameters, the perfusion system is also equipped with sensors for electrolytes, blood gases, metabolic parameters, hemoglobin, vessels and cannulas pressures, and total circulatory flow rate. In the OrganEx system, prior to the initiation of the perfusion protocol, autologous blood of the mammal is drained into the OrganEx system and mixed with the perfusate, which is then used to perfuse the animal.
As used herein, ECMO refers to a clinical standard of a heart-and-lung substitution perfusion device - extracorporeal membrane oxygenation system (ECMO). In the ECMO system, the animals are perfused with autologous blood.
The following abbreviations are used herein: ABG arterial blood gasses
ACT activated clotting time actCASP3 activated caspase 3 AHA azidohomoalanine amino acid
AUC Augur cell type prioritization
CAI hippocampal subregion
CA3 hippocampal subregion
CCA common carotid artery
CYP cytochrome microsomal
DAPI 4',6-diamidino-2-phenylindole
DEG Differentially expressed genes
DG hippocampal subregion
DMEM Dulbecco’ s Modified Eagle Medium
DNA deoxyribonucleic acid
ECMO extracorporeal membrane oxygenation system
EEG electroencephalogram
EKG electrocardiogram
GFAP Glial fibrillary acidic protein
GO Gene ontology
HEPES 4-(2 -hydroxy ethyl)- 1 -piperazineethanesulfonic acid
IBA-1 marker for microglia
IL Interlobular artery
2-NBDG glucose analog
OA Ophthalmic Artery PBS Phosphate buffered saline
PCT proximal convoluted tubule
PCA principal component analysis
PFC prefrontal cortex
PMI post-mortem intervals
RA right atrium
RBFOX3/NeuN marker for mature neurons
RC Renal cortex
RM Renal medulla
RO Retro orbital
ROI region of interest
RT room temperature
SCM sternocleidomastoid muscle
SCT subcutaneous tissue
TUNEL Terminal deoxynucleotidyl transferase dUTP Nick End Labeling UMAP uniform manifold approximation and projection
UMI unique molecular identifier
VFib ventricular fibrillation
WIT warm ischemia time
Or anEx Perfusate and Uses
The invention provides a novel OrganEx technology and its experimental application that has the potential for recovery of key molecular and cellular processes in multiple porcine organs after prolonged warm ischemia.
The data presented herein demonstrate that mammalian cells are more resilient to ischemic injury than previously understood. Further, the data establish that cellular deterioration is a more protracted process that is not scripted within narrowly-defined sequences or timeframes.
In one embodiment, the application of the OrganEx technology can halt the process of cell demise. In another embodiment, the application of the OrganEx technology can shift cellular states towards recovery at molecular and cellular levels. In another embodiment, the application of the present invention can shift cellular states towards recovery, even following prolonged warm ischemia. In another embodiment, the invention provides a comprehensive single-cell transcriptomic analysis of the brain and vital peripheral organs over varying warm ischemic intervals. In another embodiment, the comprehensive single-cell transcriptomic analysis of the brain and vital peripheral organs over varying warm ischemic intervals is obtained utilizing perfusion with either autologous blood, the OrganEx perfusate, or a mixture of autologous blood and the OrganEx perfusate.
In some embodiments, the invention provides a transcriptome dataset and a unique resource for future basic and translational studies on cell-types, organs and ischemia.
In one embodiment, the OrganEx platform and acellular perfusate, connected to an intact dead mammal, provides a solution to the problem of ischemic stress in tissue culture and isolated organs.
The invention provides a means to reinstate circulation and systemic metabolic parameters across multiple organs in an intact animal. In one embodiment, the invention provides for the removal of deleterious processes and lack of oxygen, crucial for the control of multiple non-specific injury mechanisms affecting end-organ recovery and overall prognosis after global ischemia.
In one embodiment, the invention facilitates or enables repair responses at the molecular and cellular level in several or all organs. In another embodiment, the repair at the molecular and cellular level translate to processes supporting recovery of organs. In another embodiment, recovery of organs last for an extended period of time. In another embodiment, rigor mortis can be prevented in an animal following warm ischemia. In another embodiment, rigor mortis can be reversed. In another embodiment, dead spots in the heart can be prevented. In another embodiment, electrical activity can be measured in the heart. In another embodiment, contractile activity can be measured in the heart. In another embodiment, electrical activity can be measured in the brain. In another embodiment, the movements can be initiated in the animal. In another embodiment, the animal may regain consciousness. In another embodiment, the animal may regain the ability to move.
In one embodiment, enduring effects on cellular recovery post perfusion occurs in slices from the tissue most susceptible to ischemia, the hippocampus. In another embodiment, long term in vivo recovery of the hippocampus, and other organs is observed at the organ level. In one embodiment, long OrganEx perfusions of the whole-body can prevent organs from undergoing ischemic injury. In another embodiment, long OrganEx perfusion can lead to recovery of vital organs, including the brain, the hearth, the kidney, the pancreas, or the liver.
In another embodiment, the OrganEx technology can be used in combination with mammals that are still alive. In one embodiment, the live mammal is a human. In one embodiment, the live mammal being treated has experienced a stroke or a heart attack prior to perfusion with the blood perfusate mixture. In one embodiment, the human recovers and/or recovers more quickly from the stroke or the heart attack. In one embodiment, the invention preserves and recovers brain function. In one embodiment, the recovery from ischemic injury in the brain is measurable by magnetic resonance imaging (MRI). In one embodiment, long OrganEx perfusion can be applied to the mammal, e.g., a human, following a cardiac event, e.g., a heart attack. In one embodiment, the invention preserves and recovers heart function. In one embodiment, the mammal recovers and/or recovers more quickly from the heart attack. In one embodiment, the recovery from ischemic injury in the heart is measurable with an electrocardiogram (EKG). In another embodiment, death of a mammal may be reversed.
In one embodiment, the technology provides for new avenues for whole-body global ischemia research. In another embodiment, the invention provides a means to conduct clinical resuscitation science or transplantation medicine. In one embodiment, the invention provides for larger donor organ pools by recovering previously marginalized organs.
The invention includes a novel perfusion composition for the preservation of organs in the mammalian body. In certain embodiments, the perfusion composition can be used to preserve organs in a mammal after warm ischemia. In certain embodiments, the blood perfusate mixture can preserve the brain, the liver, lung, heart, pancreas, kidney, and the like.
In certain embodiments, the perfusion composition is a perfusate comprising a solution comprising one or more artificial oxygen carrier compounds and one or more compounds selected from the group consisting of anti-cytotoxic compounds, antioxidants, anti-inflammatory compounds, antiepileptic compounds, anti-apoptotic compounds, antibiotics, cell death inhibitors, neuroprotectants and oxidative/nitrosative stress inhibitors.
In certain embodiments, the perfusate comprises priming solution. In certain embodiments, the priming solution comprises sodium chloride, sodium bicarbonate, magnesium chloride, calcium chloride, glucose and dextrane. In certain embodiments, the concentrations of the components in the priming solutions is as shown in Table 1.
In certain embodiments, the perfusate comprises hemodiafiltration exchange solution. In certain embodiments, the hemodiafiltration exchange solution comprises one or more amino acids selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L- threonine, L-tryptophan, L-tyrosine, L-valine and salts and solvates thereof; one or more vitamins selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i-inositol and salts and solvates thereof; and one or more inorganic salts selected from the group consisting of calcium chloride, ferric nitrate, magnesium sulfate, potassium chloride, sodium bicarbonate, sodium chloride, sodium phosphate and salts and solvates thereof. In certain embodiments, the concentration of the components in the hemodiafiltration solution is as shown in Table 2.
In certain embodiments, the perfusate contains hemoglobin glutamer-250 (Hemopure ® (HBOC-250)) or an alternative oxygen carrier, one or more cytoprotective agents selected from Hexahydro-2-imino-lH-thieno[3,4-d]imidazole-4-pentanoic acid (2-Iminobiotin), 5-(lH-Indol-3- ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone (Necrostatin-1), Sodium 3 -Hydroxybutyric Acid, Glutathione Monoethyl Ester, Minocycline, Lamotrigine, 5-(2,6-Difluorophenoxy)-3-[[3- methyl-l-oxo-2-[(2-quinolinylcarbonyl)amino]butyl]amino]-4-oxo-pentanoic acid hydrate (QVD-Oph), Methylene Blue, and one or more antibiotics and anti-inflammatory agents selected from Ceftriaxone, Dexamethasone, and Cetirizine. In certain embodiments, the concentrations of the components recited above is listed in Table 3.
In certain embodiments, the perfusate comprises one or more artificial oxygen carrier compounds. In certain embodiments, the one or more artificial oxygen carrier compounds are hemoglobin derivatives. The hemoglobin derivatives can be one or more compounds selected from the group consisting of isolated, cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin and functionalized hemoglobin. In certain embodiments, the artificial oxygen carrier compound can be hemoglobin glutamer-250 ( HEMOPURE®), a cross-linked hemoglobin tetramer comprising two alpha hemoglobin and two beta hemoglobin subunits cross-linked by a carbon linker. In other embodiments, the one or more artificial oxygen carrier compounds can be artificial red blood cell substitutes, such as ERYTHROMER™, PolyHeme, Oxyglobin, PolyHb-SOD-CAT-CA, PolyHb-Fibrinogen, Hemspan or MP4. In other embodiments, the artificial oxygen carrier compound can be any blood substitute compound known in the art.
In certain embodiments, the perfusion composition comprises one or more compounds selected from the group consisting of anti-cytotoxic compounds, antioxidants, anti-inflammatory compounds, antiepileptic compounds, anti-apoptotic compounds, antibiotics, cell death inhibitors, neuroprotectants and nitrite stress inhibitors. In certain embodiments, the perfusion composition comprises at least one imaging contrast agent. In other embodiments, the perfusion composition further comprises one or more ultrasound contrast agents, that also can be used under certain ultrasound settings as clot disintegrator and blood-brain barrier opener. In some embodiments, the one or more ultrasound contrast agents can be micrometer-sized air-filled polymeric particles. In yet other embodiments, the perfusion composition comprises at least one MRI contrast agent or CT contrast agent. In other embodiments, the perfusion composition comprises one or more compounds selected from the group consisting of the compounds of Tables. 1-3, or salts, solvates, tautomers, and prodrugs thereof.
Perfusion system
The invention provides a novel system for in situ hypothermic preservation of organs in a mammalian body.
In certain embodiments, the invention provides a system for the hypothermic, in situ preservation system, the system comprising: a perfusion device for the perfusion of a mammalian body, comprising a means for regulating the temperature, flow, pressure, dissolved gases, and concentration of metabolites in the system; and the perfusate composition of the invention. In certain embodiments, the means for regulating the temperature of the system comprises a controller programmed to regulate at least a perfusate temperature within the system to maintain hypothermic conditions. In certain embodiments, the means for regulating the flow, pressure, dissolved gases, and metabolite concentrations in the system comprises a controller programmed to regulate these parameters within the system to maintain constant or alterable 1 evel s/ concentrati ons .
In certain embodiments, the system is configured to introduce oxygen to a perfusate of the invention and circulate the perfusate through mammal. In certain embodiments, the perfusion unit is adapted and configured to introduce oxygen and carbon dioxide to the perfusate. In other embodiments, the perfusion unit is adapted and configured to dialyze the perfusate.
In certain embodiments, the system comprises an intrarenal arterial cannula, an animal input line, a pressure sensor, a flow sensor, a pulse generator, an arterial oxygenator, an exchange solution, one or more roller pumps, a hemodiafiltration membrane, one or more reservoirs with perfusate drugs, one or more perfusate reservoirs, a pressure senor, a centrifugal pump, a hemoglobin sensor a return line from the mammal.
In certain embodiments, the electronic components of the perfusion system are built in a modular manner. Each sensor, motor or electronic component that requires external control has a separate logical controller built on Arduino Uno platform, local circuits and software. Each logical controller has a serial output and input and is connected via com port to the computer. In certain embodiments, the computer has modulus, scripts and functions written in Python that either control or collect data from these logical controllers.
In certain embodiments, the pulse generator consists of (1) 3D printed flow chamber (fluid space for blood/perfusate passage, and air space that is separated by a membrane from the fluid space and can change volume against fluid space) connected to the main circuit, downstream from the centrifugal pump, (2) high resolution electronic pressure regulator (0-10 PSI) which is connected to the air source on one end and to the flow chamber on the opposite end, (3) logical controller regulating electronic pressure regulator, (4) and a computer with control software. The Logical controller is made out of Arduino Uno microprocessor board and has a DAC converter (MCP 4725) with an operational amplifier (LT1215 CN8); it produces continuous analog output (0-10V) for electronic pressure regulator. Logical controller has a script which runs the electronic pressure regulator, based on sinusoidal function, and it can receive input from a computer via serial port to regulate variables within sinusoidal function (e.g. amplitude, iteration/looping speed, baseline value). In certain embodiments, continuous output is produced and sent to the electronic pressure regulator which then controls flow chamber volume, by moving a membrane which separates fluid space from the air space, thus producing pulsatility and oscillations in venous and arterial pressures throughout the perfusion system. Computer is connected to the logical controller, and custom-made scripts in Python allow for manual or automatic control. In certain embodiments, the software also monitors flow and pressure in the arterial and venous cannula and stores the data. In certain embodiments, the automated hemodiafiltration system consists of (1) two peristaltic pumps which have separate logical controllers and are connected via serial ports to the computer, (2) liquid level solid-state sensor with a resistive output (0-5V), in a clear, elliptical polycarbonate tube integrated with logical controller, for monitoring fluid level in exchange solution canister, connected to the computer. Logical controllers for peristaltic pumps and level sensor have custom made scripts which allow for higher-order language control. In certain embodiments, the computer governs two peristaltic pumps and collects data from the sensor via Python script. The script performs proportional control over peristaltic pumps and allows for continuous dialysis while keeping the animal euvolemic.
Perfused Organs in the mammalian body
The invention provides methods of preserving organs in the mammalian body. In some embodiments, the organs are perfused with a solution comprising a priming solution, a hemodialysis solution and a solution comprising pharmacological components. The constituents and concentrations of the components in the priming solution, hemodialysis solution and solution comprising the pharmacological components are as shown in Tables 1-3. In certain embodiments, the mammalian body is perfused with a mixture of the perfusate and autologous blood. In some embodiments, the autologous blood is mixed with any of the components of the perfusate solution before perfusion of the mammalian body. In some embodiments, one or more artificial oxygen carriers are present in the mixture.
In some embodiments, the mammalian organs maintain morphofunctional integrity under hypothermic conditions after perfusion with the blood perfusate mixture.
In certain embodiments, the organs in the mammal are ischemic prior to perfusion with the blood perfusate mixture.
In certain embodiments, the organs are perfused while the mammal is still alive. In other embodiments, the organs are perfused immediately upon death of the mammal. In other embodiments, there is a 20 minute delay between death and perfusion of the organs. In other embodiments, the time between death and perfusion is at least one hour. In other embodiments, the time between death and perfusion is 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.
In certain embodiments, the perfused organs are organs that can be transplanted from one mammal to another, including, but not limited to the kidney, the pancreas, the heart, the lung, the intestine, the corneas, the middle ear, bone, bone marrow, heart valves, connective tissue, skin, uterus, muscles, blood vessels, nerves and connective tissue. In some embodiments, the organs are removed from the mammal following perfusion with the blood perfusate mixture.
In certain embodiments, perfusion with the blood perfusate mixture helps maintain an in vivo rate of cellular metabolism and preserves functional responses of cells. The blood perfusate perfused organs can maintain longer viability than organs perfused with the ECMO system.
In certain embodiments, the perfused organs belong to any mammal. Non-human mammals include, for example, livestock and pets, such as ovine, bovine, porcine, canine, feline and murine mammals. Mammals can also include primates, including humans. In certain embodiments, the perfused mammal is a human.
In some embodiments, rigor mortis is prevented by perfusion of the deceased mammal. In one embodiment, perfusion of the deceased mammal with the technologies described herein prevents stiffening of the muscles. In another embodiment, the tissues in the perfused mammal continue or regain the consumption of. In another embodiment, the tissues in the perfused mammalian continue or regain the ability to produce ATP.
EXPERIMENTAL EXAMPLES
The invention is further described in detail by reference to the following experimental examples. These examples are provided for purposes of illustration only, and are not intended to be limiting unless otherwise specified. Thus, the invention should in no way be construed as being limited to the following examples, but rather, should be construed to encompass any and all variations which become evident as a result of the teaching provided herein.
Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the compounds of the present invention and practice the claimed methods. The following working examples therefore, specifically point out the preferred embodiments of the present invention, and are not to be construed as limiting in any way the remainder of the disclosure.
The materials and methods employed in practicing the following examples are here described: Materials and Methods
Overview of the OrganEx perfusion system and perfusate
Overview of the OrganEx perfusion system
The perfusion system consists of the main closed-loop circuit directly connected to an animal, and it includes a centrifugal pump (Medtronic Bio-Console 560, Medtronic, Minneapolis, MN) that drives the mixture of autologous blood and OrganEx perfusate through the oxygenator (Affinity Fusion, Medtronic), and custom-made pulsatility generator into animal arterial system. The oxygenator is connected to a refrigerated bath (Polystat, Cole-Parmer, Niles, IL) for temperature control and the gas blender (Sechrist Industries, Anaheim, CA), for control of dissolved gases and anesthesia infusion. The perfusion system has a fluid reservoir, which is used to prime the system and hold the supplement fluid. In parallel, an automated hemodiafiltration system and a reservoir are connected to the main circuit (FIG. IB). The automated hemodiafiltration system is used to exchange plasma fraction against custom-made dialysis exchange solution. The hemodiafiltration system consists of a roller-pump (Cobe Shiley, Stockert, Lake wood, CO), dialyzer (Diacap Pro 13H, Braun, Melsungen, Germany) and two peristaltic pumps (Masterflex L/S, Cole-Parmer) integrated with level sensor (eTape, Milone Technologies, Sewell, NJ) and custom-made logical controller. Two infusion pumps (Sigma Spectrum, Baxter Healthcare Corporation, Deerfield, IL) are connected to the arterial side of the main circuit supplementing heparin and pharmacological compounds of the perfusate. The CDI blood parameter module and the hematocrit/oxygen saturation probe (Terumo Cardiovascular Systems Corp., Elkton, MD) are connected on the arterial and venous side, respectively, along with pressure (PendoTECH, Princeton, NJ) and flow sensors (Bio-Probe TX50, Medtronic). OrganEx perfusion system components, logical controllers and sensors are connected to a computer for automated control and data gathering. Detailed schematics available upon request.
Preparation and application of the OrganEx perfusate
The OrganEx perfusate is a final mixture of a custom-made priming solution (Table 1), Hemopure (HbO2 Therapeutics, Waltham, MA), custom-made dialysis exchange solution (Table 2) and the solution of pharmacological compounds (Table 3). Table 1. Components of the priming solution
Figure imgf000030_0001
Table 2. Components of the hemodiafiltration exchange solution:
Figure imgf000030_0002
Table 3. Pharmacological components of OrganEx Perfusate
Figure imgf000031_0001
In detail, prior to connecting an animal, the OrganEx perfusion system is flooded and primed with 2200 mL of custom-made priming solution (5000 mL), followed by infusion of 1000 mL of Hemopure into the system. These solutions are left to mix and equilibrate throughout the perfusion system, after which 600 mL is extracted from the perfusion system to achieve desired concentrations of electrolytes and oncotic agents in the perfusion system and prepare it for addition of the autologous blood.
Prior to initiation of the perfusion protocol, animal femoral vessels are cannulated and connected to the main circuit. At 30 minutes of WIT, 5 000 USP units of heparin (Sigma- Aldrich, St Louis, MO) is administered into the system, followed by approximately 1000 mL of venous blood from the dead animal, which is drained into the perfusion system. At this point, circulatory volume in the OrganEx perfusion system is approximately 3600 mL, out of which 2600 mL is the priming solution and 1000 mL of autologous blood. Next, the mixture of the perfusate and autologous blood is left to equilibrate, and counter dialyzed against the residual priming solution over 30 minutes to allow for correction of metabolic derangements in the drained venous blood. In parallel, approximately 1600 mL of fluid is filtered out of the perfusion system over 30 minutes while the residual fluid is cooled to 28°C, yielding a final volume of 2000 mL in the OrganEx perfusion system. Next, at Ih of WIT, 1000 mL of the perfusate and autologous blood mixture is infused back into the animal, ensuring circulatory system filling following venous drainage, and the perfusion protocol is initiated. The remaining 1000 mL of the mixture is stored in the reservoir and used for fluid supplementation, if required. Following infusion of the perfusate and autologous blood mixture, pharmacological compounds and dialysis exchange solution, containing amino acids, vitamins and inorganic salts, are continuously infused into the main perfusion circuit by infusion pump and hemodiafiltration system, respectively. The OrganEx perfusion system utilizes automated hemodiafiltration circuit which corrects and maintains certain metabolic and electrolyte parameters by performing 1 :1 (vol: vol) exchange of solutes and particles smaller than 40 kDa against a custom dialysis exchange solution (20,000 mL), while maintaining euvolemia. Hemodiafiltration flux was kept at 30-35 mL/kg/hr throughout 6-hour perfusion.
Overview of the ECMO perfusion system
The ECMO perfusion system was assembled according to clinical standard. ECMO perfusion system has the main closed-loop circuit directly connected to an animal and consists of a centrifugal pump (Bio-Console 560, Medtronic) that drives autologous blood through the oxygenator (Affinity Fusion, Medtronic) into animal arterial system. The oxygenator is connected to a refrigerated bath (Polystat, Cole-Parmer) for temperature control and the gas blender (Sechrist Industries), for control of dissolved gases and anesthesia infusion. The perfusion system has a fluid reservoir, which is used to prime the system and hold the supplement fluid. Furthermore, ECMO perfusion system contained the CDI blood parameter module, and the hematocrit/oxygen saturation probe (Terumo Cardiovascular Systems Corp.) are connected on the arterial and venous side, respectively, along with pressure (PendoTECH) and flow sensors (Bio-Probe TX50, Medtronic). All probes and sensors from the ECMO perfusion system are connected to a computer to allow data gathering. Detailed schematics available upon request.
The ECMO perfusion system is primed with 1000 mL 0.9% Sodium Chloride (Baxter Healthcare Corporation, Deerfield, IL) and 5000 USP units of heparin (Sigma- Aldrich). Upon initiation of the perfusion protocol, the reservoir is taken out of the main circuit and the residual priming solution is stored for later supplementation. Animal anesthesia and surgical protocol
This research project was approved and overseen by Yale’s Institutional Animal Care and Use Committee (IACUC) and guided by an external advisory and ethics committee. Experimental animals were procured from the local farm breeder, female domestic pigs (Sus scrofa domesticus; ~30-35kg). All animals were housed at Yale School of Medicine Division of Animal Care’s facilities at a minimum of 3 days before the experiment.
Prior to experimental protocol, all animals received a Fentanyl patch, 50 ug/hr (Duragesic, Henry Schein, Melville, New York, NY, USA) for sedation. To induce anesthesia, 6mg/kg of Telazol (Henry Schein) and 2.2 mg/kg of Xylazine (Henry Schein) were administered. Next, animals were intubated and connected to the ventilator utilizing FiO2 of 40% and FiN2 of 60% with standard parameters of tidal volume 10-15 ml/kg and frequency of 14-16 breaths per minute, along with 1-2% isoflurane (Henry Schein). Following ventricular fibrillation and induction of cardiac arrest, ventilation was stopped for Ih. Upon initiation of the perfusion protocol, in ECMO and OrganEx groups, ventilation was continued utilizing a tidal volume of 3- 4 ml/kg, frequency 5 breaths per minute, positive end-expiratory pressure (PEEP) of 10 cm H2O, low inflation pressure, FiO2 50%, FiN2 50%. During the 6-hour perfusion protocol, 0.5% isoflurane was administered through the vaporizer connected to the gas blender.
Cardiac arrest and subsequent circulatory collapse were induced by ventricular fibrillation through the substernal window by applying a 9V battery to the myocardial wall. Prior to the ventricular fibrillation, animals received 7 000 USP units of heparin (Sigma- Aldrich). In order to connect the circulatory system of the animal to ECMO or OrganEx perfusion system, an incision was made in the right inguinal region exposing femoral artery and vein (FIGS.1 A-1G). Both, arterial and venous cannulas were inserted into femoral artery and vein, respectively. Artery was cannulated with 14 Fr and the vein with 19 Fr cannula (Edwards Lifesciences LLC, Irvine, CA). The tip of the venous cannula was placed in the inferior vena cava opening of the right atrium, and arterial cannula was positioned inferior to renal arteries.
Perfusion protocol and monitoring of physiologic and metabolic parameters
At the start of the perfusion protocol in the OrganEx group, a mixture of the perfusate and autologous blood was slowly infused over 5 minutes resulting in an average flow rate of 600 mL/min at the end of infusion. Following this step, the flow rate was gradually increased over the next 20 minutes to a targeted flow rate of 80-100 mL/kg/min or highest possible flow rate without introducing overspinning of the centrifugal pump. Throughout the flow rate ramping-up process, pulsatility was set to oscillate around the mean flow rate at approximately ±10% of the given total flow rate. Residual mixture of the synthetic perfusate and autologous blood which was stored in the reservoir was used for fluid supplementation at 1-2 mL/kg/hr. Targeted arterial pressure was set to 50-80 mmHg, and it was controlled with phenylephrine, not more than 2 mg/hr. Similarly, in the ECMO group, flow rate was gradually increased over 25 minutes, targeting flow rates and arterial pressures as in the OrganEx group. Ringer’s lactate (Baxter Healthcare Corporation) was used as a supplementation fluid at 3-4 ml/kg/hr. In both, ECMO and OrganEx group hypothermic perfusion protocol at 28°C was utilized throughout the entire 6- hours of the perfusion protocol.
The animals in both, ECMO and OrganEx groups received 50 mL of 8.4% sodium bicarbonate (Henry Schein) during the first hour of perfusion. Glucose was supplemented according to the blood levels with the goal of maintaining euglycemia. Protamine, 25mg, was administered immediately following initiation of the perfusion protocol to control activated clotting time, which was maintained between 180 and 220 seconds with titrated heparin administration. In both perfusion groups, partial pressure of arterial CO2 and O2 were targeted to 35 and 250 mmHg via gas blender, respectively.
Electrocardiogram (EKG) assessment was done with 4 leads placed at each corner of the trunk. Real time arterial and central venous pressure monitoring was done through cutdown of the brachial artery and jugular vein, respectively. Urine output was measured via Foley catheter. Animal core temperature was continuously monitored with a rectal probe. Monitoring of EKG, pressure and temperature was done utilizing Philips IntelliVue MP50 (Philips, Eindhoven, NL). During the preoperative procedure temperature was kept at 37°C using a heating pad, which was turned off following ventricular fibrillation. Electroencephalogram (EEG) was monitored with Natus long-term monitoring (LTM) system and EMU40 breakout box (Natus Medical Inc., San Carlos, CA). Six electrodes were placed subcutaneously along the scalp (FIG. 11 A) at the start of the sedation. EEG monitoring was conducted throughout the entire 6-hour perfusion protocol. Baseline and hourly arterial and venous samples were collected from the arterial and venous cannulas respectively. Sixty microliters of each sample were immediately analyzed using the GEM4000 clinical blood analyzer system (Instrumentation Laboratory, Bedford, MA). Continuous monitoring of blood electrolytes and hemoglobin concentration and saturation were done with CDI-500 (Terumo Cardiovascular Systems Corp.).
Radiographic and ultrasound imaging of circulation
Fluoroscopy
Imaging of the abdominal and head blood vessels was performed using Philips Allura Xper FD20 system. In selected animals that underwent fluoroscopy, baseline physiological imaging was performed prior to the induction of ventricular fibrillation in both ECMO and OrganEx experimental protocol. The contrast-injecting catheter was introduced through the femoral artery cutdown and positioned in suprarenal aorta for renal and in the common carotid artery for brain imaging. Omnipaque Contrast 350 mg/mL (General Electric Inc., Boston, MA), 24 mL and 45 mL were introduced utilizing Medrad power injector (Bayer Vital GmbH, Leverkusen, Germany) for brain and kidney imaging acquisition. Following baseline imaging, all animals underwent additional fluoroscopy at hour 3 of perfusion. In both, ECMO and OrganEx group, imaging of abdominal blood vessels was modified by placing the contrast-injecting catheter in the infrarenal aorta due to the reversal of arterial flow direction, a consequence of femoral artery/vein perfusion approach in both, ECMO and OrganEx groups. The reconstructed images were saved in DICOM format and further post-processed using RadiAnt DICOM Viewer software (Medixant; Poznan, Poland).
Ultrasonography
Perfusion dynamics were monitored via Triplex Ultrasonography (Spectral Doppler, Colour Doppler, and B-mode) using the LOGIQe portable ultrasound system (General Electric) and an 8L-RS linear array probe (General Electric). In all assessed animals, left ophthalmic artery, common carotid artery and intrarenal arteries were used to profile perfusion dynamics. Power waveform analysis was done using Frq 4.4 MHz, Gn 17, SV 2 and DR 40.
Cell nuclei isolation
Following the appropriate experimental workflow, regions of interest were extracted from each organ and frozen at -80 °C. To ensure consistency between the specimens, all dissections were performed by the same person. Cell nuclei isolation from each organ (brain, heart, liver, kidney) were treated the same according to our already established protocol with some modifications in order to acknowledge each organ’s specific structural qualities and to have identical buffers to enable inter-organ comparison within the same experimental animal. To avoid experimental bias nuclei isolation was done by the same person blinded for the replicates of experimental conditions. Furthermore, to randomly and fully represent the full tissue section, each tissue was pulverized to fine powder in liquid nitrogen with mortar and pestle (Coorstek, Golden, CO). All reagents were molecular biology grade and sourced from Sigma unless stated otherwise. Small amounts of pulverized tissue (5-10 mg) were then added into 1 ml of ice-cold lysis buffer (“Buffer A” is 250 mM sucrose, 25 mM KC1, 5 mM MgCh, lOmM NaCl, 10 mM Tris-HCl (pH 7.4), protease inhibitors w/o EDTA (Roche), RNAse inhibitor (80 U/ml) (Roche), ImM DTT, 1% BSA (m/v) (Gemini Bio-Products, Woodland, CA), 0.1% NP-40 (v/v), 0.1% Tween-20 (v/v) (Bio-Rad), 0.01% Digitonin (m/v) (Thermo-Fisher, Cleveland, OH). For lysis of heart, 0.1% TX-100 (v/v) was additionally added. DTT, RNAse Protector, protease inhibitors, and all detergents were added immediately before use. The suspension was transferred to 2ml Dounce tissue homogenizer and lysed with constant pressure and without introduction of air with pestle A (30x) and pestle B (30x). The homogenate was strained through pre-wetted 40 pm tube top cell strainer (Thermo-Fisher). All subsequent centrifugation was performed in a refrigerated, bench-top centrifuge with swing-out rotor (Eppendorf, Hamburg, Germany). Heart lysate was centrifuged at 100g for 5 min at 4°C, pellet of myofibrils and non-dissociated connective tissue was discarded, and supernatant saved. All lysates (brain, liver, kidney) and heart supernatant (post 100g) were centrifuged at 1000g, 10 min, 4 °C, pellets were saved, and resuspended in 0.4 ml resuspension buffer (“Buffer B” is “Buffer A” w/o detergents). Final 0.4 ml of solution was mixed with 0.4 ml (1 : 1) of Optiprep solution (Buffer “C” is iodixanol 50% (v/v), 25 mM KC1, 5 mM MgC12, 10 mM NaCl, 10 mM Tris-HCl (pH 7.4), protease inhibitors w/o EDTA, RNAse inhibitor (80U/ml), ImM DTT, 1% BSA (m/v)). The suspension (25% iodixanol final) was mixed lOx head over head and overlayed on 0.6 ml of 29% iodixanol cushion (appropriate mix of Buffer “B” and “Buffer “C”). The tubes were then centrifuged at 3000g, for 30 min at 4°C. Following centrifugation, the supernatant was removed and total of 1 ml of wash buffer (“Buffer D” is 25 mM KC1, 5 mM MgC12, lOmM NaCl, 10 mM Tris-HCl (pH 7.4), RNAse inhibitor (80 U/ml), 1 mM DTT, 1% BSA (m/v), 0.1% Tween 20 (v/v), in DPBS (w/o Ca2+ and Mg2+) (Gibco) )was added in tubes and centrifuged at 1000g, for 10 min at 4 °C. Supernatants were then completely removed, pellets were gently dissolved by adding 100 ul of resuspension buffer (“Buffer E” is “Buffer D” w/o detergent) and pipetting 30x with 1ml pipette tip, pooled and filtered through 20 micrometer cell strainer. Finally, nuclei were counted on hemocytometer and diluted to 1 million/ml.
Single nuclei microfluidic capture and cDNA synthesis
Extracted nuclei samples were placed on ice and processed in the laboratory within 15 minutes for single nucleus RNA sequencing with targeted nuclei recovery of 10000 nuclei, respectively, on microfluidic Chromium System (lOx Genomics, Pleasanton, CA) by following the manufacturer’ s protocol
(CG000315_ChromiumNextGEMSingleCell3'_GeneExpression_v3. l(DualIndex)_RevA), with Chromium Single Cell 3' GEM, Library & Gel Bead Kit v3.1, (PN-1000268, lOx Genomics) and Chromium Single Cell G Chip Kit (PN- 1000120, lOx Genomics), Dual Index Kit TT Set A (PN- 1000215, lOx Genomics) on Chromium Controller (lOx Genomics). Since the input material were nuclei, cDNA was amplified for 14 cycles.
Single-nucleus RNA-Seq library preparation and sequencing
Post cDNA amplification cleanup and construction of sample-indexed libraries and their amplification followed manufacturer’s directions
(CG000315_ChromiumNextGEMSingleCell3'_GeneExpression_v3. l(DualIndex)_RevA), with the amplification step directly dependent on the quantity of input cDNA.
In order to reach sequencing depth of 20000 raw reads per nucleus, single nucleus libraries were run using paired end sequencing with single indexing on the NovaSeq 6000 S4 (Illumina) by following manufacturer’s instructions (Illumina, San Diego, CA; lOx Genomics). To avoid lane bias, multiple uniquely indexed samples were mixed and distributed over several lanes.
Single-nucleus transcriptome analysis
Quality control and analysis of single nuclei transcriptome data
Sequencing reads were aligned to the reference pig genome (susScrl 1) with the combined exon-intron gene annotations from NCBI RefSeq using CellRanger 5.0.1. pipeline, which also performed UMI counting, barcode counting and distinguishing true cells from background. The filtered count matrices were then moralized by library size using the “NormalizeData” function in Seurat. To compare cellular and transcriptomic changes across conditions, feature selection was first performed for each batch and the features from the same conditions were summarized using “SelectlntegrationFeatures”. The union of the highly variable genes across conditions were then passed to the data integration pipeline in Seurat to generate a batch-corrected expression matrix. To reveal the cellular diversity among the cells, we scaled the integrated data followed by dimension reduction using principal component analysis (PCA) and selecting principal components via elbow plot. The cell clusters in the k-nearest neighbor graph were then identified and visualized clustering results by Uniform Manifold Approximation and Projection (UMAP). The initial clustering analysis revealed some low-quality clusters with low number of unique molecular identifiers (UMIs), and normally high mitochondria percentage and no meaningful cluster markers, which were all removed for downstream analysis. To annotate the identity of the cell clusters, the pig data was then integrated with published human data from the same organ using the same data integration pipeline described above. The cluster markers were calculated using “FindMarkers” function and manually removed the doublet clusters that showing high expression of markers of two different type of cells. To gain more accurate cell annotations and clearer UMAP visualizations, the same pipelines of data integration, dimension reduction and cell clustering were reperformed on the filtered data.
Global transcriptomic comparisons with public datasets.
To validate the cluster annotation of the data, global transcriptomic comparison with public reference datasets for the four organs was performed. For each organ, the log-transformed average expression for each cell clusters was calculated followed by performing pairwise Pearson correlation between the clusters in the present dataset and the corresponding dataset using the highly variable genes. The resulted correlation coefficients were visualized on gradient heatmaps (FIGS. 12C-12F).
Cell type annotations.
The cell type classification for hippocampus data (FIG. 12C) was based on the gene markers derived from recent data in adult human hippocampus and entorhinal cortex. The cells were initially classified into several major groups based on marker gene expression: excitatory neurons (SLC17A7+), inhibitory neurons (GAD1+), oligodendrocyte progenitor cells (PDGFRA+), oligodendrocytes (PLPl+ astrocytes (AQP4+ microglia (PTPRC+), vascular cells (COL1A1+). Because of the high heterogeneity present in excitatory and inhibitory neuron populations, these two populations were further subclustered. For excitatory neurons, they were classified to mature granule cells (PROX1+), mossy cells (ADCYAP1+), CA2-4 excitatory neurons (FREM1+IGALNT3+), CAI and subiculum excitatory neurons (SATB2+IBCL11B+ITLE-), entorhinal cortex upper layer (CUX2+) and deep layer (TLE4+) excitatory neurons. For inhibitory neurons, they were classified based on their developmental origins, either derived from medial ganglionic eminence (MGE, LHX6+) and caudal ganglionic eminence (CGE, ARADB2+). For a small group of cells connecting granule cells on the UMAP that are devoid of all these markers but marked by DCX and CALB2 expression, they were annotated as neuroblast cells, intermediate cell populations in pig adult neurogenesis.
The heart data (FIG. 12D) was annotated based on the gene markers derived from recent data in adult human heart. We classified the cells based on marker expression: cardiomyocyte (MYH7+/FHL2+ immune cells (PTPRC+), pericytes (RGS5+/ABCC9+), smooth muscle cells (MYH11+/ACTA2+), endothelial cells (CDH5+/PECAM1+), fibroblast-like cells (DCN+/GSN+) and neuronal cells (NRXN1+/XKR4+). The endothelial cells have two subgroups that have differential expression of FWF and TBX1. Immune cells were further classified to myeloid cells (BANK1+/C1QA+) and lymphoid cells (SKAP 1+/CD8A+).
The kidney data (FIG.12E) was annotated based on the gene markers derived from recent data in adult human kidney. We classified the cells based on marker expression: proximal tubule (CUBN+ILRP2+), connecting tubule and principal cells (SAMD5+ILINGO2+), loop of Henle (NHSL2+/UMOD2+), intercalated cells (HEPACAM2+ISLC26A7+), podocyte (PTPRQ+/ PTPRO+), immune cells (PTPRC+), endothelium (CEIRM3+IPTPRB+) and fibroblasts (PRKG1+/FBLN5+). Immune cells were further classified to myeloid cells (BANK1+/MARCH1+) and lymphoid cells (SKAP1+/THSD7B+).
The liver data (FIG.12F) was annotated based on the gene markers derived from recent data in adult mouse liver. The cells were classified based on marker expression: hepatocytes (APOB+/PCK1+), stellate cells (RELN+/ ACTA2+), cholangiocytes (CFTR+/PKHDl+\ immune cells (PTPRC+), endothelial cells (FLT1+/PECAM1+). The immune cells were further classified to multiple subgroups: B cells (MS4A1+), plasma cells JCHAIN+!MZBl+ natural killer cell and T cells (SKAP1+), myeloid cells (CD163+/EMR4+, which are predominantly Kupffer cells).
Heterogeneity of cells.
FindMarkers function from Seurat was used to determine marker genes for high resolution clusters. P-value adjustment is performed using Bonferroni correction with the cutoff set at 0.05. Top 10 genes for each cluster were ranked by fold changes and were visualized on a heatmap by using DoHeatmap function (Seurat). The dataset was randomly sampled to have 1000 cells per condition for each t-type prior to differential expression analysis.
Cell type prioritization using Augur
In order to find the cell populations that exhibit high degree of transcriptomic changes, Augur was applied to prioritize the cell types between each pair of conditions. Since there are three samples per condition, the Augur analysis was performed on all of the nine sample pairs in each condition pair using the high-resolution cell clusters identified via Seurat. The median of the calculated area under curve (AUC) scores of each cluster were then visualized on the UMAP layout. Comparison of the AUC scores for each specific cell type and a given condition pair were done by comparing the specific cell type of interest AUC score and AUC scores of all the other cell types in that given condition pair by using Wilcoxon Rank Sum test (one tailed).
Differential expression analysis and gene ontology analysis
In order to find differentially expressed genes (DEGs) between OrganEx and other conditions (Oh PMI, Ih PMI, 7h PMI, ECMO) in major cell-types for each organ Seurat “FindMarkers” function was used. DEGs were defined at cut-off criteria of adjusted P-value (Bonferroni) < 0.05, expression ratio greater than 0.1 in one condition and average log2 fold change (log2FC) greater than 0.2 in the same condition. Top 15 DEGs ranked by absolute values of log2FC, were visualized using Bioconductor EnhancedVolcano package. Top 100 DEGs were used for HumanBase Functional Module Detection. Gene symbols starting with ma and LOC were excluded since HumanBase Functional Module Detection does not recognize those gene symbols. Identifying enriched biological pathways between OrganEx and all other groups in major cell-types for each organ, was performed using “enrichGO” function from clusterProfiler. Multiple testing was adjusted by false discovery rate (FDR) with the cutoff set at 0.2. Top 15 biological processes ranked by P-value were visualized by in-house made ggplot2 script.
Gene set enrichment analysis
In order to assess whether gene sets of interest are upregulated in a specific condition (e.g., Oh WIT, Ih WIT, 7h WIT, ECMO and OrganEx), gene set enrichment analysis was performed in hippocampal neurons, astrocytes and microglial cells, cardiomyocytes in the heart, hepatocytes in the liver and proximal convoluted tubule cells in the kidney. This method is commonly used in Gene Ontology enrichment analysis and has been widely applied in multiple published studies. Specifically, all the expressed genes (expressed in at least one cell) were set as the gene universe and considered each set of condition-enriched genes as a sampling from the gene universe. The gene set enrichment, performed by Hypergeometric test (also named one- tailed Fisher’s Exact test), is an assessment of whether genes from a given gene sets are overrepresented in condition-enriched genes than drawing from the gene universe by chance. To identify condition-enriched genes in the above-mentioned t-types, differential expression (DE) analysis was performed using Seurat FindMarkers function. In brief, one condition group was taken, its expression profiles were compared with the rest of the conditions using Wilcoxon Rank Sum test. For any given comparison, genes with false discovery rate (FDR) smaller than 0.01 were considered statistically significant and were kept. Because Wilcoxon Rank Sum test can be biased by the differences of cell numbers, that is, more cells lead to more differentially expressed genes, the datasets were randomly sampled to have 1000 cells per condition in each t-type prior to differential expression. With the condition-enriched genes and certain selected gene sets downloaded from GeneOntology (http://geneontology.org/), it was possible to assess the significance of gene set enrichment in a given condition. P-value of less than 0.05 was considered significant. Significance of the enrichment was visualized in a dot plot where size and color of the dot shows significance as -loglO(p-value). As shown in the FIG.6A-6D, enrichment in all conditions in all organs was tested for positive regulation of DNA repair (G0:0045739), negative regulation of apoptotic process (GO: 0043066), positive regulation of cytoskeleton organization (G0:0051495) and ATP metabolic process (G0:0046034). The same approach was used in assessment of functional enrichment analysis for each organ. Therefore, in hippocampus microglial cells were tested in enrichment for pro-inflammatory markers, and in astrocytes for pan-reactive markers as shown in FIG.6 A. Cardiomyocytes in heart were tested for Cardiac Muscle Cell Action Potential (GO: 0086001), Fatty Acid Beta-Oxidation (GO: 0006635) and Glycolysis (G0:0006096) as can be seen in FIG.6B. In the liver, Hepatocytes enrichment of acute phase reactants and all expressed CYP isoforms (FIG.6C) were tested in, and at last, proximal tubule cells in the kidney were tested for injury molecule genes and PCT transporter genes (FIG.6D).
Gene set expression enrichment analysis.
The expression dynamics of selected cell death-related gene set across conditions was also evaluated. For each gene of the given gene set, its expression enrichment was tested in each condition by comparing its expression in the given condition to that of other conditions. Similarly, Wilcoxon Rank Sum test was used to measure the significance. The resulted log- transformed P-values (-log l0[P-value]) across conditions were visualized in a bar plot.
Hierarchical clustering for top DEGs.
To acquire the dynamic changes of transcriptome among different conditions and time points for each tissue, the top differential expressed genes for all the paired conditions were identified: Oh vs Ih, Oh vs 7h, Oh vs ECMO, Oh vs OrganEx, Ih vs 7h, Ih vs ECMO, Ih vs OrganEx, 7h vs ECMO, 7h vs OrganEx, and ECMO vs OrganEx using FindMarkers() function in Seurat. For hippocampus, significant DEG was selected with average log2FC greater than 0.5 or less than -0.5. The top 50 upregulated genes were merged with 50 downregulated differentially expressed genes (DEGs, in total 100 genes) from each paired condition for the following analysis. To identify gene expression patterns, the average expression of the merged DEGs across t-types and experimental groups was calcualted and the correlation coefficients subtracted from 1 as gene-gene distances was defined, which was passed to hierarchical clustering using the hclust function in R with ward.D2 algorithm. To define gene modules (clusters), the genes were parcellated using the cutreeDynamic function from R WGCNA package with a setting minClusterSize = 45, sensitivity = 2. The scaled eigengenes were the plotted, the first principal component of the expression matrix of each module to show the expression trend of the genes in each module. Using TopGO, the gene ontology analysis was performed for the genes in each module, and used fisher’s exact test to calculate the P values. For heart, kidney and liver, the same methods with hippocampal data to select the genes were used. To keep the numbers of selected gene are comparable with hippocampus samples, significantly DEG with average log2FC greater than 0.75 or less than -0.75 in heart data, significantly DEG with average log2FC greater than 1.00 or less than -1.00 in kidney data and selected significantly DEG with average log2FC greater than 1.75 or less than -1.75 in liver data. Then the same setting was used to build the gene expression network using hierarchical clustering. The scaled eigengenes of each module was plotted and used the same method (TopGO) for gene ontology analysis.
Evaluation of the perfusate components effects.
To evaluate the effects of the perfusate components on OrganEx, the expression enrichment of the related pathways (cell death, inflammation, and oxidative response) between OrganEx and ECMO conditions (Tables 4, 5, and 6) were compared. Specifically, the AUC (area under curve) scores were calculated using the AUCell package and a one-sided Wilcoxon Rank- Sum test was performed to evaluate the significance of the pathway enrichment.
Trajectory analysis.
The monocle2 was used and in-house R scripts to conduct pseudotime analysis for hippocampus, heart, liver, and kidney. The recommended analysis protocol was followed, except using FindMarkers function from Seurat package to perform pairwise comparison across different conditions to find the statistically significant up- and down-regulated genes. To reduce false positive results, some parameters were customized based on computational permutation. For examples, it was required that minimum percentage of expressed cells for each gene in either condition is larger than 0.1, and fold change larger than 1.25. Maximum number of cells in either condition was down sampled to 1000 cells to balance the comparison. Consequently, the identified differentially expressed genes by Seurat were used as the informative genes to order cells using setOrderingFilter function from monocle2, and the advanced nonlinear reconstruction algorithm called DDRTree was chosen to execute data dimensional reduction.
Cell-cell communication analysis. Cell-cell interactions based on the expression of known ligand-receptor pairs in different t-types were inferred using CellChat (v.1.1.3). The official CellChat workflow was followed for analyzing multiple datasets (Oh WIT, Ih WIT, 7h WIT, ECMO and OrganEx). each dataset was first randomly down sampled to 1000 cells per t-type to to balance the comparison. Next, normalized counts were loaded into CellChat. After that, CellChatDB human database was selected for cell-cell communication analysis. The preprocessing was then applied as functions identifyOverExpressedGenes and identifyOverExpressedlnteractions with standard parameters set. Next, communication probability was computed between interacting cell groups with truncated mean set at 0.1. After that filterCommunication, computeCommunProbPathway, and aggregateNet were applied using standard parameters. To identify conserved and contextspecific signaling pathways rankNet function was applied on the netP data slot which showed in a stacked bar plot overall information flow of each signaling pathway. To determine strength of the reactions and t-types involved in each signaling pathway, netAnalysis signalingRole heatmap was performed and visualized overall signaling by aggregating outgoing and incoming signaling together.
Pseudotime analysis
The monocle2 and in-house R scripts were used to conduct pseudotime analysis for all major organs, including hippocampus, heart, liver, and kidney. The recommended analysis protocol was followed, except using FindMarkers function from Seurat package to perform pairwise comparison across different conditions to find the statistically significant up- and down- regulated genes. To reduce false positive results, some parameters were customized based on computational permutation. For examples, it was required that minimum percentage of expressed cells for each gene in either condition is larger than 0.1, and fold change larger than 1.25. Maximum number of cells in either condition was down sampled to 1000 cells to balance the comparison. Consequently, the identified differentially expressed genes by Seurat were used as the informative genes to order cells using setOrd eringFilter function from monocle2, and the advanced nonlinear reconstruction algorithm called DDRTree was chosen to execute data dimensional reduction.
Tissue processing and histology Tissue preparation
Following the completion of each experimental protocol brain, heart, lungs, kidney, liver, and pancreas were extracted and immersion-fixed in a solution containing 10% (w/v) neutral buffered formalin with gentle shaking. After fixation each tissue piece was processed and embedded into a paraffin block using the Excelsior tissue processor (Thermo Scientific, Waltham, MA).
Tissue staining with hematoxylin and eosin (H&E) and TUNEL Assay
Heart, lungs, kidney, liver and pancreas paraffin blocks were trimmed on the Shandon Finesse 325 microtome (Thermo Scientific) to 5 pm sections. Sections were mounted on TruBond 380 adhesive slides and allowed to dry overnight at room temperature. All slide were then stained simultaneously for H&E using the automatic Shandon Linistain slide Stainer (Thermo Scientific).
For Nissl staining, brain sections (hippocampus and prefrontal cortex) were stained with 0.1% cresyl violet solution (Abeam, ab246816) for 5 min and were rinsed quickly in 1 change of distilled water. Then these sections were dehydrated quickly in absolute alcohol and later cleared in Histo-Clear II and finally cover-slipped with Prolong Gold Antifade Mountant (ThermoFisher, P36934).
All slides for the TUNEL Assay (Millipore, S7101, 3542625) were processed simultaneously. They were fist deparaffinized, rehydrated and incubated with proteinase K (20 pg/mL in PBS) for 30 min at 37°C. Slides were rinsed with PBS and incubated with 3% H2O2 in PBS for 10 min at room temperature to block endogenous peroxidase activity, followed by PBS washing and incubation in 0.1% Triton X-100 in 0.1% sodium citrate for 2 min on ice (4°C). Sections were incubated with a mixture of TdT solution and fluorescein isothiocyanate dUTP solution in a humidified chamber at 37°C for 60 min. This was followed by washings with PBS and incubation with antifluorescein antibody Fab fragments conjugated with horseradish peroxidase in a humidified chamber at 37°C for 30 min. After washing with PBS, methyl green counterstain was applied to stain for nuclei.
Immunohi stochemi stry All slides used for a specific immunohistochemistry staining were processed simultaneously. Slides containing formalin-fixed paraffin-embedded histological sections were first deparaffinized in 2 changes of Histo-Clear II (64111-04, Electron Microscopy Sciences, Hatfield, PA) for 10 minutes each. Slides were then transferred to 100% alcohol, for two changes, 10 minutes each, and then transferred once through 95%, 70%, and 50% alcohol respectively for 5 minutes each. Slides were then rinsed in water and washed in wash buffer (0.05% Tween 20 in IX PBS) for 10 minutes. Slides were then placed into a chamber filled with antigen retrieval buffer (10X R-Buffer A diluted to IX by water, pH 6, 62706-10, Electron Microscopy Sciences). Slides then underwent heat-mediated antigen retrieval in the Unique Retriever system (Electron Microscopy Sciences). After antigen retrieval, slides were washed in wash buffer and blocked for 1 hour in 10% normal goat serum diluted in wash buffer at room temperature. Slides were then incubated in primary antibodies at 4 degrees C overnight at the following dilutions: rabbit anti-NeuN (1/1000, Abeam, abl77487, GR3275112-10), mouse anti- GFAP (1/1000, Sigma-Aldrich, G3893-100UL, 0000082460), rabbit anti-Ibal (1/500, Wako, 019-19741, PTR2404), mouse anti-albumin (1/500, Abeam, 4A1C11, GR3215248- 15), mouse anti-beta actin (1/500, Invitrogen, AC-15, 01003256), rabbit cleaved caspase-3 (1/50, R&D Systems, MAB835, KHK0821021). The next day, slides were washed and then incubated with fluorescently tagged secondary anti-rabbit (Cell Signaling Technology, 8889S, 12) and antimouse (Abeam, abl50113, GR3370569-1) antibodies at a dilution of 1/500 for 1 hour at room temperature. After staining with secondary antibodies, slides were washed and incubated in DAPI (1/1000 for 5 minutes) at room temperature. Finally, slides were washed and mounted with coverslips using Prolong Gold Antifade Mountant (P36934, ThermoFisher).
Microscopy and image processing
Tissue sections were imaged using an LSM880 confocal microscope (Zeiss; Jena, Germany) equipped with a motorized stage using 10x (0.3 NA) or 20* (0.8 NA) objective lenses with identical settings across all experimental conditions. Lasers used: argon 458, 488, and 514; diode 405; and DPSS 561-10. The DPSS 561-10 laser intensity was increased during imaging of the control perfusate samples for the intravascular hemoglobin fluorescence study in order to obtain a background signal comparable to other groups. Images were acquired at either 1,024 x 1,024 or 2,048 x 2,048-pixel resolution. Images are either representative confocal tile scans, high-magnification maximum intensity Z-stack projections (approximately 7-9-pm stacks; ~1 pm per Z-step), or high magnification confocal images. Alternatively, histological images were acquired using an Aperio CS2 Pathology Slide Scanner (Leica; Wetzlar, Germany) as described above. Image adjustments were uniformly applied to all experimental conditions in Zeiss Zen. Digitized images were assembled in Zeiss Zen, ImageScope, and Adobe Illustrator.
Histological data analysis and quantification
H&E staining - pathology injury score
All H&E slides were scanned. Four images were randomly selected from each slide and from the corresponding areas. Blinded observers scored each image accordingly. Criteria for heart were nuclear damage, myocyte vacuolization, widened spaces between myofibers and edema. Criteria for lungs were nuclear damage, pneumocyte vacuolization and hemorrhage. Criteria for kidney were nuclear damage, tubule vacuolization, hemorrhage, and tubule damage. Criteria for liver were nuclear damage, tissue vacuolization, hepatocyte vacuolization, and congestion. Criteria for pancreas were nuclear damage, cell vacuolization, hemorrhage, edema.
Cresyl violet (Nissl) staining injury score.
Two images were taken per region of interest (hippocampal CAI region or PFC) and were evaluated by blinded observer using the cell counter function in Imaged according to already established criteria.
Kidney periodic acid-Schiff (PAS) staining - pathology injury score.
All kidney PAS-stained slides were examined by blinded kidney pathologist. Score (0-3) was assigned depending on the severity of the damage which included: Bowman space dilation, tubular dilation, tubular vacuolization, brush border disruption and presence of the casts.
Brain immunofluorescence cell analysis and quantification
All images were normalized to the regions of interests (hippocampal CAI, CA3 and DG) using Imaged and randomized. The number of labeled astrocytes (GFAP+ cells), microglia (IBA1+ cells) cells were quantified manually by a blinded observer using the cell counter plugin and averaged based on the acquired area/cells. The particle analysis of astrocytes was performed using a custom pipeline in the open-source software, CellProfiler56, where a uniform threshold was set on GFAP to identify GFAP+ skeleton objects. The number of GFAP+ fragments in each area were then auto-counted and averaged according to the number of the astrocytes. The mean intensity of NeuN per neuron were quantified by a custom pipeline where neurons were identified based on the DAPI segmented objects expressing NeuN. Data were analyzed and plotted in GraphPad Prism9 software. All data are shown as mean ± SEM. “n” refers to the number of biological replicates.
Kidney, liver, and heart immunofluorescence analysis.
In the kidney, three images were taken randomly of the kidney cortex. All images were randomized and analyzed by a blinded observer. Glomerulus and the proximal convoluted tubule were manually selected as the regions of interest in the four same-size circles respectively in corresponding regions across images. The mean intensity of ACTB and TIM1 was calculated using ImageJ software. The number of Ki-67 positive cells were manually counted.
In the liver, immunolabelling quantification was done the same for albumin and factor V. Three images were randomly taken from the same region of the liver. The mean intensity of albumin and factor V was automatically quantified using ImageJ across the whole slide.
In the heart, three images were taken randomly from the left ventricle just slightly below the epicardium. All images were randomized, after which a blinded observer selected cardiac muscle tissue as a region of interest. The amount of cytoplasmic troponin I was then quantified using mean intensity function in ImageJ.
Cell death pathway quantification and analysis (actCASP3, IL1B, RIPK3, and GPX4/
For kidney, liver, heart, and pancreas, three images were taken randomly from each slide and from the corresponding areas of each organ. actCASP3+ cell intensity was quantified manually by a blinded observer using ImageJ. Mean immunolabelling intensity of IL1B, RIPK3 and GPX4 in kidney, liver and heart was quantified using ImageJ with background subtraction and measure functions. In the brain, the number of actCASP3+ and RIPK3+ cells were counted manually in the hippocampal CAI region and prefrontal cortex. Expression of IL IB and GPX4 in hippocampal CAI was measured in cells that were manually selected in the granule cell layer using ImageJ measure function. TUNEL quantification and analysis.
All images were taken with a bright field microscope followed by a random same-size snapshots of the slides. A blinded observer analyzed randomized images using Fiji to separate channels of nuclei staining (hematoxylin) and DNA fragments (DAB). Total DNA fragments were quantified based on the total DAB intensity using CellProfiler.
Functional organ assessments
Heart contractility measurements
Small piece of the apical portion of the hearts’ left ventricle was excised and placed in the carbonated Tyrode’s solution (140 mM NaCl, 6 mM KC1, 10 mM glucose, 10 mM HEPES, 1 mM MgC12, 1.8 mM CaC12, pH=7.4). The tissue was then dissected into 1-2 cm3 cubes and placed on a holder with the epicardium facing down so the cutting align with the cardiac myofibril orientation. Using a vibratome, the heart was sliced at 150 pm thickness at 4°C. After slicing, spontaneous rate and rhythm of heart contraction were characterized and recorded using a slice microscope with temperature control set to 37°C (Scientifica SliceScope, Uckfield, UK). Beating frequency was quantified within the time course of 30 seconds.
Glucose assays
At the end of each perfusion, two identical tissue samples with 5 mm length were acquired from each organ (kidney, heart, and cerebral cortex) using a 3 mm biopsy punch (Miltex, Integra, York, PA) and were placed in cold PBS (fresh) and PFA (fix overnight) solutions respectively. The fresh tissues and the fixed controls were incubated in 2-NBDG working solution (Cayman 11046, 100 pM, Ann Arbor, MI) for 30 min at 37°C followed by 15 min of wash in PBS. The images were acquired immediately using widefield microscope (Zeiss) under 2.5x objective (Ex: 465-495 nm, Em: 5210-560 nm) with exposure time of 295 ms (kidney and heart) and 50 ms (cerebral cortex). Images were analyzed using Imaged to quantify the mean intensity of the ROI with normalization based on the fixed controls.
Organotypic hippocampus culture and nascent protein synthesis assay Hippocampus was isolated at the end of appropriate experimental protocol and sectioned with a vibratome at 250 pm thickness in carbonated NMDG-HEPES aCSF solution (92 mM NMDG, 2.5 mM KC1, 1.25 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 2 mM thiourea, 5 mM Sodium ascorbate, 3mM Sodium pyruvate, 0.5 mM CaC12 2H2O, and 10 mM MgSO4 7H2O, pH=7.3). Hippocampal slices were then collected and transferred onto culture membranes (Falcon culture insert, 0.4 pm) and cultured in a six-well culture dish with 1.5 ml medium (48% DMEM/F-12 (Gibco), 48% Neurobasal (Gibco), lx N-2 (Gibco), lx B-27 (Gibco), lx Glutamax (Gibco), lx NEAA (Gibco), lx Pen Strep (Gibco). The plates were maintained in an incubator at 37°C with 5% CO2 for up to 2 weeks. The amino acid methionine analog, azidohomoalanine (AHA, ThermoFisher), was added to the hippocampal slice at a final concentration of 50 pM in HEPES buffered solution (HBS) followed by the incubation of 6 hours at 37°C. Slices were washed with PBS and immediately fixed in 4% paraformaldehyde at 4°C overnight. Detection of nascent protein synthesis was performed with the modified Click-iT 1-azidohomoalanine (AHA) Alexa Fluor 488 Protein Synthesis HCS Assay kit (ThermoFisher). To visualize neurons simultaneously, the slices were then blocked with 5% NDS for 1 hour at room temperature, and incubated with Rabbit anti-NeuN antibody (abeam, 1 : 1000) overnight at 4°C followed by the incubation of anti-rabbit AlexaFluor647 (1 :500) for 1 hour at room temperature. The slices were then co-stained with DAPI to visualize nuclei. Images were acquired using Zeiss LSM800 confocal microscope with 20x objective. The combined Z-stack images of DAPI, Al exaFluor 488 and Al exaFluor 647 channels were acquired with optical slice thickness of around 20 pm and images of maximum projection are shown. Proteins detected around the nucleus (perinuclear) are the most abundant newly synthesized proteins in cells28, and were quantified using Imaged intensity measurement function.
Image visualization
Depiction of the pig in FIG.1A, and pig’s head in FIG.11 A, were adapted from BioRender.com with postprocessing in Adobe Illustrator and Adobe Photoshop.
Statistical analysis and reproducibility
All data are reported as mean ± standard error of mean with data analysis being conducted using one-way ANOVA with Dunnett’s post hoc multiple comparisons in reference to the OrganEx perfusion group, or unpaired t-test for comparisons between two groups. Fisher’s exact test was used to compare occurrence of QRS complexes in OrganEx and ECMO groups during the perfusion protocol. For the number of replicates in each experimental group together with appropriate statistical analyses please see below. Significance was set at P < 0.05. All statistical analysis and plotting were done in GraphPad 9 (GraphPad Software, San Diego, CA) or in Python. All figures were created using Adobe Illustrator (Adobe Systems, San Jose, CA).
Further information on statistical analyses
Further information regarding statistical values and reproducibility of the results is given below.
In FIGS. 2C-2E, the results are taken at the baseline (where applicable) and every hour throughout the perfusion experiment from ECMO and OrganEx perfusion groups. Each group consisted of n=6 biological replicates. In FIG. 2C, Total flow rate: P values for hours 1-6, Ih: <0.0001, 2h: <0.0001, 3h: <0.0001, 4h: <0.0001, 5h: <0.0001, 6h: <0.0001; t values for hours 1- 6, Ih: 12.34, 2h: 8.120, 3h: 8.869, 4h: 9.683, 5h: 17.64, 6h: 22.96. Brachial arterial pressure: P values for hours 0-6, Oh: 0.9704, Ih: <0.0001, 2h: 0.0002, 3h: 0.0003, 4h: 0.0006, 5h: 0.0027, 6h: <0.0001; / values for hours 0-6, Oh: 0.03807, Ih: 12.24, 2h: 5.645, 3h: 5.480, 4h: 4.890, 5h: 3.953, 6h: 7.590. In FIG. 2D, Mixed venous O2 saturation: P values for hours 0-6, Oh: 0.8996, Ih: 0.0837, 2h: 0.0002, 3h: 0.0003, 4h: 0.0015, 5h: <0.0001, 6h: 0.0036; t values for hours 1-6, Oh: 0.1295, Ih: 1.920, 2h: 5.582, 3h: 5.453, 4h: 4.338, 5h: 7.691, 6h: 3.781. In FIG. 2E, Serum K+: P values for hours 0-6, Oh: 0.8365, Ih: 0.0001, 2h: 0.0008, 3h: <0.0001, 4h: <0.0001, 5h: <0.0001, 6h: <0.0001; / values for hours 0-6, Oh: 0.2118, Ih: 6.156, 2h: 4.707, 3h: 7.224, 4h: 12.24, 5h: 7.401, 6h: 9.358. Serum pH: P values for hours 0-6, Oh: 0.3489, Ih: <0.0001, 2h: <0.0001, 3h: <0.0001, 4h: <0.0001, 5h: <0.0001, 6h: <0.0001; t values for hours 0-6, Oh: 0.9827, Ih: 6.285, 2h: 9.256, 3h: 9.668, 4h: 8.427, 5h: 7.056, 6h: 7.034.
In FIGS. 3B-3D, data points are from a representative brain per condition; the experiment was repeated in n=3 independent brains per condition. In FIG. 3B, One-way ANOVA P = 0.0001, F[4, 10] = 19.12) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.009; OrganEx vs ECMO: P = 0.003. In FIG. 3C, One-way ANOVA (P = 0.0098, F[4, 10] = 6.035) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0059; OrganEx vs ECMO: P = 0.0356. In FIG. 3D One-way ANOVA (P = 0.0076, F[4, 10] = 6.495) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0109.
In FIGS. 3F-3H, data points are from a representative organ (heart, liver and kidney) per condition, the experiment was repeated in n=5 independent organs per condition. In FIG. 3F, One-way ANOVA (P < 0.0001, F[4,20] = 52.16) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0429; OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P < 0.0001. In FIG. 3G, One-way ANOVA (P < 0.0001, F[4,20] = 50.79) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.006; OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P = 0.0009. In FIG. 3g, One-way ANOVA (P < 0.0001, F[4,20] = 50.79) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.006; OrganEx vs 7h WIT: P < 0.0001. OrganEx vs ECMO: P = 0.0009; In FIG. 3H, One-way ANOVA (P < 0.0001, F[4,20] = 17.79) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0001; OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P = 0.0022.
In FIGS. 3 J-3K, data points are from a representative kidney per condition, the experiment was repeated in n=3 independent kidneys per condition In FIG. 3 J, One-way ANOVA (P = 0.0262, F[4, 10] = 4.398) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0103. In FIG. 3K, One-way ANOVA (P = 0.0057, F[4, 10] = 7.082) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0023.
In FIGS. 5A-5C, data points are from a representative organ (brain, heart, and kidney) per condition, the experiment was repeated in n=3 independent organs per condition. In FIG. 5 A, One-way ANOVA (P = 0.003, F[2,6] = 17,73) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0024. In FIG. 5B, One-way ANOVA (P = 0.0033, F[2,6] = 17,07) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0033. In FIG. 5C, One-way ANOVA (P = 0.0033, F[2,6] = 6.453) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0320.
In FIG. 5D, each data points are from representative perfusion experiment per condition, the experiment was repeated in n=5. Two-sided Fisher’s exact t test was used: P = 0.0476.
In FIG.5F, each data point is from the representative liver per condition, the condition was repeated in n=3 times. One-way ANOVA (P < 0.0001, F[4, 10] = 15.52) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0002; OrganEx vs 7h WIT: P = 0.0005; OrganEx vs ECMO: P = 0.0007.
In FIGS. 5H, 5J, each data point is from the representative hippocampal slice per condition, the experiment was repeated n=3-5 times per condition. In FIG. 5H, for day 1 : Oneway ANOVA (P = 0.0352, F[2, 10] = 4.766) with post-hoc Dunnett’s adjustment was performed; for day 14: One-way ANOVA (P = 0.0027, F[2, 10] = 11.35) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0026. In FIG. 5J, for day 1 : One-way ANOVA (P = 0.0077, F[2, 10] = 8.246) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0216; for day 14: One-way ANOVA (P = 0.0270, F[2,9] = 5.544) with post- hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.027.
In FIG. 7C-7D, each data point is from the representative perfusion experiment per condition, the experiment was repeated in n=6. In FIG. 7C, Arterial cannula pressure: P values for hours 1-6, Ih: < 0.0001, 2h: < 0.0001, 3h: < 0.0001, 4h: < 0.0001, 5h: < 0.0001, 6h: < 0.0001; / values for hours 1-6, Ih: 12.34, 2h: 8.120, 3h: 8.869, 4h: 9.683, 5h: 17.64, 6h: 22.96. In FIG. 7C, Venous cannula pressure: P values for hours 1-6, Ih: < 0.0001, 2h: = 0.0306, 3h: = 0.0237, 4h: = 0.0003, 5h: = 0.0069, 6h: = 0.0027; / values for hours 1-6, Ih: 9.058, 2h: 2.516, 3h: 2.665, 4h: 5.516, 5h: 3.386, 6h: 3.946. In FIG. 7D, O2 delivery: P values for hours 1-6, Ih: < 0.0001, 2h: < 0.0001, 3h: < 0.0001, 4h: < 0.0001, 5h: < 0.0001, 6h: < 0.0001; / values for hours 1-6, Ih: 10.44, 2h: 6.957, 3h: 8.578, 4h: 9.462, 5h: 14.32, 6h: 18.56. In FIG. 7D, O2 consumption: P values for hours 1-6, Ih: = 0.8432, 2h: = 0.1815, 3h: = 0.3195, 4h: = 0.3667, 5h: = 0.2152, 6h: = 0.0394; / values for hours 1-6, Ih: 0.2030, 2h: 1.436, 3h: 1.048, 4h: 0.9455, 5h: 1.323, 6h: 2.368. In FIGS. 8B-8E, data points are from a representative brain per condition, the experiment was repeated in n=3 independent brains per condition. In FIG. 8B, One-way ANOVA (P = 0.0008, F[4, 10] = 11.95) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0097; In FIG. 8C, One-way ANOVA (P = 0.0003, F[4,10] = 14.64) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0006. In FIG. 8D, One-way ANOVA (P < 0.001, F[4, 10] = 44.47) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P < 0.001; OrganEx vs ECMO: P < 0.001. In FIG. 8E, One-way ANOVA (P < 0.001, F[4, 10] = 60.70) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Oh WIT: P = 0.0024; OrganEx vs Ih WIT: P < 0.001; OrganEx vs 7h WIT: P < 0.001; OrganEx vs ECMO: P = 0.0159.
FIGS. 8G-8L data points are from a representative brain per condition, the experiment was repeated in n=3 independent brains per condition. In FIG. 8G, One-way ANOVA (P = 0.011, F[4, 10] = 5.819) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0287; OrganEx vs 7h WIT: P = 0.0045; OrganEx vs ECMO: P = 0.0149. In FIG. 81, One-way ANOVA (P < 0.0003, F[4, 10] = 32.20) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Oh WIT: P = 0.0243; OrganEx vs 7h WIT: P = 0.0157; OrganEx vs ECMO: P = 0.0001. In FIG. 8J, One-way ANOVA (P = 0.0231, F[4, 10] = 4.590) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0137. In FIG. 8K, One-way ANOVA (P = 0.0002, F[4, 10] = 17.45) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.09338; OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P = 0.0157. In FIG. 8L, One-way ANOVA (P = 0.0032, F[4, 10] = 8.285) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0198.
In FIGS. 9B, 9C, 9E, data points are from a representative organ (lung, pancreas, kidney) per condition, the experiment was repeated in n=5 independent organs per condition. In FIG. 9B, One-way ANOVA (P < 0.0001, F[4,20] = 45.78) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P < 0.0001. In FIG. 9C, One-way ANOVA (P < 0.0001, F[4,20] = 19.80) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0009; OrganEx vs 7h WIT: P < 0.0001; OrganEx vs ECMO: P = 0.0009. In FIG. 9E One-way ANOVA (P < 0.001, F[4,20] = 1.915) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0410.
In FIGS. 9G-9J, data points are from a representative kidney per condition, the experiment was repeated in n=5 independent kidneys per condition. In FIG. 9G, One-way ANOVA (P < 0.01, F[4, 10] = 7.983) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0159; OrganEx vs ECMO: P = 0.0118. In FIG. 91, One-way ANOVA (P < 0.01, F[4, 10] = 8.286) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0092; OrganEx vs ECMO: P = 0.0084. In FIG. 9J, One-way ANOVA (P < 0.01, F[4, 10] = 11.12) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.002; OrganEx vs ECMO: P = 0.0022.
In FIGS. 4B-4E, data points are from a representative organ (heart, liver, kidney, and pancreas) per condition, the experiment was repeated in n=3 independent organs per condition. In FIG. 4B, One-way ANOVA (P < 0.0001, F[4, 10] = 22.48) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0018; OrganEx vs ECMO: P < 0.0001. In FIG. 4C, One-way ANOVA (P = 0.0020, F[4, 10] = 9.392) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.004; OrganEx vs ECMO: P = 0.001. In FIG. 4D, One-way ANOVA (P < 0.0001, F[4, 10] = 23.50) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0022; OrganEx vs 7h WIT: P = 0.0002; OrganEx vs ECMO: P < 0.0001. In FIG. 4E, One-way ANOVA (P = 0.0008, F[4, 10] = 12.10) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO WIT: P = 0.0008.
In FIG. 4J-4M, data points are from a representative organ (heart, liver, kidney, and pancreas) per condition, the experiment was repeated in n=5 independent organs per condition In FIG. 4J, One-way ANOVA (P < 0.0001, F[4,20] = 14.35) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P < 0.0001. In FIG. 4K, One-way ANOVA (P < 0.0001, F[4,20] = 13.26) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P < 0.0001. In FIG. 4L, One-way ANOVA (P = 0.0002, F[4,20] = 9.110) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0012. In FIG. 4M, One-way ANOVA (P = 0.0387, F[4,20] = 3.102) with post- hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0216.
In FIG. 4G, 4H, each data points are from a representative brain per condition, the experiment was repeated in n = 3 independent brains per condition. In FIG. 4G, One-way ANOVA (P < 0.0001, F[4, 10] = 37.55) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Oh WIT: P = 0.0083; OrganEx vs Ih WIT: P = 0.0002; OrganEx vs 7h WIT: P = 0.016. In FIG. 4H, One-way ANOVA (P < 0.0001, F[4, 10] = 66.81) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Oh WIT: P = 0.0001; OrganEx vs Ih WIT: P < 0.0001.
In FIGS. 40, P, each data points are from a representative brain per condition, the experiment was repeated in n = 5 independent brains per condition. In FIG. 40, One-way ANOVA (P = 0.0547, F[4,20] = 2.784) with post-hoc Dunnett’s adjustment was performed. In FIG. 4P, One-way ANOVA (P = 0.1005, F[4,20] = 2.244) with post-hoc Dunnett’s adjustment was performed.
In FIGS. 10, each data point is from the representative brain specimen per condition, the experiment was repeated n=3 times per condition. In FIG. 10B, One-way ANOVA (P = 0.0013, F[4, 10] = 10.52) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.002; OrganEx vs ECMO: P = 0.0418. In FIG. 10C, One-way ANOVA (P = 0.0002, F[4, 10] = 17.06) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0386; OrganEx vs 7h WIT: P = 0.0302. In FIG. 10D, One-way ANOVA (P < 0.0001, F[4, 10] = 23.67) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0001. In FIG. 10E, One-way ANOVA (P = 0.0003, F[4, 10] = 14.74) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0006. In FIG. 10F, One-way ANOVA (P = 0.0264, F[4, 10] = 4.389) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0301; OrganEx vs ECMO: P = 0.0270. In FIG. 10H, One-way ANOVA (P = 0.0082, F[4, 10] = 6.365) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0082; OrganEx vs 7h WIT: P = 0.005; OrganEx vs ECMO: P = 0.0124. In FIG. 101, Oneway ANOVA (P = 0.0012, F[4, 10] = 10.81) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.001; OrganEx vs ECMO: P = 0.0012. In FIG. 10J, One-way ANOVA (P = 0.0001, F[4, 10] = 18.96) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0048; OrganEx vs ECMO: P = 0.0049. In FIG. 10L, One-way ANOVA (P = 0.0264, F[4, 10] = 7.430) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0437; OrganEx vs 7h WIT: P = 0.0437; OrganEx vs ECMO: P = 0.0437. In FIG. 10M, One-way ANOVA (P = 0.0082, F[4, 10] = 6.365) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0082; OrganEx vs 7h WIT: P = 0.005; OrganEx vs ECMO: P = 0.0124. In FIG. 10N, One-way ANOVA (P = 0.0002, F[4, 10] = 16.23) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0013; OrganEx vs ECMO: P = 0.044. In FIG. 10O, One-way ANOVA (P = 0.0024, F[4, 10] = 9.035) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs Ih WIT: P = 0.0019; OrganEx vs 7h WIT: P = 0.0062; OrganEx vs ECMO: P = 0.0034.
In FIGS. 11 J, 1 IK, each data point is from the representative hippocampal slice per condition, the experiment was repeated n=3-5 times per condition. In FIG. 11 J, for day 1 : Oneway ANOVA (P = 0.0078, F[2,9] = 8.749) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in OrganEx vs ECMO: P = 0.0245; for day 7: Oneway ANOVA (P = 0.0126, F[2, 10] = 6.995) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0086; for day 14: One-way ANOVA (P = 0.005, F[2,9] = 10.12) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.0037. In FIG. 1 IK, for day 1 : One-way ANOVA (P = 0.0406, F [2,9] = 4.670) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in OrganEx vs ECMO: P = 0.0375; for day 7: One-way ANOVA (P = 0.0278, F[2,9] = 5.476) with post-hoc Dunnett’s adjustment was performed, Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0. 0406; for day 14: unpaired two-tailed t-test was performed: P = 0.8691, t = 0.1735.
In FIG. 1 IM, 110, data points are from a representative organs (heart, liver) per condition, the experiment was repeated in n=3 independent organs per condition. In FIG. 1 IM, One-way ANOVA (P = 0.0207, F[4, 10] = 4.760) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs ECMO: P = 0.00434. In FIG. 110, One-way ANOVA (P = 0.0063, F[4, 10] = 6.863) with post-hoc Dunnett’s adjustment was performed; Dunnett’s multiple comparisons test resulted in: OrganEx vs 7h WIT: P = 0.0064; OrganEx vs ECMO: P = 0.0163.
Example 1: Overview of OrganEx technology
The OrganEx technology consists of a perfusion system and synthetic perfusate (FIG. 1 A, FIG. IB). The perfusion system consists of a computer driven custom-made pulse generator connected to a centrifugal pump, which enables reproduction of physiological pressure and flow waveforms, together with automated hemodiafiltration, gas mixer, and drug delivery systems which allow control of blood coagulation and supplementation of the perfusate. To ensure homeostasis and maintain the targeted perfusion parameters, the perfusion system is also equipped with sensors for electrolytes, blood gases, metabolic parameters, hemoglobin, vessels and cannulas pressures, and total circulatory flow rate. The perfusate is optimized for wholebody compatibility. The OrganEx perfusate is a final mixture of a custom-made priming solution (Table 1), Hemopure (HbO2 Therapeutics, Waltham, MA), custom-made dialysis exchange solution (Table 2) and the solution of pharmacological compounds (Table 3).
To evaluate OrganEx technology in large mammals, a porcine global warm ischemia model induced by cardiac arrest on anesthetized and heparinized animals (FIG. 1 A) was implemented. Following cardiac arrest and cessation of the systemic circulation, animals were left dead for one hour, allowing warm ischemic damage to ensue at core temperature of 36-37°C. Subsequently, animals were connected to one of the two perfusion systems via a femoral artery/vein approach with the goal of reinstating systemic circulation and nutritive rather than functional circulation of heart and lungs (FIG. 1A). Overall, this study consisted of five groups. Three different, unperfused, control groups corresponding to important experimental timepoints and distinct warm ischemia intervals were used: (1) healthy control group with minimal (up to 10 minutes) warm ischemia time (WIT) following cardiac arrest (Oh WIT), (2) an hour of warm ischemia to investigate molecular and cellular damage prior to perfusion intervention (Ih WIT), and (3) seven hours of warm ischemia to investigate damage extent that happens without any intervention (7h WIT). Additionally, in two perfusion intervention groups, following one hour of warm ischemia, perfusion was performed for six hours under hypothermic conditions (28°C) either with: (4) a clinical standard, heart-and-lung substitution perfusion device - extracorporeal membrane oxygenation system (ECMO), or (5) perfusion technology (OrganEx). Animals in ECMO group were perfused with autologous blood. In OrganEx, prior to the initiation of the perfusion protocol, autologous blood was drained into the OrganEx system and mixed with the perfusate (in for example, effective 1 : 1 ratio), which was then used to perfuse the animal.
Example 2: Systemic circulation and metabolic parameters
Since systemic circulation assures supply of oxygen, metabolites and potential therapeutic agents during recovery from ischemia, it was first queried whether circulation could be restored with external perfusion following one hour of warm ischemia. Perfusion of the whole-body with ECMO system invariantly resulted in low or no flow states due to circulatory collapse. In particular, utilizing fluoroscopic angiography, ECMO perfusion exhibited limited arterial filling of major conduit arteries and organs, such as kidney, liver and brain (FIG. 2 A, FIG. 7A). Consistent with this finding, ECMO interventions yielded inadequate organ perfusion as indicated by Color Doppler assessment (FIG. 2B). Furthermore, systemic perfusion parameters revealed collapse of circulation as shown by extremely negative venous perfusion pressure and low arterial pressures (FIG. 2C, FIG. 7C-7D).
In contrast, robust whole-body perfusion in the OrganEx treated animals was observed, as indicated by contrast enhancement of major conduit arteries and organs, demonstrating patent circulation (FIG. 2A, FIG. 7A). In addition, Color Doppler analysis demonstrated pulsatile flow throughout the whole-body in the OrganEx group (FIG. 2B). In particular, flow in the ophthalmic artery, a proxy indicator of cerebral perfusion, was present in the OrganEx, but not in ECMO perfusion group, when analyzed at hour three of the perfusion protocols (FIG. 2B). Similar findings were observed in renal intralobular arteries (FIG. 2B), while reduced flow was detected in carotid arteries as compared to OrganEx (FIG. 7B). These data were further supported with the data from the OrganEx perfusion system sensors showing restoration of physiologic flow rates and arterial pressures (FIG. 2C).
Following successful restoration of circulation, the extent that OrganEx is capable of recovering metabolic parameters was assessed. By measuring mixed venous oxygen saturation of blood returning to the venous circulation from peripheral tissues and organs, it was confirmed that the OrganEx technology was able to deliver adequate levels of oxygen to the whole body throughout the perfusion (FIG. 2D). This was coupled by stabilization of tissue expenditure (FIG. 7E-7F) and correction of physiologic imbalances in the blood that occur during prolonged ischemia, most notably hyperkalemia and metabolic acidosis (FIG. 2F-2G). In addition, postmortem rigidity and lividity observed in ECMO animals were absent after OrganEx perfusion (FIG. 7E). Taken together, these observations indicate that following one hour of warm ischemia, OrganEx could reinstate and maintain circulation, and restore observed physiologic and metabolic parameters on a whole-body scale.
Example 3: Histological analysis of tissue integrity
Upon restoration of systemic circulation and certain key metabolic parameters following OrganEx perfusion, next investigated was its effects on organ structural integrity and cytoarchitecture. The brain’s three major cell types, neurons, astrocytes, and microglia in two regions most vulnerable to ischemia, the hippocampal CAI subregion and the prefrontal cortex (PFC) were analyzed. The intensity of immunostaining for RBFOX3 (NeuN), a pan-neuronal marker, which has previously been shown to decrease in hypoxia, was lower in the ECMO and 7h WIT groups in both regions, as compared to OrganEx (FIG. 3 A, FIG. 8F, 8H). While there were no observed differences in CAI subregion between OrganEx and Oh and Ih WIT groups, we did observe reduced immunolabeling in OrganEx and Ih WIT group compared to Oh WIT in PFC (FIGS. 8H, 81). This finding could be a result of more pronounced protein degradation in PFC or incomplete recovery due to short OrganEx intervention time. In addition, the number of astrocytes immunolabeled for GFAP was comparable between OrganEx and Oh WIT but was decreased in other experimental groups, in both, CAI and PFC (FIGS. 8F, 8G, 9B, 9E). The analysis of GFAP immunolabeling fragmentation was increased in the 7h WIT and ECMO groups compared to OrganEx, which was similar to the Ih, and Oh WIT groups, suggesting loss of astrocytic integrity (FIGS. 3 A, 3B, FIG. 8B, 8H, 8K). A similar trend was observed in PFC, with increased fragmentation in 7h WIT and ECMO groups, but failed to demonstrate statistical significance due to increased variance in 7h WIT group (FIGS. 8H, 8J). The density of microglial populations noted by IBA1 immunolabeling was comparable among OrganEx, Oh and Ih WIT groups in both CAI and PFC, and differed from the ECMO group (FIGS. 3A, 3D, FIGS. 8F, 8H, 8L). Collectively, these findings indicate that across different analyzed brain regions and cell types, both tissue and cellular integrities were preserved and did not sustain additional observable damage following perfusion with OrganEx, consistent with previous study in the isolated porcine brain.
After assessing highly oxygen-sensitive brain structures and cell types, next investigated were the effects of OrganEx on tissue and cellular integrity in essential peripheral organs, including heart, lungs, liver, kidney, and pancreas. Utilizing hematoxylin and eosin (H&E) staining, hemorrhage, tissue edema, nuclear pyknosis, cell vacuolization, and cellular integrity were evaluated and were combined into a cumulative damage score according to the standard pathologic criteria. Notably, the OrganEx group showed a decrease in the H&E damage score, as compared to 7h WIT and ECMO groups (FIG. 3E-3H, FIGS. 9A-9J,). Furthermore, organs treated with OrganEx perfusion exhibited signs of reduced hemorrhage and tissue edema when compared to the Ih WIT group. These results are indicative of the absence of injury promotion and cytoarchitectural damage as compared to ECMO, and more importantly, a reduction of H&E damage scores towards the Oh WIT state with OrganEx perfusion.
To further assess recovery of cytoarchitecture in the OrganEx intervention group compared with possible injury promotion in ECMO group, the cytoskeletal features of the kidney that are well-studied in this regard were investigated. Expression of renal cytoskeletal P-actin is known to be upregulated in ischemic states. However, the reintroduction of autologous blood causes risk for cell injury and cytoskeletal disruption leading to protein loss. This analysis revealed reduced P-actin immunoreactivity in the ECMO, as compared to OrganEx and other groups, which exhibited preserved immunoreactivity (FIG. 3 J-3K). These data indicate that unlike OrganEx perfusion, the ECMO perfusion with autologous blood following prolonged warm ischemia may cause risk for further tissue damage through reperfusion.
Example 4: Analysis of cell death processes Because the OrganEx perfusate contains pharmacological suppressors of cell death and decreased cellular demise based on the histopathological analysis in the OrganEx group (FIG. 3E-3H, FIGS. 9A-9J) was observed, key proteins of key cell death pathways were next investigated by immunohistochemistry analysis. For apoptosis, immunolabeling intensity of activated caspase3 (actCASP3) and TUNEL assay was measured, and an increase was observed across peripheral organs such as heart, liver, kidney, and pancreas in the ECMO compared to the OrganEx group. Furthermore, the respective intensities of actCASP3 and TUNEL in the OrganEx were comparable to the Oh WIT group, which did not sustain ischemic injury, indicating that OrganEx perfusion diminished caspase3 activation and decreased apoptosis (FIG. 4A-4P).
The analysis of the CAI and PFC revealed that the intensity of actCASP3 immunolabeling in the OrganEx group was lower than in the Oh and Ih WIT groups (FIGS. 4K- 4M). Conversely intensity of TUNEL assay had lower trend in OrganEx group compared to the 7h WIT and ECMO groups (FIGS. 4N-4P). Thus, it is conceivable that the weak brain immunolabeling of actCASP3 in the OrganEx group can be explained by active suppression of actCAPS3 by the pharmacological compounds in the perfusate as previously reported, rather than cellular or protein destruction, as also supported by other evaluations (FIGS. 3A-3D, 6A, 8A-8L, 11H-11K, 14F,14G).
Next, to investigate pyroptosis, the cell death pathway triggered by proinflammatory signals, interleukin 1 beta (IL1B) immunohistochemistry was utilized. Across all investigated peripheral organs such as heart, liver, and kidney, IL1B immunolabeling intensity was comparable in Oh WIT and increased in ECMO when compared to OrganEx. In the brain, immunolabeling intensity was decreased in ECMO when compared to OrganEx group (FIGS. 10A-10E). Trends in both peripheral organs, and the brain are similar to the observed actCASP3 results (FIG. 4A-4E).
Finally, necroptosis and ferroptosis, two distinct cell death pathways were investigated by utilizing immunohistochemistry of their important proteins in the pathways, the receptorinteracting ser/thr kinase 3 (RIPK3) and the glutathione peroxidase 4 (GPX4), respectively. The results were consistent between the two cell death pathways and between all the organs evaluated such as brain, heart, liver, and kidney. Compared to OrganEx, immunolabeling intensity was comparable in Oh WIT and significantly decreased in 7h WIT and ECMO groups (FIGS. 10F- 10O).
Example 5: Metabolic and functional assessment of organs
After observing improvements in metabolic function, tissue cytoarchitecture and cell death outcomes using OrganEx, cellular energy balance was next investigated in detail. The glucose uptake was measured in highly metabolic organs (brain, heart, kidney) using the fluorescent glucose analog, 2-NBDG23. This showed comparable levels of glucose uptake in the OrganEx and Oh WIT groups in all assessed organs and reduced cellular glucose capture in the ECMO group that may indicate impaired glucose utilization of cellular leakage (FIGS. 5A-5C). Such findings imply that recovery of cellular metabolism may have a reciprocal relationship with the restoration of systemic metabolic parameters (FIGS. 2D, 2E, 7D).
Indicators of cell- and tissue-level recovery in relevant organs were next tested. Cardiac assessment with electrocardiography (ECG) demonstrated spontaneous reemergence of QRS complexes during OrganEx perfusion, indicating ventricular depolarization (FIG. 5D). However, no QRS reemergence was observed in the ECMO group. To further evaluate recovery of ventricular activity, cardiomyocyte contractility was examined using bright-field microscopy of left ventricle tissue slices acquired at the experimental endpoint. Contractions in OrganEx and Oh WIT samples were observed, but complete absence in the ECMO group (FIG.5E). Finally, investigated were cardiomyocyte biomarkers whose immunolabeling decreases with ischemia22. Left ventricle immunohistochemistry staining for biomarker troponin I revealed decreased immunolabeling with prolonged ischemia, and significantly lower immunolabeling intensity in the ECMO vs OrganEx group (FIGS. 1 IL, 1 IM).
Liver cellular recovery was assessed using immunostaining for albumin and factor V, which are non- structural liver-synthesized proteins with great abundance and short half-life, respectively. Compared to OrganEx group, immunolabeling intensities of both proteins were comparable in Oh WIT and significantly diminished in 7h WIT and ECMO groups (FIGS. 5F, 5G, UN, 110).
In the kidney, although many cellular features were preserved similar to Oh WIT in OrganEx groups, including tissue integrity (FIGS. 3H, 9D,9E), cell death (FIGS. 4A-4P, 10A- 10O), molecular and proliferative injury responses (FIGS. 9F-9J), and cellular metabolic indicators (FIG. 5C), the primary kidney functional metric, urine output, was minimal. Yet hypothermic perfusion is known to slow kidney function in patients with healthy organs and extracorporeal perfusion circuits can perturb endocrine, humoral, and neural factors regulating glomerular filtration even when renal perfusion and cellular health is adequate. Longer recovery time also may be required since low urine output often follows shock resuscitation.
Next, continuous electroencephalography (EEG) of the brain in OrganEx and ECMO groups was conducted, and no signs of global network activity were detected (FIGS. 11 A-l IE). In OrganEx group, we hypothesize this could be due to either inadequate brain recovery, requirement for longer recovery duration, perfusates’ neuronal activity antagonists, anesthesia, hypothermic perfusion protocol, or their combined effects. Interestingly, while receiving carotid injection of contrast for cerebrovascular fluoroscopic imaging, OrganEx-perfused animals exhibited complex, non-purposeful, non-stereotyped movements of the head, neck, and torso from coordinated agonist/antagonist actions across multiple joints and muscle units. This was not observed during imaging of sedated alive or ECMO-treated animals (FIG 1 IF). EEG patterns during these movements were not interpretable due to movement-induced artifacts but were flat immediately before and after the movements (FIG. 11G). Whether these movements are initiated from preferential interruption of cerebral descending inhibition of motor patterns or from positive action at subcortical, spinal, peripheral nerve, or neuromotor unit levels is difficult to determine. However, the ability for them to be executed does indicate the preservation of efferent motor output function at least at the level of the spinal cervical cord or its roots.
Next , it was sought to investigate the longer-term actions of OrganEx perfusion on cellular viability. Yet because of regulatory constraints and inability to extend the perfusion protocol beyond 6h, organotypic hippocampal brain slice cultures (BSCs) were utilized, to monitor features of tissues previously exposed to different perfusion interventions. BSCs were prepared at the beginning of experiments (Oh WIT), at the end of ECMO and OrganEx perfusions, and from time-matched 7h WIT controls, and were cultured for 14 days while assessing tissue integrity and protein synthesis using Click-iT assay screening. BSCs from the 7h WIT group failed these measures due to severe tissue degradation. Based on visual inspection and DAPI staining, BSCs from the ECMO group were more fragile than OrganEx samples, and most disintegrated by day 14 (FIGS 5H, 51). BSC tissue integrity was preserved through day-14 in the OrganEx group equal to Oh WIT despite having had one additional ischemic exposure (lx during initial Ih warm ischemia, lx during brain extraction, 5-10mins). Similarly, protein synthesis was comparable through day-14 in the OrganEx and Oh WIT groups and decreased in ECMO across different hippocampal regions (FIGS 5J, 5K, 11H-11K).
Example 6: Analysis of cell type-specific transcriptomic changes
To investigate transcriptomic responses to distinct ischemic exposures and the effects of the OrganEx intervention, single-nucleus RNA-sequencing (snRNA-seq, see Methods) was performed. The computational analysis of snRNA-seq data revealed major transcriptomically- defined cell types (t-types) that were comparable to publicly available human and mouse singlecell datasets (FIGS.12A-12F). Yet prominent transcriptomic distinctions were also identified between the same t-types across all experimental groups (FIGS. 14A-17I). This extensive cellular taxonomic resource expands upon previous studies and allows for systematic investigation of transcriptomic changes in multiple porcine organs and cell-types exposed to distinct WITs and reperfusion conditions ((FIGS. 13A-13D, 14A-17B), (Tables: 7-23) http ://resources. sestanlab . org/OrganEx)).
To compare cell type responsiveness to ischemia based on transcriptomic changes across experimental groups, Augur prioritization was performed and t-types with the greatest transcriptomic divergence were highlighted. This identified prominent changes in neurons, cardiomyocytes, hepatocytes, and proximal convoluted tubule (PCT) cells, consistent with t- types validated in earlier studies and prompting detailed sub-analysis (FIG 6A-6D). First, it was evaluated whether patterns of transcriptomic changes within OrganEx versus other groups reflect molecular and cellular changes observed in previous studied by assessing for transcriptomic enrichment of corresponding gene sets (Methods). Comparisons between OrganEx and other groups revealed significant enrichment of gene sets facilitating cytoskeletal assembly, DNA repair, ATP metabolism, and suppression of apoptosis and other major cell death pathways across all major cell types in the organs investigated (FIGS. 6A-6D, FIGS. 14A-17I). These data corroborate earlier findings by demonstrating that OrganEx both inhibited progression of cellular injury (e.g., cytoarchitecture, cell death, DNA fragmentation) and promoted repair by modulating cellular pathways on a transcriptomic level. Likewise, genes encoding proteins involved in celldeath, oxidative injury and inflammatory signaling (Tables. 4, 5, 6) are broadly regulated in favor of cell survival in the OrganEx group compared with ECMO in all organs studied. This correlates with choices of pharmacological compounds in the OrganEx perfusate, which had been included using a hypothesis-based, rational-polytherapy approach to modulate these pathways (FIGS. 14A-17D)
Further investigation of OrganEx actions upon glial inflammatory responses underlying brain injury progression after ischemia showed that hippocampal microglial pro-inflammatory transcriptional enhancement was absent in the OrganEx group. Conversely, microglial inflammatory and astrocytic pan-reactive transcriptomic signatures were upregulated in ECMO and Ih WIT groups, respectively. (FIG. 5A). Combined with immunofluorescence analyses of microglial IBA1 and astrocytic GFAP staining (FIGS. 3A-3D, FIGS. 8F-8L), these findings demonstrate that OrganEx intervention modulates the glial inflammatory response.
The transcriptomic signatures of tissue and cellular functioning in heart, liver, and kidney specimens were then evaluated. Cardiomyocytes in the OrganEx group exhibited enrichment of genes orchestrating action potential formation and the well-described shift28 toward glycolytic metabolism following ischemia signifying cardiomyocyte viability (FIG. 6B). In the liver and kidney, hepatocytes and PCT cells were enriched for cytochrome P450 and PCT transporter genes, respectively, in OrganEx versus other groups — though not quite to levels of Oh WIT controls — suggesting preservation of organ-specific functions (FIGS. 6C, 6D). Liver acutephase reactant and kidney injury marker genes also were notably lower following OrganEx reperfusion than after ECMO or 7h WIT (FIGS. 6C,6D). These data corroborate earlier findings on tissue integrity and cellular activity (FIGS.3E-3H, FIGS. 5B, 5G; FIGS.9A-9J; FIGS 11 A- 110).
To identify transcriptomic patterns across experimental groups more systematically, and to determine functional gene modules, we performed co-expression analysis on differentially expressed genes across groups. Eigengenes of each module designated key gene expression trends, with subsequent gene ontology (GO) analyses highlighting relevant biological pathways (FIGS 14A-17E, FIG. 34). Herein, OrganEx and ECMO had divergent trends across different modules. Gene modules having eigengene increases in the OrganEx group featured GO terms related to cellular upkeep and organ-specific functions. Conversely, modules having increased eigengenes in the ECMO group had GO terms related to cell death (liver and kidney). Finally, analysis of ligand/receptor pairings of t-types showed reduced interactions related to inflammatory pathways (e.g., IL1, IL6, ICAM, VCAM) in OrganEx versus ECMO groups (FIGS 14A-17I). This mirrors earlier findings that OrganEx reperfusion following ischemia diminishes markers of inflammation, associated with overall decreased cellular injury and augmented repair/protection processes when compared to ECMO (FIGS.10A-10E, FIGS 14A-17D).
Taken together, snRNA-seq analysis supports cellular and tissue-level findings of decreased cellular injury and the initiation of certain molecular and cellular repair processes following OrganEx intervention.
Table 4. Genes involved in cell death
Figure imgf000067_0001
Table 5. Genes involved in oxidative stress
Figure imgf000067_0002
Table 6. Genes involved in inflammation
Figure imgf000068_0001
Table 7: Upregulated modules in the hippocampus
Figure imgf000069_0001
Table 8: Downregulated modules in the hippocampus
Figure imgf000069_0002
Figure imgf000070_0001
Figure imgf000071_0001
Figure imgf000071_0002
Figure imgf000072_0001
Figure imgf000073_0001
Figure imgf000073_0002
Figure imgf000074_0001
Table 11: Upregulated modules in the liver
Figure imgf000075_0001
Figure imgf000076_0001
'able 12: Downregulated modules in the liver
Figure imgf000076_0002
Figure imgf000077_0001
Figure imgf000078_0001
Table 13: Upregulated modules in the kidney
Figure imgf000078_0002
Figure imgf000079_0001
Table 14: Downregulated modules in the kidney
Figure imgf000079_0002
Figure imgf000080_0001
Table 15:Upregulated modules in the hippocampus for OrganEx vs other experimental conditions
Figure imgf000081_0001
Figure imgf000082_0001
Figure imgf000083_0001
Figure imgf000084_0001
Figure imgf000085_0001
Table 16: Downregulated modules in the hippocampus for OrganEx vs other experimental conditions
Figure imgf000085_0002
Figure imgf000086_0001
Figure imgf000087_0001
Table 17: Upregulated modules in the heart for OrganEx vs other experimental conditions
Figure imgf000087_0002
Figure imgf000088_0001
Figure imgf000089_0001
Figure imgf000090_0001
Figure imgf000091_0001
Table 18: Downregulated modules in the heart for OrganEx vs other experimental conditions
Figure imgf000091_0002
Figure imgf000092_0001
Figure imgf000093_0001
Table 19: Upregulated modules in the liver for OrganEx vs other experimental condition
Figure imgf000094_0001
Figure imgf000095_0001
Figure imgf000096_0001
Table 20: Downregulated modules in the liver for OrganEx vs other experimental conditions
Figure imgf000096_0002
Figure imgf000097_0001
Figure imgf000098_0001
Figure imgf000099_0001
Table: 21 Upregulated modules in the kidney for OrganEx vs other experimental conditions
Figure imgf000099_0003
Figure imgf000099_0002
Figure imgf000100_0001
Figure imgf000101_0001
Figure imgf000102_0001
Table 22: Downregulated modules in the kidney for OrganEx vs other experimental conditions
Figure imgf000102_0002
Figure imgf000103_0001
Figure imgf000104_0001
Table 23: List of Enriched GO terms.
Figure imgf000104_0002
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Example 7:
Here, the OrganEx technology and its potential to support recovery of key molecular and cellular processes in multiple porcine organs after prolonged global warm ischemia are described. This also demonstrates the underappreciated capacity of the large mammalian body for restoration of hemodynamic and metabolic parameters following circulatory arrest or other severe ischemic stress. This application of the OrganEx technology demonstrates that cellular demise can be halted, and their state be shifted towards recovery at molecular and cellular levels, even following prolonged warm ischemia. Additionally, a comprehensive single-cell transcriptomic analysis of multiple porcine organs was generated to provide a unique resource for future studies on cell-types, ischemia, and reperfusion.
Although some cellular viability can be restored following prolonged ischemia in tissue cultures or isolated organs, clinical scenarios typically involve shorter-duration ischemia in the setting of cardiac arrest or regional perfusions in the setting of organ transplant. By employing a rational polytherapy approach built upon optimized perfusion dynamics and augmentations to an acellular synthetic perfusate, the OrganEx technology was able to bridge prior clinical- translational gaps by restoring circulation and metabolic homeostasis across the whole body. This quells deleterious processes caused by disturbed cellular environments and lack of oxygen, representing a distinct feature of this technology and an essential control for multiple nonspecific injury mechanisms affecting end-organ recovery and overall prognosis after global ischemia. Potential applications of this technology are manifold and could provide novel pathways in ischemia research and advance related clinical disciplines. OrganEx has the potential to extend limits of allowable warm ischemia times through regional abdominal/thoracic reperfusion, thereby increasing organ availability for transplantation. This approach would require obligatory antecedent clamping of the aorta/carotid arteries to prevent brain recirculation in the organ donor. Conversely, if any future refinements of the technology could be aimed at the recovery of the brain function after injury, then the brain circulation would remain patent. In this regard, OrganEx technology may improve outcomes in extracorporeal cardiopulmonary resuscitation with the needed circulatory support, or the OrganEx perfusate could aid in recovery wherein cardiac function is preserved but the brain is damaged, as seen in stroke. Thus, a clear distinction should be made before possible utilization of OrganEx technology, relative to inclusion of the brain circulation.
While these studies demonstrate important cellular protection and repair processes in vital organs across meaningful timepoints, questions remain concerning organ recovery over an extended timeframe. Since repeating all experiments over additional, extended durations to comprise a full, longitudinal study were not feasible under current regulatory constraints, longterm organotypic slice culture preparations of hippocampus were employed to study postperfusion cell survivability in the most ischemia-sensitive tissue possible. This demonstrated that OrganEx intervention provides enduring effects on cellular recovery following transfer to the extended survival conditions.
Enumerated Embodiments
The following enumerated embodiments are provided, the numbering of which is not to be construed as designating levels of importance.
Embodiment 1 provides an isolated perfusate mixture comprising: an inorganic salt solution; an artificial oxygen carrier; and autologous blood.
Embodiment 2 provides the isolated perfusate mixture of embodiment 1, wherein the one or more artificial oxygen carriers is selected from the group consisting of hemoglobin glutamer- 250, isolated cell-free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers.
Embodiment 3 provides the isolated perfusate mixture of embodiments 1-2, wherein the artificial oxygen carrier is hemoglobin glutamer-250.
Embodiment 4 provides the isolated perfusate mixture of embodiments 1-3, wherein the one or more inorganic salts are selected from the group consisting of sodium chloride, sodium bicarbonate, magnesium chloride, and calcium chloride.
Embodiment 5 provides the isolated perfusate mixture of embodiments 1-4, wherein the perfusate comprises a priming solution containing one or more sugars.
Embodiment 6 provides the isolated perfusate mixture of embodiments 1-5 wherein the one or more sugars are glucose or dextrane.
Embodiment 7 provides the isolated perfusate mixture of embodiments 1-6, further comprising one or more amino acids.
Embodiment 8 provides the isolated perfusate mixture of embodiments 1-7, wherein the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L- phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine and salts and solvates thereof.
Embodiment 9 provides the isolated perfusate mixture of embodiments 1-8, wherein the mixture further comprises one or more vitamins. Embodiment 10 provides the isolated perfusate mixture of embodiments 1-9, wherein the one or more vitamins are selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i-inositol and salts and solvates thereof.
Embodiment 11 provides the isolated perfusate mixture of embodiments 1-10, wherein the mixture further comprises, ferric nitrate, magnesium sulfate, potassium chloride, sodium phosphate, and derivatives thereof.
Embodiment 12 provides the isolated perfusate mixture of embodiments 1-11, wherein the mixture further comprises an anti-clotting agent.
Embodiment 13 provides the isolated perfusate mixture of embodiments 1-12, wherein the anti-clotting agent is heparin.
Embodiment 14 provides the isolated perfusate mixture of embodiments 1-13, wherein the percentage of autologous blood in the mixture is between 10% and 50%.
Embodiment 15 provides the isolated perfusate mixture of embodiments 1-14, wherein the percentage of autologous blood in the mixture is approximately 28%.
Embodiment 16 provides the isolated perfusate mixture of embodiments 1-15, wherein the mixture is dialyzed against a solution comprising inorganic salts.
Embodiment 17 provides the isolated perfusate mixture of embodiments 1-16, wherein the mixture is dialyzed against plasma.
Embodiment 18 provides the isolated perfusate mixture of embodiments 1-17, wherein the mixture comprises electrolytes and oncotic agents at levels comparable to those in autologous blood.
Embodiment 19 provides the isolated perfusate mixture of embodiments 1-18, wherein the perfusate further comprises cytoprotective agents.
Embodiment 20 provides the isolated perfusate mixture of embodiments 1-19, wherein the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and or any salts, solvates, tautomers, and prodrugs thereof.
Embodiment 21 provides the isolated perfusate mixture of embodiments 1-20, wherein the mixture further comprises antibiotics.
Embodiment 22 provides the isolated perfusate mixture of embodiments 1-21, wherein the antibiotic is ceftriazone. Embodiment 23 provides the isolated perfusate mixture of embodiments 1-22, wherein the mixture comprises one or more anti-inflammatory agents.
Embodiment 24 provides the isolated perfusate mixture of embodiments 1-23, wherein the one or more the anti-inflammatory agents is dexamathazone or cetirizine.
Embodiment 25 provides the isolated perfusate mixture of embodiments 1-24, wherein the temperature of the mixture is approximately 28°C.
Embodiment 26 provides a system for the hypothermic preservation of organs in a mammal, the system comprising: a perfusion device for the perfusion of an isolated perfusate mixture into the mammal, the perfusion device comprising: a perfusion loop; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain hypothermic conditions; and the isolated perfusate mixture of any of embodiments 1-25.
Embodiment 27 provides the system of embodiment 26 , wherein the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop.
Embodiment 28 provides the system of embodiments 26-27, wherein the perfusion loop comprises a venous loop, a filtration loop and an arterial loop, wherein: the venous loop comprises at least one perfusion pump; the filtration loop comprises at least one perfusion pump, and at least one hemodiafiltration unit adapted and configured to equilibrate the perfusate; the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate; wherein the mammal, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the mammal, through the venous loop, through the filtration loop, through the arterial loop and back to the mammal.
Embodiment 29 provides the system of embodiments 26-28, wherein one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate. Embodiment 30 provides the system of embodiments 26-29, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate.
Embodiment 31 provides the system of embodiments 26-30, wherein the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate, bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
Embodiment 32 provides the system of embodiments 26-31, wherein the mammal perfusion apparatus comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pressure and flow rate.
Embodiment 33 provides the system of embodiments 26-32, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps.
Embodiment 34 provides the system of embodiments 26-33, wherein the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device.
Embodiment 35 provides the system of embodiments 26-34, wherein the one or more sensor(s) is/are adapted and configured to measure the temperature within the perfusion device, the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device.
Embodiment 36 provides the system of embodiments 26-35, wherein the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L-Al any 1 -Glutamine, L- Arginine hydrochloride, L-Cystine, L-Histidine hydrochloride-H2O, L-Isoleucine, L-Leucine, L-Lysine hydrochloride, L- Methionine, L-Phenylalanine, L-Serine, L-Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i-Inositol, Calcium Chloride (CaC12-2H2O), Ferric Nitrate (Fe(NO3)3 9H2O), Magnesium Sulfate (MgSO4-7H2O), Potassium Chloride (KC1), Sodium Bicarbonate (NaHCO3), Sodium Chloride (NaCl), Sodium Phosphate monobasic (NaH2PO4- 2H2O), D-Glucose (Dextrose), Phenol Red, Sodium Pyruvate, free fatty acids, cholesterol and nucleic acid constitutes.
Embodiment 37 provides the system of embodiments 26-36, wherein the system is configured to perfuse the mammal with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg.
Embodiment 38 provides the system of embodiments 26-37, wherein the system is configured to perfuse the organs in the mammal with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute.
Embodiment 39 provides the system of embodiments 26-38, further comprising a controller in electronic communication with one or more elements of the system.
Embodiment 40 provides a mammal perfused with the isolated perfusate composition of any of embodiments 1-25, wherein mammalian organs are perfused under hypothermic conditions. Embodiment 41 provides the mammal of embodiment 40, wherein the mammal is a deceased mammal.
Embodiment 42 provides the mammal of embodiments 40-41, wherein the mammal is a human.
Embodiment 43 provides the mammal of embodiments 40-42, wherein the deceased mammal is deceased for longer than 1 hour.
Embodiment 44 provides the mammal of embodiments 40-45, wherein the deceased mammal has been deceased for longer than 4 hours.
Embodiment 45 provides the mammal of embodiments 40-45, wherein the mammal died of cardiac arrest.
Embodiment 46 provides the mammal of embodiments 40-45, wherein the organs in the deceased mammal are ischemic prior to perfusion with the isolated perfusate mixture of any of claims 1-25.
Embodiment 47 provides the mammal of embodiments 40-46, wherein rigor mortis is prevented.
Embodiment 48 provides the mammal of embodiments 40-47, wherein rigor mortis is reversed.
Embodiment 49 provides the mammal of embodiments 40-48, wherein the perfusate mixture flows into the ophthalmic artery.
Embodiment 50 provides the mammal of embodiments 40-49, wherein the perfusate mixture flows into the renal intralobular arteries.
Embodiment 51 provides perfused organs in a diseased mammal , wherein the perfused organs maintain one or more properties selected from the group consisting of an in vivo level of cell function and viability, and an in vivo level of morphology.
Other Embodiments
The recitation of a listing of elements in any definition of a variable herein includes definitions of that variable as any single element or combination (or subcombination) of listed elements. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiments or portions thereof.
The disclosures of each and every patent, patent application, and publication cited herein are hereby incorporated herein by reference in their entirety. While this invention has been disclosed with reference to specific embodiments, it is apparent that other embodiments and variations of this invention may be devised by others skilled in the art without departing from the true spirit and scope of the invention. The appended claims are intended to be construed to include all such embodiments and equivalent variations.

Claims

CLAIMS What is claimed is:
1. An isolated perfusate mixture comprising: an inorganic salt solution; an artificial oxygen carrier; and autologous blood.
2. The isolated perfusate mixture of claim 1, wherein the one or more artificial oxygen carrier(s) is/are selected from the group consisting of hemoglobin glutamer-250, isolated cell- free hemoglobin, cross-linked hemoglobin, polymerized hemoglobin, encapsulated hemoglobin, and perfluorocarbon oxygen carriers.
3. The isolated perfusate mixture of claim 2, wherein the artificial oxygen carrier is hemoglobin glutamer-250.
4. The isolated perfusate mixture of claim 1, wherein the one or more inorganic salts are selected from the group consisting of sodium chloride, sodium bicarbonate, magnesium chloride, and calcium chloride.
5. The isolated perfusate mixture of claim 1, wherein the perfusate comprises a priming solution containing one or more sugars.
6. The isolated perfusate mixture of claim 5, wherein the one or more sugars are glucose or dextrane.
7. The isolated perfusate mixture of claim 1, further comprising one or more amino acids.
8. The isolated perfusate mixture of claim 7, wherein the one or more amino acids are selected from the group consisting of glycine, L-alanyl-glutamine, L-arginine, L-cysteine, L- histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L- threonine, L-tryptophan, L-tyrosine, L-valine and salts and solvates thereof.
9. The isolated perfusate mixture of claim 1, further comprising one or more vitamins.
10. The isolated perfusate mixture of claim 9, wherein the one or more vitamin(s) is/ are selected from the group consisting of choline, D-calcium pantothenate, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, i-inositol and salts and solvates thereof.
11. The isolated perfusate mixture of claim 1, further comprising, ferric nitrate, magnesium sulfate, potassium chloride, sodium phosphate, and derivatives thereof.
12. The isolated perfusate mixture of claim 1, further comprising an anti-clotting agent.
13. The isolated perfusate mixture of claim 12, wherein the anti-clotting agent is heparin.
14. The isolated perfusate mixture of claim 1 wherein the percentage of autologous blood in the mixture is between about 10% and about 50%.
15. The isolated perfusate mixture of claim 14, wherein the percentage of autologous blood in the mixture is approximately 28%.
16. The isolated perfusate mixture of any of claims 1-15, wherein the mixture is dialyzed against a solution comprising inorganic salts.
17. The isolated perfusate mixture of any of claims 1-15, wherein the mixture is dialyzed against plasma.
18. The isolated perfusate mixture of any of claims 1-15, wherein the mixture comprises electrolytes and oncotic agents at levels comparable to those in autologous blood.
19. The isolated perfusate mixture of claim 1, wherein the perfusate further comprises cytoprotective agents.
20. The isolated perfusate mixture of claim 19, wherein the cytoprotective agents are selected from the group consisting of 2-Iminobiotin, Necrostatin-1, sodium 3-hydroxybutryate, glutathione, minocycline, lamotrigine, QVE-Oph, methylene blue, and or any salts, solvates, tautomers, and prodrugs thereof.
21. The isolated perfusate mixture of claim 1, wherein the mixture further comprises antibiotics.
22. The isolated perfusate mixture of claim 21, wherein the antibiotic is ceftriazone.
23. The isolated perfusate mixture of claim 1, wherein the mixture comprises one or more anti-inflammatory agent(s).
24. The isolated perfusate mixture of claim 1, wherein the one or more the anti-inflammatory agent(s) is dexamathazone or cetirizine.
25. The perfusate mixture of any of claims 1-24, wherein the temperature of the mixture is approximately 28°C.
26. A system for the hypothermic preservation of organs in a mammal, the system comprising: a perfusion device for the perfusion of an isolated perfusate mixture into the mammal, the perfusion device comprising: a perfusion loop; and a controller programmed to regulate at least a perfusate temperature within the perfusion loop to maintain hypothermic conditions; and the isolated perfusate mixture of any of claims 1-25.
-117-
27. The system of claim 26, wherein the perfusion loop further comprises at least one pulse generator programmed to generate a pressure pulse within the perfusate within the perfusion loop.
28. The system of claim 26, wherein the perfusion loop comprises a venous loop, a filtration loop and an arterial loop, wherein: the venous loop comprises at least one perfusion pump; the filtration loop comprises at least one perfusion pump, and at least one hemodiafiltration unit adapted and configured to equilibrate the perfusate; the arterial loop comprises at least one gas exchange source and at least one gas mixer adapted and configured to supply oxygen and carbon dioxide to the perfusate; wherein the mammal, the venous loop, the filtration loop and the arterial loop are in fluidic communication such that the perfusate can be carried from the mammal, through the venous loop, through the filtration loop, through the arterial loop and back to the mammal.
29. The system of claim 28, wherein one or more components selected from the group consisting of the venous loop, the filtration loop and the arterial loop further comprise a reservoir containing excess perfusate.
30. The system of claim 28, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop further comprise one or more elements selected from the group consisting of: one or more valves adapted and configured to regulate the flow of the perfusate; one or more filters adapted and configured to filter the perfusate; and one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pH, dissolved oxygen concentration, dissolved carbon dioxide concentration, dissolved metabolite concentration, temperature, pressure, and flow rate.
31. The system of claim 28, wherein the one or more sensors measure the concentration of at least one dissolved metabolite selected from the group consisting of nitric oxide, lactate,
-118- bicarbonate, oxygen, carbon dioxide, total hemoglobin, methemoglobin, oxyhemoglobin, carboxyhemoglobin, sodium, potassium, chloride, calcium, glucose, urea, ammonia, and creatinine.
32. The system of claim 28, wherein the mammal perfusion apparatus comprises one or more sensors for measuring one or more properties of the perfusate selected from the group consisting of pressure and flow rate.
33. The system of claim 28, wherein one or more components selected from the group consisting of the mammal, the venous loop, the filtration loop and the arterial loop comprise one or more heat exchange units comprising: one or more heat exchangers; one or more temperature regulation units; one or more temperature regulating pumps; a thermoregulation fluid; and one or more pipes configured and adapted to transport the thermoregulation fluid, wherein the one or more pipes are in fluidic communication with the one or more heat exchangers, the one or more temperature regulation units and the one or more temperature regulating pumps.
34. The system of claim 28, wherein the one or more components selected from the group consisting of the brain enclosure unit, the venous loop, the filtration loop and the arterial loop comprise one or more sensors adapted and configured to measure the temperature within the perfusion device.
35. The system of claim 28, wherein the one or more sensor(s) is/are adapted and configured to measure the temperature within the perfusion device, the one or more temperature regulation units and the one or more temperature regulating pumps are in electronic communication with a computer programmed to regulate the temperature of the thermoregulation fluid and the specified flow rate of the one or more temperature regulating pumps to maintain a specified temperature within the perfusion device.
-119-
36. The system of claim 28, wherein the hemodiafiltration unit is adapted and configured to supply one or more nutrients to the perfusate, selected from the group consisting of Glycine, L- Alanyl-Glutamine, L- Arginine hydrochloride, L-Cy stine, L-Histidine hydrochi oride-H2O, L- Isoleucine, L-Leucine, L-Lysine hydrochloride, L-Methionine, L-Phenylalanine, L-Serine, L- Threonine, L-Tryptophan, L-Tyrosine, L-Valine, Choline chloride, D-Calcium pantothenate, Folic Acid, Niacinamide, Pyridoxine hydrochloride, Riboflavin, Thiamine hydrochloride, i- Inositol, Calcium Chloride (CaCh-2H2O), Ferric Nitrate (Fe(NO3)3 9H2O), Magnesium Sulfate (MgSO4-7H2O), Potassium Chloride (KC1), Sodium Bicarbonate (NaHCCh), Sodium Chloride (NaCl), Sodium Phosphate monobasic (NaH2PO4-2H2O), D-Glucose (Dextrose), Phenol Red, Sodium Pyruvate, free fatty acids, cholesterol and nucleic acid constitutes.
37. The system of any of claims 26-36, wherein the system is configured to perfuse the mammal with the perfusate at a cardiac pulsatile pressure of about 20 mmHg to about 140 mmHg.
38. The system of any of claims 26-36, wherein the system is configured to perfuse the organs in the mammal with the perfusate through the pulse generator at a rate of about 40 to about 180 beats per minute.
39. The system of any of claim 26-36, further comprising a controller in electronic communication with one or more elements of the system.
40. A mammal perfused with the isolated perfusate mixture of any of claims 1-25, wherein mammalian organs are perfused under hypothermic conditions.
41. The mammal of claim 40, wherein the mammal is a deceased mammal.
42. The mammal of claim 40, wherein the mammal is a human.
-120-
43. The mammal of claim 41 wherein the deceased mammal is deceased for longer than 1 hour.
44. The deceased mammal of claim 43, wherein the deceased mammal has been deceased for longer than 4 hours.
45. The deceased animal of claim 41, wherein the mammal died of cardiac arrest.
46. The deceased mammal of claim 41, wherein the organs in the deceased mammal are ischemic prior to perfusion with the isolated perfusate mixture of any of claims 1-25.
47. The deceased mammal of claim 41, wherein rigor mortis is prevented.
48. The deceased mammal of claim 41, wherein rigor mortis is reversed.
49. The diseased mammal of claim 41, wherein the perfusate mixture flows into the ophthalmic artery.
50. The diseased mammal of claim 41, wherein the perfusate mixture flows into the renal intralobular arteries.
51. The perfused organs in a diseased mammal , wherein the perfused organs maintain one or more properties selected from the group consisting of an in vivo level of cell function and viability, and an in vivo level of morphology.
-121-
PCT/US2022/043816 2021-09-17 2022-09-16 Methods, systems and compositions for restoration and preservation of intact organs in a mammal Ceased WO2023044014A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA3231611A CA3231611A1 (en) 2021-09-17 2022-09-16 Methods, systems and compositions for restoration and preservation of intact organs in a mammal
JP2024516762A JP2024535843A (en) 2021-09-17 2022-09-16 Methods, systems, and compositions for recovering and preserving intact organs in mammals
AU2022345865A AU2022345865A1 (en) 2021-09-17 2022-09-16 Methods, systems and compositions for restoration and preservation of intact organs in a mammal
US18/690,785 US20240373840A1 (en) 2021-09-17 2022-09-16 Methods, systems and compositions for restoration and preservation of intact organs in a mammal
EP22870751.9A EP4402242A4 (en) 2021-09-17 2022-09-16 Methods, systems and compositions for restoring and preserving intact organs in a mammal

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245632P 2021-09-17 2021-09-17
US63/245,632 2021-09-17

Publications (1)

Publication Number Publication Date
WO2023044014A1 true WO2023044014A1 (en) 2023-03-23

Family

ID=85603531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/043816 Ceased WO2023044014A1 (en) 2021-09-17 2022-09-16 Methods, systems and compositions for restoration and preservation of intact organs in a mammal

Country Status (6)

Country Link
US (1) US20240373840A1 (en)
EP (1) EP4402242A4 (en)
JP (1) JP2024535843A (en)
AU (1) AU2022345865A1 (en)
CA (1) CA3231611A1 (en)
WO (1) WO2023044014A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254223A3 (en) * 2023-06-07 2025-04-17 Case Western Reserve University Method and systems for isolating nuclear rna from a high degradation tissue
WO2025188754A3 (en) * 2024-03-06 2025-12-04 Bexorg, Inc. Perfusion and metabolic restoration of organs
WO2025247852A1 (en) * 2024-05-27 2025-12-04 Artidis Ag Method for stabilising a biological sample

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119193578A (en) * 2024-11-27 2024-12-27 山东省农业科学院畜牧兽医研究所 A tissue lysis solution and a method for extracting DNA from animal tissue

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699231B1 (en) * 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US20040259769A1 (en) * 1999-11-12 2004-12-23 Baxter International Inc. Reduced side-effect hemoglobin compositions
US20050272148A1 (en) * 2000-12-06 2005-12-08 Hariri Robert J Method of collecting placental stem cells
WO2011149602A1 (en) * 2010-05-27 2011-12-01 Bing Lou Wong High-temperature stable oxygen-carrier-containing pharmaceutical composition
US20120238998A1 (en) * 2005-12-22 2012-09-20 Csl Behring Gmbh Octanoate-reduced Human Albumin
US20150342177A1 (en) * 2014-06-02 2015-12-03 Transmedics, Inc Ex vivo organ care system
US20170007616A1 (en) * 2014-01-27 2017-01-12 Susanne GARDNER Antimicrobial formulations and applications thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11850313B2 (en) * 2019-12-20 2023-12-26 The London Health Sciences Centre Research Inc. Method and compositions for protecting tissue

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699231B1 (en) * 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US20040259769A1 (en) * 1999-11-12 2004-12-23 Baxter International Inc. Reduced side-effect hemoglobin compositions
US20050272148A1 (en) * 2000-12-06 2005-12-08 Hariri Robert J Method of collecting placental stem cells
US20120238998A1 (en) * 2005-12-22 2012-09-20 Csl Behring Gmbh Octanoate-reduced Human Albumin
WO2011149602A1 (en) * 2010-05-27 2011-12-01 Bing Lou Wong High-temperature stable oxygen-carrier-containing pharmaceutical composition
US20170007616A1 (en) * 2014-01-27 2017-01-12 Susanne GARDNER Antimicrobial formulations and applications thereof
US20150342177A1 (en) * 2014-06-02 2015-12-03 Transmedics, Inc Ex vivo organ care system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4402242A4 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024254223A3 (en) * 2023-06-07 2025-04-17 Case Western Reserve University Method and systems for isolating nuclear rna from a high degradation tissue
WO2025188754A3 (en) * 2024-03-06 2025-12-04 Bexorg, Inc. Perfusion and metabolic restoration of organs
WO2025247852A1 (en) * 2024-05-27 2025-12-04 Artidis Ag Method for stabilising a biological sample

Also Published As

Publication number Publication date
EP4402242A1 (en) 2024-07-24
US20240373840A1 (en) 2024-11-14
AU2022345865A1 (en) 2024-03-14
JP2024535843A (en) 2024-10-02
EP4402242A4 (en) 2025-08-06
CA3231611A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Andrijevic et al. Cellular recovery after prolonged warm ischaemia of the whole body
EP4402242A1 (en) Methods, systems and compositions for restoration and preservation of intact organs in a mammal
Liu et al. Gene therapy knockdown of Hippo signaling induces cardiomyocyte renewal in pigs after myocardial infarction
Glorioso et al. Pivotal preclinical trial of the spheroid reservoir bioartificial liver
Kitahara et al. Heterotopic transplantation of a decellularized and recellularized whole porcine heart
Bishawi et al. A normothermic ex vivo organ perfusion delivery method for cardiac transplantation gene therapy
CN106687152B (en) human liver scaffold
Seki et al. Adipose tissue-derived mesenchymal stem cell transplantation promotes hepatic regeneration after hepatic ischemia-reperfusion and subsequent hepatectomy in rats
Diaz et al. Injectable myocardial matrix hydrogel mitigates negative left ventricular remodeling in a chronic myocardial infarction model
US20100093066A1 (en) Decellularization and recellularization apparatuses and systems containing the same
EP2893806B1 (en) Method for maintaining organ or tissue for transplantation use for long period
CA2993955A1 (en) Materials and methods for treating and evaluating ischemic and/or reperfusion-injured tissue and/or tissue susceptible to same
Stone et al. Recovery of hibernating myocardium using stem cell patch with coronary bypass surgery
Xue et al. A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs
Aggarwal et al. Stem cell-derived exosome patch with coronary artery bypass graft restores cardiac function in chronically ischemic porcine myocardium
Chen et al. Nonvirally modified autologous primary hepatocytes correct diabetes and prevent target organ injury in a large preclinical model
Stenvinkel et al. Implantation of autologous selected renal cells in diabetic chronic kidney disease stages 3 and 4—clinical experience of a “first in human” study
Whalen et al. A novel rodent model of severe renal ischemia reperfusion injury
Smolenski et al. Reduction of hyperacute rejection and protection of metabolism and function in hearts of human decay accelerating factor (hDAF)-expressing pigs
Moor et al. Comparative analysis of kidney transplantation modeled using precision-cut kidney slices and kidney transplantation in pigs
Moyer et al. Endovascular Nephrectomy in Swine for Evaluation of Implantable Devices for Renal Replacement Therapy: SA-PO018
Laguens et al. Cardiac regeneration: the gene therapy approach
US20250067728A1 (en) Normothermic perfusion of kidneys
Wang et al. Therapeutic evaluation of a microbioartificial liver with recombinant HepG2 cells for rats with hepatic failure
Otani et al. Early effects of the ex vivo evaluation system on graft function after swine lung transplantation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22870751

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2022345865

Country of ref document: AU

Ref document number: AU2022345865

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 18690785

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 3231611

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2022345865

Country of ref document: AU

Date of ref document: 20220916

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2024516762

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022870751

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022870751

Country of ref document: EP

Effective date: 20240417